JP5985453B2 - Pharmaceutical composition - Google Patents

Description

  The present invention relates to a pharmaceutical composition containing a novel sulfonamide compound having a TRPM8 blocking effect as an active ingredient.

  TRP (transient receptor potential) channels are non-selective cation channels that are activated by various physical (eg, temperature, osmotic pressure, mechanical) and chemical stimuli. Some of the TRP channel superfamily is temperature responsive, and these channels are activated in the unique temperature range of each channel, from nociceptive cold to nociceptive heat. TRP melastatin 8 (TRPM8) belongs to the melastatin subgroup of the TRP channel superfamily. Since TRPM8 is sensitive to cold and menthol, it is also called cold menthol receptor-1 (CMR-1) (for example, Non-Patent Document 1). TRPM8 is known to be activated by chemical substances such as menthol and icilin, and activated by cold to low temperature (8 to 28 ° C.).

  TRPM8 is present in primary nociceptive neurons (A-δ and C-fibers) and is also regulated by inflammatory second messenger signals (eg, Non-Patent Documents 2 and 3). TRPM8 present on A-δ and C-fibers can cause cold-sensitive abnormalities that often present with burning pain in conditions in which these neurons have changed. In a rat strangulated nerve injury (CCI) model, which is a neuropathic pain model that expresses cold allodynia in the hind limbs, an increase in TRPM8 immunostaining in primary afferent nerves has been observed (eg, Non-Patent Document 4). Further, in the mouse oxaliplatin-induced cold allodynia model, an increase in TRPM8 expression in primary afferent nerves is observed (for example, Non-Patent Document 5).

  Cold tolerance due to cooling with chemicals or thermal cooling is a closely related symptom and is seen in a wide range of clinical diseases, so TRPM8 regulation as a novel antihyperalgesic or antiallodynic agent It is expected to develop drugs. Since TRPM8 is also expressed in brain, lung, bladder, gastrointestinal tract, blood vessel, prostate and immune cells, it may have a therapeutic effect on a wide range of diseases.

  TRPM8 modulators include N-benzothiophenylsulfonamide compounds (for example, Patent Document 1), N-benzimidazolylsulfonamide compounds (for example, Patent Document 2), N-phenylsulfonamide compounds, N-pyridylsulfonamide compounds. (For example, patent document 3) etc. are known. However, a compound having a structure in which a bicyclic aromatic heterocycle in which pyridine and benzene are condensed or in which pyridine and a monocyclic aromatic heterocycle are condensed has a structure bonded to a sulfonylamino group has a blocking effect on TRPM8. Has not been reported so far.

International Publication No. 2009/012430 Pamphlet International Publication No. 2010/144680 Pamphlet International Publication No. 2010/125831 Pamphlet

D. D. McKemi, 2 others, “Identification of a cold receptor reveals a general role for TRP channels in thermosensation”, Nature, 2002, 416, 6876, p.52-58 J. et al. Abe and 4 others, “Ca2 + -dependent PKC activation mediates menthol-induced desensitization of transient receptor potential M8”, Neuroscience Letters, 2006, 397, 1-2, p.140-144 L. S. Premkumar and 4 others, “Downregulation of Transient Receptor Potential Melastatin 8 by Protein Kinase C-Mediated Dephosphorylation”, The Journal of Neuroscience, 2005, 25, 49, p.11322-11329 H. Xing, 4 others, “TRPM8 Mechanism of Cold Allodynia after Chronic Nerve Injury”, The Journal of Neuroscience, 2007, 27, 50, p.13680-13690 P. Gauchan and three others, “Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice”, Neuroscience Letters, 2009, 458, 2, p.93-95

  The object of the present invention is to provide a pharmaceutical composition containing a novel sulfonamide compound having a TRPM8 blocking effect as an active ingredient.

The present invention relates to a compound of formula (I):

[Wherein ring A is a bicyclic aromatic heterocyclic ring in which (a) pyridine and benzene are condensed; or (b) pyridine and a monocyclic aromatic heterocyclic ring are condensed (the ring A is , Bonded to the sulfonylamino group at the carbon atom adjacent to the nitrogen atom of the pyridine ring constituting the ring A),
Ring B represents (a) a monocyclic or bicyclic aromatic hydrocarbon; (b) a monocyclic or bicyclic alicyclic hydrocarbon; (c) a monocyclic or bicyclic aromatic hydrocarbon; A heterocycle; or (d) a monocyclic or bicyclic non-aromatic heterocycle,
Ring C is (a) benzene; or (b) a monocyclic aromatic heterocycle,
R ¹ is (a) hydrogen; (b) optionally substituted alkyl; (c) optionally substituted cycloalkyl; (d) optionally substituted alkoxy; (e) substituted. Or (f) halogen; or (g) nitrile,
R ^2a , R ^2b , R ^2c and R ^2d are each independently (a) hydrogen; (b) optionally substituted alkyl; (c) optionally substituted cycloalkyl; (d) substituted (E) an optionally substituted phenyl; (f) an optionally substituted monocyclic aromatic heterocyclic group; (g) an optionally substituted monocyclic. A non-aromatic heterocyclic group; (h) a halogen; or (i) a nitrile,
R ^3a , R ^3b , R ^3c and R ^3d are each independently (a) hydrogen; (b) optionally substituted alkyl; (c) optionally substituted cycloalkyl; (d) substituted (E) an optionally substituted cycloalkoxy; (f) an optionally substituted phenyl; (g) an optionally substituted monocyclic aromatic heterocyclic group; h) an optionally substituted monocyclic non-aromatic heterocyclic group; (i) an optionally substituted phenoxy; (j) a halogen; or (k) a hydroxy, or
Two substituents selected from R ^3a , R ^3b , R ^3c and R ^3d together form an oxo;
R ⁵ and R ⁶ are each independently (a) hydrogen; (b) alkyl; (c) halogenoalkyl; (d) cycloalkyl; or (e) halogenocycloalkyl, or R ⁵ and R 6 ⁶ bind to each other at their ends to form a monocyclic alicyclic hydrocarbon with adjacent carbon atoms;
n is 0, 1 or 2;
X is carboxy, alkoxycarbonyl, hydroxyalkyl, optionally substituted aminocarbonyl, or optionally substituted alkanoyl. ]
Or a pharmacologically acceptable salt thereof, or a prodrug thereof as an active ingredient.

  The pharmaceutical composition containing the compound represented by the formula (I) as an active ingredient exhibits an excellent TRPM8 blocking effect and an excellent inhibitory effect on behavior induced by a TRPM8 agonist. For this reason, the pharmaceutical composition containing the compound represented by the formula (I) is used for various diseases involving TRPM8 (for example, neuropathic pain (preferably neuropathic pain caused by cold allodynia or diabetic neuropathy)). It is useful as a medicine for prevention / treatment of chronic pain).

  The definition of each term used in this specification is as follows.

The term “alkyl” means a straight or branched saturated hydrocarbon chain having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, and the like. These include various branched chain isomers, preferably a linear or branched saturated hydrocarbon chain having 1 to 4 carbon atoms.
The term “alkenyl” means a C 2-6 linear or branched unsaturated hydrocarbon chain having one carbon-carbon double bond, such as vinyl, propenyl, butenyl, and These various branched-chain isomers are mentioned, Preferably, it means a C2-C4 linear or branched unsaturated hydrocarbon chain.
The term “cycloalkyl” means an alicyclic saturated hydrocarbon group having 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and preferably an alicyclic ring having 3 to 6 carbon atoms. Means a saturated hydrocarbon group.
The term “cycloalkenyl” means an alicyclic unsaturated hydrocarbon having 3 to 7 carbon atoms having one carbon-carbon double bond, and examples thereof include cyclopropenyl, cyclobutenyl, cyclopentenyl, and cyclohexenyl. , Preferably, it means an alicyclic unsaturated hydrocarbon having 3 to 6 carbon atoms.
The term “halogen” or “halogeno” means fluorine, chlorine, bromine and iodine, with chlorine and fluorine being preferred.

The term “alkoxy” means a group in which an oxygen atom is bonded to a linear or branched alkyl having 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy. , Isobutoxy, and various branched chain isomers thereof, preferably a group in which an oxygen atom is bonded to a linear or branched saturated hydrocarbon chain having 1 to 4 carbon atoms.
The term “cycloalkoxy” means a group in which an oxygen atom is bonded to the cycloalkyl having 3 to 7 carbon atoms, and examples thereof include cyclopropoxy, cyclobutoxy, cyclopentoxy, and cyclohexoxy. The group which the oxygen atom couple | bonded with the alicyclic saturated hydrocarbon of several 3-6 is meant.
The term “alkanoyl” means a group in which alkyl is bonded to carbonyl, and examples thereof include acetyl, propanoyl, butyryl, pentanoyl, and various branched isomers thereof. It means a group in which a chain or branched saturated hydrocarbon chain is bonded to carbonyl.
The terms “halogenoalkyl”, “halogenoalkoxy” and “halogenocycloalkyl” refer to the above alkyl, alkoxy and cycloalkyl, respectively, substituted with 1-7 halogen atoms.

The term “monocyclic or bicyclic aromatic hydrocarbon” means a monocyclic or bicyclic aromatic hydrocarbon having 6 to 11 ring carbon atoms, for example, monocyclic such as benzene. A bicyclic aromatic hydrocarbon having 9 to 11 ring carbon atoms such as naphthalene, tetrahydronaphthalene, indene, indane or azulene.
The term “monocyclic alicyclic hydrocarbon” means a monocyclic alicyclic hydrocarbon having 3 to 7 carbon atoms, such as cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane or Cyclohexene is mentioned, and preferably a monocyclic alicyclic hydrocarbon having 3 to 6 ring carbon atoms.

  The term “monocyclic or bicyclic alicyclic hydrocarbon” means a monocyclic or bicyclic alicyclic hydrocarbon having 3 to 12 carbon atoms, such as cyclopropane and cyclobutane. , Cyclopentane, cyclopentene, cyclohexane or cyclohexene, etc., monocyclic alicyclic hydrocarbons having 3 to 7 carbon atoms; bicyclooctane, bicyclononane, bicyclononene, bicyclodecane, bicyclodecene, spirooctane, spirononan, spirodecane or spiroundecane And bicyclic alicyclic hydrocarbons having 8 to 12 ring carbon atoms.

  The term “monocyclic aromatic heterocycle” means a 5- to 6-membered monocyclic aromatic heterocycle containing 1 to 4 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom in addition to a carbon atom. Meaning a group, for example, pyrrole, furan, thiophene, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, thiadiazole, pyridine, pyrimidine or pyridazine.

  The term “monocyclic or bicyclic aromatic heterocycle” means a 5- to 11-membered monocyclic or cyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom in addition to a carbon atom. Means a bicyclic aromatic heterocycle, for example pyrrole, furan, thiophene, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, thiadiazole, pyridine, pyrimidine or pyridazine Aromatic heterocycles of the formula: indole, indoline, isoindoline, indazole, benzofuran, dihydrobenzofuran, dihydroisobenzofuran, benzothiophene, dihydrobenzothiophene, dihydroisobenzothiophene, benzoxazole, dihydrobenzoxazole, benzothiazole, dihydroben Thiazole, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, naphthyridine, tetrahydronaphthyridine, quinoxaline, aromatic heterocyclic bicyclic 8-11 membered like tetrahydroquinoxaline or quinazoline and the like.

  The term “monocyclic or bicyclic non-aromatic heterocycle” means a 4- to 12-membered monocyclic containing 1 to 4 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom in addition to a carbon atom. Or a bicyclic non-aromatic heterocycle, for example, a 4- to 7-membered monocyclic non-aromatic heterocycle such as pyrrolidine, piperidine, tetrahydrofuran, tetrahydrothiophene, dihydroisoxazole and morpholine; , Octahydrobenzofuran, octahydrobenzothiophene, decahydroquinoline, decahydroisoquinoline, oxaazaspironene, oxaazaspirodecene, oxaazaspiroundecene and the like, an 8- to 12-membered bicyclic non-aromatic heterocycle Can be mentioned.

  The term “monocyclic aromatic heterocyclic group” means a 5- to 6-membered monocyclic aromatic heterocycle containing 1 to 4 heteroatoms selected from oxygen atoms, sulfur atoms and nitrogen atoms in addition to carbon atoms. Means a cyclic group, for example, pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyrimidyl or pyridadyl;

  The term “monocyclic non-aromatic heterocyclic group” means a 4- to 7-membered monocyclic non-aromatic group containing 1 to 4 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom in addition to a carbon atom. Means a heterocyclic group, and examples include pyrrolidinyl, piperidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroisoxazolyl and morpholyl.

  Below, the definition of each symbol in the compound represented by the formula (I) will be described in detail.

  The monocyclic aromatic heterocycle in the “bicyclic aromatic heterocycle in which pyridine and monocyclic aromatic heterocycle are condensed” represented by ring A is preferably pyrrole, thiophene or pyridine.

  Ring A is preferably (a) pyridine and benzene condensed; (b) pyridine and pyrrole condensed; (c) pyridine and thiophene condensed; or (d) pyridine and pyridine condensed. An aromatic heterocycle, particularly preferably a bicyclic aromatic heterocycle in which pyridine and benzene are condensed, specifically quinoline (especially quinolin-2-yl) or isoquinoline (especially isoquinoline-3- Is preferred.

The “monocyclic or bicyclic aromatic hydrocarbon” represented by ring B is preferably benzene, naphthalene, tetrahydronaphthalene, or indane.
As the “monocyclic or bicyclic alicyclic hydrocarbon” represented by ring B, cyclopentane or cyclohexane is preferable.

Examples of the “monocyclic or bicyclic aromatic heterocycle” represented by ring B include thiophene, pyridine, pyrimidine, indole, indazole, dihydrobenzofuran, dihydroisobenzofuran, benzothiophene, benzoxazole, benzothiazole, quinoline. Or isoquinoline is preferred.
As the “monocyclic or bicyclic non-aromatic heterocycle” represented by ring B, piperidine or oxaazaspirodecene is preferable.

  Ring B is preferably (a) a monocyclic or bicyclic aromatic hydrocarbon; or (b) a monocyclic or bicyclic aromatic heterocycle, specifically benzene, naphthalene, tetrahydro Naphthalene, indane, thiophene, pyridine, pyrimidine, indole, indazole, dihydrobenzofuran, dihydroisobenzofuran, benzothiophene, benzoxazole, benzothiazole, quinoline or isoquinoline are preferred, more preferably benzene, naphthalene, tetrahydronaphthalene, indane, thiophene Pyridine, indole or benzothiophene, particularly preferably benzene, naphthalene (especially naphthalen-2-yl), tetrahydronaphthalene (especially 1,2,3,4-tetrahydronaphthalene- - yl) indan (especially indan-1-yl or indan-5-yl) pyridine (especially, pyridin-2-yl) or benzothiophene (especially benzothiophen-2-yl) and the like.

The “monocyclic aromatic heterocycle” represented by ring C is preferably thiophene or pyridine.
Ring C is preferably benzene, thiophene or pyridine, with benzene being particularly preferred.

The number of substituents of “optionally substituted alkyl” in R ¹ may be 1 or more (for example, 1-7), and the substituents may be the same or different. Such substituents can include, for example, cycloalkyl, alkoxy, halogen, oxo and hydroxy.
The number of substituents of “optionally substituted cycloalkyl” in R ¹ may be 1 or more (for example, 1-7), and the substituents may be the same or different. Such substituents can include, for example, alkyl, alkoxy and halogen.
The number of substituents of “optionally substituted alkoxy” in R ¹ may be 1 or more (for example, 1-7), and the substituents may be the same or different. Such substituents can include, for example, cycloalkyl, alkoxy, halogen, and hydroxy.
The number of substituents of “optionally substituted phenyl” in R ¹ may be 1 or more (for example, 1 to 3), and the substituents may be the same or different. Such substituents can include, for example, alkyl, halogenoalkyl, cycloalkyl, halogenocycloalkyl, alkoxy, halogenoalkoxy and halogen.

R ¹ is preferably (a) hydrogen; (b) optionally substituted alkyl; (c) optionally substituted cycloalkyl; (d) optionally substituted alkoxy; or (e) halogen. It is. More preferably, (a) hydrogen; (b) C ₁ -C ₆ alkyl optionally substituted with 1-7 groups selected from halogen, oxo and hydroxy; (c) C ₃ -C ₇ cycloalkyl (D) C ₁ -C ₆ alkoxy; or (e) a halogen, specifically hydrogen, methyl, trifluoromethyl, ethyl, oxoethyl, hydroxyethyl, isopropyl, cyclopropyl, methoxy, chloro or bromo preferable. In particular, (a) C ₁ -C ₆ alkyl optionally substituted with 1-7 halogens; (b) C ₃ -C ₇ cycloalkyl; (c) C ₁ -C ₆ alkoxy; or (d) Halogen is preferred, specifically methyl, trifluoromethyl, isopropyl, cyclopropyl, or methoxy. More preferably, it is methyl, trifluoromethyl, or cyclopropyl.

The number of substituents of “optionally substituted alkyl” in R ^2a , R ^2b , R ^2c or R ^2d may be 1 or more (for example, 1-7), and the substituents are the same or different. It's okay. Such substituents can include, for example, alkoxy, cycloalkyl, halogen, oxo and hydroxy.
The number of substituents of “optionally substituted cycloalkyl” in R ^2a , R ^2b , R ^2c or R ^2d may be 1 or more (for example, 1-7), and the substituents may be the same or different. It may be. Such substituents can include, for example, alkyl, alkoxy and halogen.
The number of the substituents of “optionally substituted alkoxy” in R ^2a , R ^2b , R ^2c or R ^2d may be 1 or more (for example, 1-7), and the substituents are the same or different. It's okay. Such substituents can include, for example, alkoxy, cycloalkyl and halogen.
The number of substituents of “optionally substituted phenyl” in R ^2a , R ^2b , R ^2c, or R ^2d may be 1 or more (eg, 1-3), and the substituents are the same or different. It's okay. Such substituents can include, for example, alkyl, halogenoalkyl, cycloalkyl, halogenocycloalkyl, alkoxy, halogenoalkoxy and halogen.
The number of substituents of the “optionally substituted monocyclic aromatic heterocyclic group” in R ^2a , R ^2b , R ^2c or R ^2d may be 1 or more (for example, 1 to 3), respectively. The substituents may be the same or different. Such substituents can include, for example, alkyl, halogenoalkyl, cycloalkyl, halogenocycloalkyl, alkoxy, halogenoalkoxy and halogen.
The number of substituents of “optionally substituted monocyclic non-aromatic heterocyclic group” in R ^2a , R ^2b , R ^2c or R ^2d is 1 or more (for example, 1 to 3), respectively. Often, the substituents may be the same or different. Such substituents can include, for example, alkyl, halogenoalkyl, cycloalkyl, halogenocycloalkyl, alkoxy, halogenoalkoxy and halogen.

R ^2a , R ^2b and R ^2c are preferably each independently (a) hydrogen; (b) optionally substituted alkyl; (c) optionally substituted cycloalkyl; or (d) halogen. It is. More preferably, (a) hydrogen; _(b) C 1 -C ₆ alkyl; _{(c) C} 3 -C ₇ cycloalkyl; or (d) halogen, specifically, hydrogen, methyl, cyclopropyl or chlorine preferable. In particular, hydrogen is preferable.
R ^2d is preferably (a) hydrogen; (b) optionally substituted alkyl; (c) optionally substituted cycloalkyl; (d) optionally substituted alkoxy; (e) substituted. (F) an optionally substituted monocyclic aromatic heterocyclic group; (g) an optionally substituted monocyclic non-aromatic heterocyclic group; or (h) Halogen. More preferably, (a) hydrogen; _(b) C 1 -C ₆ alkoxy, optionally substituted with 1-7 groups selected from halogen and hydroxy _C 1 -C ₆ alkyl; (c) _{C 3} -C ₇ cycloalkyl; _(d) C 1 -C ₆ alkoxy; (e) phenyl; (f) 5-6 membered aromatic heterocyclic group monocyclic; (g) non-aromatic heterocyclic monocyclic A cyclic group; or (h) halogen, specifically, hydrogen, methyl, trifluoromethyl, methoxymethyl, ethyl, hydroxyethyl, propyl, isopropyl, cyclopropyl, cyclopentyl, methoxy, ethoxy, isopropoxy, phenyl, Pyridyl, pyrrolidyl, fluorine, chlorine or bromine are preferred. In particular, (a) hydrogen; (b) C ₁ -C ₆ alkyl; (c) C ₃ -C ₇ cycloalkyl; or (d) C ₁ -C ₆ alkoxy are preferred, specifically hydrogen, methyl, Ethyl, isopropyl, cyclopropyl, cyclopentyl, methoxy or ethoxy are preferred. More preferred is hydrogen, isopropyl, or cyclopropyl.

The number of substituents of “optionally substituted alkyl” in R ^3a , R ^3b , R ^3c or R ^3d may be 1 or more (for example, 1-7), and the substituents are the same or different. It's okay. Examples of such substituents include cycloalkyl and halogenocycloalkyl (the cycloalkyl and halogenocycloalkyl may be each independently substituted with 1 to 3 groups selected from alkyl and halogenoalkyl). , Alkoxy, halogenoalkoxy, phenyl, monocyclic aromatic heterocyclic group, monocyclic non-aromatic heterocyclic group (the phenyl, aromatic heterocyclic group and non-aromatic heterocyclic group are each independently And optionally substituted by 1-3 groups selected from alkyl, halogenoalkyl, cycloalkyl, halogenocycloalkyl, alkoxy, halogenoalkoxy and halogen), halogen, oxo and hydroxy.
The number of substituents of “optionally substituted cycloalkyl” in R ^3a , R ^3b , R ^3c or R ^3d may be 1 or more (for example, 1-7), and the substituents may be the same or different It may be. Such substituents can include, for example, alkyl, halogenoalkyl, alkoxy, halogenoalkoxy, halogen and hydroxy.

The number of substituents of “optionally substituted alkoxy” in R ^3a , R ^3b , R ^3c or R ^3d may be 1 or more (for example, 1-7), and the substituents are the same or different. It's okay. Examples of such substituents include cycloalkyl and halogenocycloalkyl (the cycloalkyl and halogenocycloalkyl may be each independently substituted with 1 to 3 groups selected from alkyl and halogenoalkyl). , Alkoxy, halogenoalkoxy, phenyl, monocyclic aromatic heterocyclic group, monocyclic non-aromatic heterocyclic group (the phenyl, aromatic heterocyclic group and non-aromatic heterocyclic group are each independently And optionally substituted by 1-3 groups selected from alkyl, halogenoalkyl, cycloalkyl, halogenocycloalkyl, alkoxy, halogenoalkoxy and halogen), halogen and hydroxy.
The number of substituents of “optionally substituted cycloalkoxy” in R ^3a , R ^3b , R ^3c or R ^3d may be 1 or more (for example, 1-7), and the substituents may be the same or different. It may be. Such substituents can include, for example, alkyl, halogenoalkyl, alkoxy, halogenoalkoxy, halogen and hydroxy.

The number of substituents of “optionally substituted phenyl” in R ^3a , R ^3b , R ^3c, or R ^3d may be 1 or more (eg, 1-3), and the substituents may be the same or different. It's okay. Such substituents can include, for example, alkyl, halogenoalkyl, cycloalkyl, halogenocycloalkyl, alkoxy, halogenoalkoxy and halogen.
The number of substituents of “optionally substituted monocyclic aromatic heterocyclic group” in R ^3a , R ^3b , R ^3c or R ^3d may be 1 or more (for example, 1 to 3), respectively. The substituents may be the same or different. Such substituents can include, for example, alkyl, halogenoalkyl, cycloalkyl, halogenocycloalkyl, alkoxy, halogenoalkoxy and halogen.
The number of substituents of the “optionally substituted monocyclic non-aromatic heterocyclic group” in R ^3a , R ^3b , R ^3c or R ^3d is 1 or more (for example, 1 to 3), respectively. Often, the substituents may be the same or different. Such substituents can include, for example, alkyl, halogenoalkyl, cycloalkyl, halogenocycloalkyl, alkoxy, halogenoalkoxy and halogen.
The number of the substituents of “optionally substituted phenoxy” in R ^3a , R ^3b , R ^3c or R ^3d may be 1 or more (for example, 1 to 3), and the substituents may be the same or different. It's okay. Such substituents can include, for example, alkyl, halogenoalkyl, cycloalkyl, halogenocycloalkyl, alkoxy, halogenoalkoxy and halogen.

R ^3a , R ^3b , R ^3c and R ^3d are preferably each independently (a) hydrogen; (b) optionally substituted alkyl; (c) optionally substituted cycloalkyl; d) optionally substituted alkoxy; (e) optionally substituted cycloalkoxy; (f) optionally substituted phenyl; (g) optionally substituted monocyclic aromatic heterocycle. A group; (h) an optionally substituted phenoxy; (i) a halogen; or (j) hydroxy. More preferably, (a) hydrogen; substituted with _(b) C 3 -C ₇ cycloalkyl (said _cycloalkyl, 1-3 groups selected from C 1 -C ₆ alkyl and _C 1 -C ₆ halogenoalkyl and may _be), C 1 -C _{6 alkoxy,} C 1 -C ₆ halogenoalkoxy, optionally substituted with 1-7 groups selected from halogen and hydroxy _C 1 -C ₆ alkyl; (c ) _C 1 -C _{6 alkyl,} C 1 -C ₆ halogenoalkyl and 1-7 pieces of good _C 3 -C ₇ cycloalkyl optionally substituted by a group selected from halogen; _(d) C 3 -C ₇ cycloalkyl _alkyl, C 1 -C _{6 alkoxy,} C 1 -C ₆ halogenoalkoxy and 1-7 groups are _C 1 optionally -C ₆ alkoxy substituted by selected from halogen; (e) _{C 3} - ₇ cycloalkoxy; (f) 1-3 amino phenyl optionally substituted with halogen; (g) 5-6 membered monocyclic aromatic heterocyclic group; (h) phenoxy; (i) halogen; Or (j) hydroxy, especially (a) hydrogen; (b) C ₃ -C ₇ cycloalkyl, wherein the cycloalkyl is selected from C ₁ -C ₆ alkyl and C ₁ -C ₆ halogenoalkyl optionally substituted with 1-3 groups may _be), C 1 -C _{6 alkoxy,} C 1 -C ₆ halogenoalkoxy and 1-7 pieces of good _C 1 -C be substituted by a group selected from halogen ₆ Alkyl; (c) C ₁ -C ₆ alkyl, C ₁ -C ₆ halogenoalkyl and C ₃ -C ₇ cycloalkyl optionally substituted with 1-7 groups selected from halogen; (d) C ₃ -C ₇ Sik _Alkyl, C 1 -C _{6 alkoxy,} C 1 -C ₆ halogenoalkoxy and 1-7 amino _C 1 -C ₆ alkoxy optionally substituted by a group selected from halogen; or (e) halogen are preferred.

R ⁵ and R ⁶ are preferably each independently hydrogen or alkyl, with hydrogen being particularly preferred.
n is preferably 0 or 1.
The number of substituents of “optionally substituted aminocarbonyl” in X may be one. Examples of such substituents include alkyl, alkoxy and nitrile.
The number of substituents of “optionally substituted alkanoyl” in X may be 1 or more (for example, 1 to 3), and the substituents may be the same or different. Examples of such a substituent include halogen.

X is preferably, (a) carboxy; _(b) C 1 -C ₆ alkoxycarbonyl; (c) hydroxy _-C 1 -C ₆ alkyl; _(d) C 1 -C _{6 alkyl,} C 1 -C ₆ alkoxy and Aminocarbonyl optionally substituted with one group selected from nitriles; (e) C ₂ -C ₇ alkanoyl optionally substituted with 1-3 halogens. In particular, (a) carboxy or (b) aminocarbonyl optionally substituted with one group selected from C ₁ -C ₆ alkyl, C ₁ -C ₆ alkoxy and nitrile is preferable, and carboxy is particularly preferable. .

Examples of the pharmacologically acceptable salt of the compound represented by formula (I) include alkali metal salts such as lithium, sodium and potassium; Group 2 metal salts such as calcium and magnesium; salts with zinc or aluminum; Salts with amines such as ammonia, choline, diethanolamine, lysine, ethylenediamine, t-butylamine, t-octylamine, tris (hydroxymethyl) aminomethane, N-methyl-glucosamine, triethanolamine, dehydroabiethylamine; hydrochloric acid, odor Salts with inorganic acids such as hydrofluoric acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid; or formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid , Tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, etc. Salts with acids; or aspartic acid, and salts with acidic amino acids glutamic acid and the like.
Furthermore, pharmacologically acceptable salts of the compounds represented by formula (I) include their inner salts, hydrates, and solvates.

  The term “prodrug” means a compound that is converted within the body, eg by hydrolysis in blood, into an active form having a pharmacological action. Examples of pharmacologically acceptable prodrugs can be found in the literature [T. Higuchi and V. Stella, Prodrugs as Novel Drug Delivery Systems, “Bioreversible Carriers in Drug Design”. Drug Design ", edited by Edward B. Roche, American Pharmaceutical Association and Pergamon Press, ACS Symposium Series, Volume 14, (1987); and D. Fleischer, R. Bonn and BH Stewart "Improved oral drug delivery: Solubility limitations overcome by the use of prodrugs", Advanced Drug Delivery Reviews (1996) 19 (2): 115-130. )]It is described in. Examples of prodrugs include esters such as methyl ester, ethyl ester and double ester when the compound represented by formula (I) is a carboxylic acid compound.

  The compounds of the present invention can optionally have one or more asymmetric carbon atoms contained in any one of the substituents. The compounds of formula (I) can also exist in the form of enantiomers or diastereomers or mixtures thereof. The compounds of the present invention include a mixture of stereoisomers or each pure or substantially pure isomer. If the compounds of formula (I) are obtained in diastereomeric or enantiomeric form, they can be separated by conventional methods well known in the art, for example chromatography or fractional crystallization.

In a preferred embodiment of the invention, R ¹ is 1-7 groups selected from (a) hydrogen; (b) C ₃ -C ₇ cycloalkyl, C ₁ -C ₆ alkoxy, halogen, oxo and hydroxy. optionally substituted _C 1 -C ₆ alkyl; _(c) C 1 -C _{6 alkyl,} C 1 -C ₆ alkoxy and optionally substituted with 1-7 groups selected from halogen _{C 3} - C ₇ cycloalkyl; _(d) C 3 -C _{7 cycloalkyl,} C 1 -C ₆ alkoxy, halogen and 1-7 amino which may be optionally _C 1 -C ₆ alkoxy optionally substituted with a group selected from hydroxy, ( e) C ₁ -C ₆ alkyl, C ₁ -C ₆ halogenoalkyl, C ₃ -C ₇ cycloalkyl, C ₃ -C ₇ halogenocycloalkyl, C ₁ -C ₆ alkoxy, C ₁ -C ₆ halogen Phenyl optionally substituted with 1-3 groups selected from noalkoxy and halogen; (f) halogen; or (g) nitrile,

R ^2a , R ^2b , R ^2c and R ^2d are each independently selected from (a) hydrogen; (b) C ₁ -C ₆ alkoxy, C ₃ -C ₇ cycloalkyl, halogen, oxo and hydroxy -7 amino optionally _C 1 -C ₆ alkyl optionally substituted with group; _(c) C 1 -C _{6 alkyl,} substituted with 1-7 groups selected from C 1 -C ₆ alkoxy and halogen C ₃ -C ₇ cycloalkyl which may be substituted; (d) C ₁ -C which may be substituted with ₁ to 7 groups selected from C ₁ -C ₆ alkoxy, C ₃ -C ₇ cycloalkyl and halogen ₆ alkoxy; _(e) C 1 -C _{6 alkyl,} C 1 -C _{6 halogenoalkyl,} C 3 -C _{7 cycloalkyl,} C 3 -C ₇ halogenocyclopropyl _alkyl, C 1 -C _{6 alkoxy,} C 1 -C ₆ 1-3 phenyl which may be substituted with a group selected from the Rogenoarukokishi and halogen; _(f) C 1 -C _{6 alkyl,} C 1 -C _{6 halogenoalkyl,} C 3 -C ₇ cycloalkyl, C ₃ -C ₇ halogenocyclopropyl _alkyl, C 1 -C _{6 alkoxy,} C 1 -C ₆ halogenoalkoxy and monocyclic aromatic of 1-3 5-6 membered optionally substituted with a group selected from a halogen group a heterocyclic group; _(g) C 1 -C _{6 alkyl,} C 1 -C _{6 halogenoalkyl,} C 3 -C _{7 cycloalkyl,} C 3 -C ₇ halogenocyclopropyl _alkyl, C 1 -C ₆ alkoxy, _{C 1} - C ₆ halogenoalkoxy and non-aromatic heterocyclic group monocyclic 1-3 4-7 membered optionally substituted by a group selected from halogen, (h) halogen; or (i) nitrile Yes,

R ^3a , R ^3b , R ^3c and R ^3d are each independently (a) hydrogen; (b) C ₃ -C ₇ cycloalkyl, C ₃ -C ₇ halogenocycloalkyl (the cycloalkyl and halogenocycloalkyl). Each independently may be substituted with 1-3 groups selected from C ₁ -C ₆ alkyl and C ₁ -C ₆ halogenoalkyl), C ₁ -C ₆ alkoxy, C ₁ -C ₆ Halogenoalkoxy, phenyl, 5-6 membered monocyclic aromatic heterocyclic group, 4-7 membered monocyclic nonaromatic heterocyclic group (the phenyl, aromatic heterocyclic group and nonaromatic heterocyclic ring) groups are each independently _C 1 -C _{6 alkyl,} C 1 -C _{6 halogenoalkyl,} C 3 -C _{7 cycloalkyl,} C 3 -C ₇ halogenocyclopropyl _alkyl, C 1 -C ₆ alkoxy, _{C 1} - ₆ halogenoalkoxy with alkoxy and 1-3 groups selected from halogen may be substituted), halogen, oxo and 1-7 pieces of good C ₁ -C ₆ alkyl optionally substituted by a group selected from hydroxy (C) substituted with 1-7 groups selected from C ₁ -C ₆ alkyl, C ₁ -C ₆ halogenoalkyl, C ₁ -C ₆ alkoxy, C ₁ -C ₆ halogenoalkoxy, halogen and hydroxy; C ₃ -C ₇ cycloalkyl; (d) C ₃ -C ₇ cycloalkyl, C ₃ -C ₇ halogenocycloalkyl (the cycloalkyl and halogenocycloalkyl are each independently C ₁ -C ₆ alkyl) And optionally substituted with 1-3 groups selected from C ₁ -C ₆ halogenoalkyl), C ₁ -C ₆ alkoxy, C ₁ -C ₆ halogenoalkoxy, phenyl, 5-6 membered monocyclic aromatic heterocyclic group, 4-7 membered monocyclic non-aromatic heterocyclic group (the phenyl, aromatic heterocyclic group and non-aromatic group) Group heterocyclic groups are each independently C ₁ -C ₆ alkyl, C ₁ -C ₆ halogenoalkyl, C ₃ -C ₇ cycloalkyl, C ₃ -C ₇ halogenocycloalkyl, C ₁ -C ₆ alkoxy, C _{1 1} -C ₆ halogenoalkoxy and may be substituted with 1-3 groups selected from halogen), 1-7 pieces are substituted with a group C ₁ optionally -C selected from halogen and hydroxy ₆ Alkoxy; (e) 1-7 groups selected from C ₁ -C ₆ alkyl, C ₁ -C ₆ halogenoalkyl, C ₁ -C ₆ alkoxy, C ₁ -C ₆ halogenoalkoxy, halogen and hydroxy In optionally substituted _C 3 -C ₇ cycloalkoxy; _(f) C 1 -C _{6 alkyl,} C 1 -C _{6 halogenoalkyl,} C 3 -C _{7 cycloalkyl,} C 3 -C ₇ halogenoalkyl cycloalkyl, Phenyl optionally substituted with 1-3 groups selected from C ₁ -C ₆ alkoxy, C ₁ -C ₆ halogenoalkoxy and halogen; (g) C ₁ -C ₆ alkyl, C ₁ -C ₆ halogeno _alkyl, C 3 -C _{7 cycloalkyl,} C 3 -C ₇ halogenocyclopropyl _alkyl, C 1 -C _{6 alkoxy,} optionally substituted with 1-3 groups selected from C 1 -C ₆ halogenoalkoxy and halogen monocyclic aromatic heterocyclic group having good 5-6 membered; _(h) C 1 -C _{6 alkyl,} C 1 -C _{6 halogenoalkyl,} C 3 -C _{7 cycloalkyl,} C 3 -C ₇ Rogge Bruno cycloalkyl alkyl, C ₁ -C ₆ alkoxy, C ₁ -C ₆ halogenoalkoxy and non-aromatic heterocyclic monocyclic 1-3 4-7 membered optionally substituted by a group selected from halogen ring group; _(i) C 1 -C _{6 alkyl,} C 1 -C _{6 halogenoalkyl,} C 3 -C _{7 cycloalkyl,} C 3 -C ₇ halogenocyclopropyl _alkyl, C 1 -C _{6 alkoxy,} C 1 -C ₆ Phenoxy optionally substituted with 1-3 groups selected from halogenoalkoxy and halogen; (j) halogen; or (k) hydroxy, or
Two substituents selected from R ^3a , R ^3b , R ^3c and R ^3d together form an oxo;

R ⁵ and R ⁶ are each independently (a) hydrogen; (b) C ₁ -C ₆ alkyl; (c) C ₁ -C ₆ halogenoalkyl; (d) C ₃ -C ₇ cycloalkyl; or (E) C ₃ -C ₇ halogenocycloalkyl, or R ⁵ and R ⁶ are bonded together at their ends to form a 3-7 membered alicyclic monocyclic hydrocarbon with adjacent carbon atoms And
X is, (a) carboxy; from _(d) C 1 -C _{6 alkyl,} C 1 -C ₆ alkoxy and nitriles; _(b) C 1 -C ₆ alkoxycarbonyl; (c) hydroxy _-C 1 -C ₆ alkyl Aminocarbonyl optionally substituted with one selected group; or (e) C ₂ -C ₇ alkanoyl optionally substituted with 1-3 halogen.

  In another preferred embodiment of the invention, ring A is quinoline, isoquinoline or pyrrolopyridine.

［式中、

は、（ａ）ピリジンとベンゼンが縮合した；または（ｂ）ピリジンと単環式の芳香族複素環が縮合した二環式の芳香族複素環であり（当該式中ＹおよびＺは、いずれか一方がＣＲ^２ｄであり、他方が化学結合である）、
他は、上記と同義である］で表される。この実施態様において、

は、好ましくは

［式中、記号は上記と同義である。］である。 In yet another preferred embodiment of the invention, the compounds of the invention have the following formula (IA):

[Where:

Is a bicyclic aromatic heterocyclic ring in which (a) pyridine and benzene are condensed; or (b) pyridine and a monocyclic aromatic heterocyclic ring are condensed (wherein Y and Z are either One is CR ^2d and the other is a chemical bond),
Others have the same meaning as above]. In this embodiment,

Is preferably

[Wherein the symbols are as defined above. ].

  In another embodiment of the present invention, preferably ring C is benzene and X is carboxy, wherein carboxy is in position 4 of the aminosulfonyl group in ring C.

［式中、記号は上記と同義である。］で表される。 In another preferred embodiment, the compounds of the invention have the following formula (IB):

[Wherein the symbols are as defined above. ].

［式中、記号は上記と同義である。］で表される。 In another embodiment of the present invention, preferably ring A, R ¹ , R ^2a , R ^2b , R ^2c and R ^2d have the formula

[Wherein the symbols are as defined above. ].

  In yet another embodiment of the invention, preferably ring B is (a) a monocyclic or bicyclic aromatic hydrocarbon; or (b) a monocyclic or bicyclic aromatic heterocycle , N is 0 or 1. More preferably, ring B is benzene, naphthalene, tetrahydronaphthalene, indane, pyridine, indole, dihydrobenzofuran, dihydroisobenzofuran, or benzothiophene, particularly preferably benzene, naphthalene (especially naphthalen-2-yl), Tetrahydronaphthalene (especially 1,2,3,4-tetrahydronaphthalen-6-yl), indan (especially indan-1-yl or indan-5-yl), pyridine (especially pyridin-2-yl) or benzothiophene (Especially benzothiophen-2-yl).

は、式（Ａ）：

［式中、記号は上記と同義である。］である。 In this embodiment, preferably the partial structure

Is the formula (A):

[Wherein the symbols are as defined above. ].

は、式（Ｂ）：

［式中、記号は上記と同義である。］である。 In another embodiment, preferably a partial structure

Is the formula (B):

[Wherein the symbols are as defined above. ].

In another embodiment of the present invention, preferably R ¹ is (a) C ₁ -C ₆ alkyl optionally substituted with 1-7 halogens; (b) C ₃ -C ₇ cycloalkyl; c) C ₁ -C ₆ alkoxy; or (d) halogen;
R ^2a , R ^2b and R ^2c are hydrogen,
R ^2d is (a) hydrogen; (b) C ₁ -C ₆ alkyl optionally substituted with 1-7 halogens; (c) C ₃ -C ₇ cycloalkyl; or (d) C ₁ -C ₆ alkoxy,
R ^3a and R ^3b are each independently (a) hydrogen; (b) C ₃ -C ₇ cycloalkyl, wherein the cycloalkyl is selected from C ₁ -C ₆ alkyl and C ₁ -C ₆ halogenoalkyl. 1-3 may be substituted with a _group), C 1 -C _{6 alkoxy,} C 1 -C ₆ halogenoalkoxy, and optionally _{C 1} optionally substituted with 1-7 groups selected from halogen -C ₆ alkyl; (c) C ₁ -C ₆ alkyl, C ₁ -C ₆ halogenoalkyl, and C ₃ -C ₇ cycloalkyl optionally substituted with 1-7 groups selected from halogen; _d) C 3 -C _{7 cycloalkyl,} C 1 -C _{6 alkoxy,} C 1 -C ₆ halogenoalkoxy, and 1-7 amino substituted with a group _C 1 -C ₆ optionally alcohol selected from halogen A or (e) halogen; Shi
R ^3c and R ^3d are hydrogen;
R ⁵ and R ⁶ are hydrogen,
n is 1.

は、式（Ｃ）：

［式中、ｐは１または２を意味し、その他の記号は上記と同義である。］であり、
Ｒ^１は（ａ）１−７個のハロゲンで置換されていても良いＣ_１−Ｃ_６アルキル；（ｂ）Ｃ_３−Ｃ_７シクロアルキル；（ｃ）Ｃ_１−Ｃ_６アルコキシ；または（ｄ）ハロゲンであり、
Ｒ^２ａ，Ｒ^２ｂおよびＲ^２ｃは水素であり、
Ｒ^２ｄは（ａ）水素；（ｂ）１−７個のハロゲンで置換されていてもよいＣ_１−Ｃ_６アルキル；（ｃ）Ｃ_３−Ｃ_７シクロアルキル；または（ｄ）Ｃ_１−Ｃ_６アルコキシであり、
Ｒ^３ａおよびＲ^３ｂは、それぞれ独立して、（ａ）水素；（ｂ）Ｃ_３−Ｃ_７シクロアルキル（当該シクロアルキルは、Ｃ_１−Ｃ_６アルキルおよびＣ_１−Ｃ_６ハロゲノアルキルから選ばれる１−３個の基で置換されていてもよい）、Ｃ_１−Ｃ_６アルコキシ、Ｃ_１−Ｃ_６ハロゲノアルコキシ、およびハロゲンから選ばれる１−７個の基で置換されていてもよいＣ_１−Ｃ_６アルキル；（ｃ）Ｃ_１−Ｃ_６アルキル、Ｃ_１−Ｃ_６ハロゲノアルキル、およびハロゲンから選ばれる１−７個の基で置換されていてもよいＣ_３−Ｃ_７シクロアルキル；（ｄ）Ｃ_３−Ｃ_７シクロアルキル、Ｃ_１−Ｃ_６アルコキシ、Ｃ_１−Ｃ_６ハロゲノアルコキシ、およびハロゲンから選ばれる１−７個の基で置換されていてもよいＣ_１−Ｃ_６アルコキシ；または（ｅ）ハロゲンである。 In another embodiment of the invention, preferably a partial structure

Is the formula (C):

[Wherein, p represents 1 or 2, and other symbols are as defined above. ],
R ¹ is (a) C ₁ -C ₆ alkyl optionally substituted with 1-7 halogens; (b) C ₃ -C ₇ cycloalkyl; (c) C ₁ -C ₆ alkoxy; or (d ) Halogen,
R ^2a , R ^2b and R ^2c are hydrogen,
R ^2d is (a) hydrogen; (b) C ₁ -C ₆ alkyl optionally substituted with 1-7 halogens; (c) C ₃ -C ₇ cycloalkyl; or (d) C ₁ -C ₆ alkoxy,
R ^3a and R ^3b are each independently (a) hydrogen; (b) C ₃ -C ₇ cycloalkyl, wherein the cycloalkyl is selected from C ₁ -C ₆ alkyl and C ₁ -C ₆ halogenoalkyl. 1-3 may be substituted with a _group), C 1 -C _{6 alkoxy,} C 1 -C ₆ halogenoalkoxy, and optionally _{C 1} optionally substituted with 1-7 groups selected from halogen -C ₆ alkyl; (c) C ₁ -C ₆ alkyl, C ₁ -C ₆ halogenoalkyl, and C ₃ -C ₇ cycloalkyl optionally substituted with 1-7 groups selected from halogen; _d) C 3 -C _{7 cycloalkyl,} C 1 -C _{6 alkoxy,} C 1 -C ₆ halogenoalkoxy, and 1-7 amino substituted with a group _C 1 -C ₆ optionally alcohol selected from halogen Shea; or (e) halogen.

は、以下の部分構造式（Ａ−Ｉ）：

［式中、記号は上記と同義である。］であり、
環Ｂはベンゼンまたはピリジン（とりわけ、ピリジン−２−イル）であり、
Ｒ^１はメチル、トリフルオロメチル、イソプロピル、シクロプロピル、またはメトキシであり、
Ｒ^２ｄは（ａ）水素；（ｂ）１−７個のハロゲンで置換されていてもよいＣ_１−Ｃ_６アルキル；（ｃ）Ｃ_３−Ｃ_７シクロアルキル；または（ｄ）Ｃ_１−Ｃ_６アルコキシであり、
Ｒ^３ａおよびＲ^３ｂは、それぞれ独立して（ａ）水素；（ｂ）Ｃ_３−Ｃ_７シクロアルキル（当該シクロアルキルは、Ｃ_１−Ｃ_６アルキルおよびＣ_１−Ｃ_６ハロゲノアルキルから選ばれる１−３個の基で置換されていてもよい）、Ｃ_１−Ｃ_６アルコキシ、Ｃ_１−Ｃ_６ハロゲノアルコキシ、およびハロゲンから選ばれる１−７個の基で置換されていてもよいＣ_１−Ｃ_６アルキル；（ｃ）Ｃ_３−Ｃ_７シクロアルキル；（ｄ）１−７個のハロゲンで置換されていてもよいＣ_１−Ｃ_６アルコキシ；または（ｅ）ハロゲンであり、
Ｒ^３ｃおよびＲ^３ｄは水素であり、
Ｒ^５およびＲ^６は水素であり、
ｎは１である。 In another embodiment of the invention, preferably the partial structural formula (A):

Is the following partial structural formula (AI):

[Wherein the symbols are as defined above. ],
Ring B is benzene or pyridine (especially pyridin-2-yl);
R ¹ is methyl, trifluoromethyl, isopropyl, cyclopropyl, or methoxy;
R ^2d is (a) hydrogen; (b) C ₁ -C ₆ alkyl optionally substituted with 1-7 halogens; (c) C ₃ -C ₇ cycloalkyl; or (d) C ₁ -C ₆ alkoxy,
R ^3a and R ^3b are each independently (a) hydrogen; (b) C ₃ -C ₇ cycloalkyl, wherein the cycloalkyl is selected from C ₁ -C ₆ alkyl and C ₁ -C ₆ halogenoalkyl may be substituted with -3 _groups), C 1 -C _{6 alkoxy,} C 1 -C ₆ halogenoalkoxy, and it may be substituted with 1-7 groups selected from halogen _{C 1} - C ₆ alkyl; (c) C ₃ -C ₇ cycloalkyl; (d) C ₁ -C ₆ alkoxy optionally substituted with 1-7 halogens; or (e) halogen.
R ^3c and R ^3d are hydrogen;
R ⁵ and R ⁶ are hydrogen,
n is 1.

は、以下の部分構造式（Ａ−ＩＩ）：

であり、
環Ｂはベンゼンまたはピリジン（とりわけ、ピリジン−２−イル）であり、
Ｒ^３ａおよびＲ^３ｂは、それぞれ独立して（ａ）水素；（ｂ）Ｃ_３−Ｃ_７シクロアルキル（当該シクロアルキルは、Ｃ_１−Ｃ_６アルキルおよびＣ_１−Ｃ_６ハロゲノアルキルから選ばれる１−３個の基で置換されていてもよい）、Ｃ_１−Ｃ_６アルコキシ、Ｃ_１−Ｃ_６ハロゲノアルコキシ、およびハロゲンから選ばれる１−７個の基で置換されていてもよいＣ_１−Ｃ_６アルキル；（ｃ）Ｃ_３−Ｃ_７シクロアルキル；（ｄ）１−７個のハロゲンで置換されていてもよいＣ_１−Ｃ_６アルコキシ；または（ｅ）ハロゲンであり、
Ｒ^３ｃおよびＲ^３ｄは水素であり、
Ｒ^５およびＲ^６は水素であり、
ｎは１である。 In this embodiment, preferably the partial structural formula (A):

Is the following partial structural formula (A-II):

And
Ring B is benzene or pyridine (especially pyridin-2-yl);
R ^3a and R ^3b are each independently (a) hydrogen; (b) C ₃ -C ₇ cycloalkyl, wherein the cycloalkyl is selected from C ₁ -C ₆ alkyl and C ₁ -C ₆ halogenoalkyl may be substituted with -3 _groups), C 1 -C _{6 alkoxy,} C 1 -C ₆ halogenoalkoxy, and it may be substituted with 1-7 groups selected from halogen _{C 1} - C ₆ alkyl; (c) C ₃ -C ₇ cycloalkyl; (d) C ₁ -C ₆ alkoxy optionally substituted with 1-7 halogens; or (e) halogen.
R ^3c and R ^3d are hydrogen;
R ⁵ and R ⁶ are hydrogen,
n is 1.

は、以下の部分構造式（Ａ−ＩＩＩ）：

であり、
環Ｂはベンゼンであり、
Ｒ^３ａおよびＲ^３ｂは、それぞれ独立して（ａ）水素；（ｂ）Ｃ_３−Ｃ_７シクロアルキル（当該シクロアルキルは、Ｃ_１−Ｃ_６アルキルおよびＣ_１−Ｃ_６ハロゲノアルキルから選ばれる１−３個の基で置換されていてもよい）、Ｃ_１−Ｃ_６アルコキシ、Ｃ_１−Ｃ_６ハロゲノアルコキシ、およびハロゲンから選ばれる１−７個の基で置換されていてもよいＣ_１−Ｃ_６アルキル；（ｃ）Ｃ_３−Ｃ_７シクロアルキル；（ｄ）１−７個のハロゲンで置換されていてもよいＣ_１−Ｃ_６アルコキシ；または（ｅ）ハロゲンであり、
Ｒ^３ｃおよびＲ^３ｄは水素であり、
Ｒ^５およびＲ^６は水素であり、
ｎは１である。 In this embodiment, more preferably, R ^3a and R ^3b are each independently substituted with 1-7 groups selected from (a) hydrogen; (b) C ₃ -C ₇ cycloalkyl and halogen. Optionally C ₁ -C ₆ alkyl; (c) C ₁ -C ₆ alkoxy optionally substituted with 1-7 halogens; or (d) halogen.
In another embodiment of the invention, preferably the partial structural formula (A):

Is the following partial structural formula (A-III):

And
Ring B is benzene,
R ^3a and R ^3b are each independently (a) hydrogen; (b) C ₃ -C ₇ cycloalkyl, wherein the cycloalkyl is selected from C ₁ -C ₆ alkyl and C ₁ -C ₆ halogenoalkyl may be substituted with -3 _groups), C 1 -C _{6 alkoxy,} C 1 -C ₆ halogenoalkoxy, and it may be substituted with 1-7 groups selected from halogen _{C 1} - C ₆ alkyl; (c) C ₃ -C ₇ cycloalkyl; (d) C ₁ -C ₆ alkoxy optionally substituted with 1-7 halogens; or (e) halogen.
R ^3c and R ^3d are hydrogen;
R ⁵ and R ⁶ are hydrogen,
n is 1.

In this embodiment, more preferably, R ^3a and R ^3b are each independently substituted with 1-7 groups selected from (a) hydrogen; (b) C ₃ -C ₇ cycloalkyl and halogen. Optionally C ₁ -C ₆ alkyl; (c) C ₁ -C ₆ alkoxy optionally substituted with 1-7 halogens; or (d) halogen.

は、以下の部分構造式（Ａ−ＩＶ）：

［式中、Ｍｅはメチルであり、他の記号は上記と同義である］であり、
環Ｂはベンゼンであり、
Ｒ^２ｄは（ａ）水素；（ｂ）１−７個のハロゲンで置換されていてもよいＣ_１−Ｃ_６アルキル；または（ｃ）Ｃ_３−Ｃ_７シクロアルキルであり、
Ｒ^３ａおよびＲ^３ｂは、それぞれ独立して（ａ）水素；（ｂ）Ｃ_３−Ｃ_７シクロアルキル（当該シクロアルキルは、Ｃ_１−Ｃ_６アルキルおよびＣ_１−Ｃ_６ハロゲノアルキルから選ばれる１−３個の基で置換されていてもよい）、Ｃ_１−Ｃ_６アルコキシ、Ｃ_１−Ｃ_６ハロゲノアルコキシ、およびハロゲンから選ばれる１−７個の基で置換されていてもよいＣ_１−Ｃ_６アルキル；（ｃ）Ｃ_３−Ｃ_７シクロアルキル；（ｄ）１−７個のハロゲンで置換されていてもよいＣ_１−Ｃ_６アルコキシ；または（ｅ）ハロゲンであり、
Ｒ^３ｃおよびＲ^３ｄは水素であり、
Ｒ^５およびＲ^６は水素であり、
ｎは１である。 In another embodiment of the invention, preferably the partial structural formula (A):

Is the following partial structural formula (A-IV):

[Wherein Me is methyl, and other symbols are as defined above],
Ring B is benzene,
R ^2d is (a) hydrogen; (b) C ₁ -C ₆ alkyl optionally substituted with 1-7 halogens; or (c) C ₃ -C ₇ cycloalkyl;
R ^3a and R ^3b are each independently (a) hydrogen; (b) C ₃ -C ₇ cycloalkyl, wherein the cycloalkyl is selected from C ₁ -C ₆ alkyl and C ₁ -C ₆ halogenoalkyl may be substituted with -3 _groups), C 1 -C _{6 alkoxy,} C 1 -C ₆ halogenoalkoxy, and it may be substituted with 1-7 groups selected from halogen _{C 1} - C ₆ alkyl; (c) C ₃ -C ₇ cycloalkyl; (d) C ₁ -C ₆ alkoxy optionally substituted with 1-7 halogens; or (e) halogen.
R ^3c and R ^3d are hydrogen;
R ⁵ and R ⁶ are hydrogen,
n is 1.

In this embodiment, more preferably R ^2d is hydrogen, isopropyl or cyclopropyl;
R ^3a and R ^3b are each independently (a) hydrogen; (b) C ₁ -C ₆ alkyl optionally substituted with 1-7 groups selected from C ₃ -C ₇ cycloalkyl and halogen. (C) C ₁ -C ₆ alkoxy optionally substituted with 1-7 halogens; or (d) halogen.

は、以下の部分構造式（Ａ−Ｖ）：

［式中、記号は上記と同義である。］であり、
環Ｂはベンゼンであり、
Ｒ^１はイソプロピルまたはメトキシであり、
Ｒ^３ａおよびＲ^３ｂは、それぞれ独立して（ａ）水素；（ｂ）Ｃ_３−Ｃ_７シクロアルキル（当該シクロアルキルは、Ｃ_１−Ｃ_６アルキルおよびＣ_１−Ｃ_６ハロゲノアルキルから選ばれる１−３個の基で置換されていてもよい）、Ｃ_１−Ｃ_６アルコキシ、Ｃ_１−Ｃ_６ハロゲノアルコキシ、およびハロゲンから選ばれる１−７個の基で置換されていてもよいＣ_１−Ｃ_６アルキル；（ｃ）Ｃ_３−Ｃ_７シクロアルキル；（ｄ）１−７個のハロゲンで置換されていてもよいＣ_１−Ｃ_６アルコキシ；または（ｅ）ハロゲンであり、
Ｒ^３ｃおよびＲ^３ｄは水素であり、
Ｒ^５およびＲ^６は水素であり、
ｎは１である。 In another embodiment of the invention, preferably the partial structural formula (A):

Is the following partial structural formula (A-V):

[Wherein the symbols are as defined above. ],
Ring B is benzene,
R ¹ is isopropyl or methoxy;
R ^3a and R ^3b are each independently (a) hydrogen; (b) C ₃ -C ₇ cycloalkyl, wherein the cycloalkyl is selected from C ₁ -C ₆ alkyl and C ₁ -C ₆ halogenoalkyl may be substituted with -3 _groups), C 1 -C _{6 alkoxy,} C 1 -C ₆ halogenoalkoxy, and it may be substituted with 1-7 groups selected from halogen _{C 1} - C ₆ alkyl; (c) C ₃ -C ₇ cycloalkyl; (d) C ₁ -C ₆ alkoxy optionally substituted with 1-7 halogens; or (e) halogen.
R ^3c and R ^3d are hydrogen;
R ⁵ and R ⁶ are hydrogen,
n is 1.

は、式（Ｄ）：

［式中、記号は上記と同義である。］であり、
Ｒ^３ａおよびＲ^３ｂは、それぞれ独立して（ａ）水素；（ｂ）Ｃ_３−Ｃ_７シクロアルキルおよびハロゲンから選ばれる１−７個の基で置換されていてもよいＣ_１−Ｃ_６アルキル；（ｃ）１−７個のハロゲンで置換されていてもよいＣ_１−Ｃ_６アルコキシ；または（ｄ）ハロゲンである。 In this embodiment, more preferably, R ^3a and R ^3b are each independently substituted with 1-7 groups selected from (a) hydrogen; (b) C ₃ -C ₇ cycloalkyl and halogen. Optionally C ₁ -C ₆ alkyl; (c) C ₁ -C ₆ alkoxy optionally substituted with 1-7 halogens; or (d) halogen.
In another embodiment of the invention, preferably the partial structural formula:

Is the formula (D):

[Wherein the symbols are as defined above. ],
R ^3a and R ^3b are each independently (a) hydrogen; (b) C ₁ -C ₆ alkyl optionally substituted with 1-7 groups selected from C ₃ -C ₇ cycloalkyl and halogen. (C) C ₁ -C ₆ alkoxy optionally substituted with 1-7 halogens; or (d) halogen.

The active ingredients of the present invention are preferably in the following groups:
4-({(4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-{[[3-Fluoro-4- (trifluoromethoxy) benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-({(1-cyclopropyl-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-{[[4- (1-Ethoxy-2,2,2-trifluoro-1-methylethyl) benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-({(3-methylquinolin-2-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-{[[4-Fluoro-3- (trifluoromethyl) benzyl] (3-methylquinolin-2-yl) amino] sulfonyl} benzoic acid;
4-{[(4-t-butylbenzyl) (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[[[4- (Cyclopropylmethyl) benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[[4-Fluoro-3- (trifluoromethyl) benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[(4-methylisoquinolin-3-yl) (2-naphthylmethyl) amino] sulfonyl} benzoic acid;
4-({(1-methoxy-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-({(4-chloroisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-{[(4-Methylisoquinolin-3-yl) (5,6,7,8-tetrahydronaphthalen-2-ylmethyl) amino] sulfonyl} benzoic acid;
4-{[(2,3-dihydro-1H-inden-5-ylmethyl) (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[[(1,1-dimethyl-2,3-dihydro-1H-inden-5-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[[(2,2-dimethyl-2,3-dihydro-1H-inden-5-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[[(3,3-dimethyl-2,3-dihydro-1-benzofuran-6-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[[[(1-benzothiophen-2-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-({(1,4-dimethylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid; and 4-({(4-methylisoquinolin-3-yl) [4 -(2,2,2-trifluoro-1-methoxy-1-methylethyl) benzyl] amino} sulfonyl) benzoic acid; or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

Other preferred active ingredients of the present invention include the following groups:
4-({(1-cyclopropyl-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-({(1-methoxy-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-({(1-Isopropyl-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-{[{3-chloro-4- [cyclopropyl (difluoro) methyl] benzyl} (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-({(4-cyclopropylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-{[{3-chloro-4- [cyclopropyl (difluoro) methyl] benzyl} (1-cyclopropyl-4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[{4- [cyclopropyl (difluoro) methyl] -3-fluorobenzyl} (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-({[4- (trifluoromethoxy) benzyl] [4- (trifluoromethyl) isoquinolin-3-yl] amino} sulfonyl) benzoic acid;
4-[((4-cyclopropylisoquinolin-3-yl) {[5- (trifluoromethyl) pyridin-2-yl] methyl} amino) sulfonyl] benzoic acid;
4-{[{3-chloro-4- [cyclopropyl (difluoro) methyl] benzyl} (4-cyclopropylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[{4- [cyclopropyl (difluoro) methyl] -3-fluorobenzyl} (4-cyclopropylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-({(4-cyclopropylisoquinolin-3-yl) [5- (trifluoromethoxy) -2,3-dihydro-1H-inden-1-yl] amino} sulfonyl) benzoic acid;
4-({{3-chloro-4- [cyclopropyl (difluoro) methyl] benzyl} [4- (trifluoromethyl) isoquinolin-3-yl] amino} sulfonyl) benzoic acid; and 4-({{4- [Cyclopropyl (difluoro) methyl] -3-fluorobenzyl} [4- (trifluoromethyl) isoquinolin-3-yl] amino} sulfonyl) benzoic acid; or a pharmaceutically acceptable salt thereof, or a prodrug thereof Chosen from.

  The active ingredient of the present invention has a novel structure in which a bicyclic aromatic heterocyclic ring in which pyridine and benzene are condensed or pyridine and a monocyclic aromatic heterocyclic ring are condensed is bonded to a sulfonylamino group. It shows an excellent TRPM8 blocking effect in the induced calcium influx suppression test. In addition, the active ingredient of the present invention exhibits an excellent inhibitory effect on, for example, wet dog shakes induced by TRPM8 agonists (eg, menthol and icilin) in rats.

For this reason, the pharmaceutical composition of the present invention comprises:
(A) Chronic pain: for example, neuropathic pain (eg cold allodynia, diabetic neuropathy, postherpetic neuralgia, complex regional pain syndrome, peripheral neuropathy due to chemotherapy, trigeminal neuralgia, poststroke pain, spinal cord injury pain , Neuralgia, or neuropathic pain due to nerve damage), nociceptive pain (eg, rheumatoid arthritis, osteoarthritis, postoperative pain, or myofascial pain), or mixed pain (eg, cancer pain, fibrosis) Myalgia syndrome or chronic low back pain);
(B) Headache: for example, migraine or cluster or tension headache;
(C) Urological diseases: for example, detrusor overactivity, overactive bladder, urinary incontinence, neurogenic bladder, detrusor hyperreflexia, idiopathic detrusor overactivity, detrusor instability, interstitial cystitis, prostatic hypertrophy Disease, chronic prostatitis, or lower urinary tract symptoms;
(D) Cancer diseases: for example, prostate cancer or breast cancer;
(E) respiratory disease: for example, asthma, COPD (chronic obstructive pulmonary disease), or pulmonary hypertension;
(F) Gastrointestinal disease: for example, irritable bowel syndrome;
(G) Psychiatric disorders: for example, mood disorders (eg depression or bipolar disorder) or anxiety disorders (eg anxiety);
(H) neurological diseases: for example, neurodegenerative diseases, or stroke; or (i) skin diseases: useful for, for example, prevention or treatment of pruritus. The pharmaceutical composition of the present invention is preferably useful for the prevention or treatment of chronic pain or urological diseases, especially chronic pain.

  The active ingredient of the present invention can be administered orally or parenterally and can be used in the form of a suitable pharmaceutical preparation. Examples of pharmaceutical preparations suitable for oral administration include solid preparations such as tablets, granules, capsules and powders, or solution preparations, suspension preparations and emulsion preparations. Pharmaceutical preparations suitable for parenteral administration include, for example, suppositories; injections and intravenous drops using distilled water for injection, physiological saline or aqueous glucose; and inhalation preparations.

  The pharmaceutical composition of the present specification contains about 0.01 mg / kg to about 100 mg / kg of the active ingredient per dose unit, for example, tablet, capsule, powder, injection, suppository, cup of teacup, etc. About 0.01 mg / kg to about 50 mg / kg, more preferably about 0.01 mg / kg to about 30 mg / kg), about 0.01 mg / kg / day to about 100 mg / kg / day (preferably about 0.01 mg / kg / day to about 50 mg / kg / day, more preferably about 0.01 mg / kg / day to about 30 mg / kg / day). The method of treating a disease described in the present invention is also carried out using a pharmaceutical composition comprising any of the active ingredients defined herein and a pharmaceutically acceptable carrier. The dosage form contains about 0.01 mg / kg to about 100 mg / kg (preferably about 0.01 mg / kg to about 50 mg / kg, more preferably about 0.01 mg / kg to about 30 mg / kg) of the active ingredient. And can be constructed in any form suitable for the selected mode of administration. However, the dosage will depend on the route of administration, the requirements of the subject, the severity of the condition being treated and the active ingredient used. Either daily administration or post-cycle administration can be used.

Although the compound (I) of this invention can be manufactured by the method of the following scheme 1, 2, or 3, the manufacturing method of compound (I) is not limited to these.
During any manufacturing process of the compounds of the invention, it is required and / or desirable to protect sensitive or reactive groups in the molecules involved. This can be achieved using conventional protecting groups. For a general description of protecting groups and their use, see TWGreene et al., “Protecting Groups in Organic Synthesis”, John Wiley & Sons, New York, 2006. The protecting groups can be removed in subsequent steps using methods conventional to those skilled in the art.

（上記のスキームにおいて、ＬＧは、脱離基を意味し、例えば、塩素、臭素等のハロゲン、ｐ−トルエンスルホニルオキシ、メタンスルホニルオキシおよびトリフルオロメチルスルホニルオキシ等の置換スルホニルオキシが挙げられ、
その他の記号は、上記と同様である）
化合物（ＩＶ）を化合物（Ｖ）と反応させることにより、化合物（ＩＩ）を得ることができる。得られた化合物を化合物（ＩＩＩ）と反応させることにより、化合物（Ｉ）を得ることができる。 Scheme 1:

(In the above scheme, LG means a leaving group, and examples thereof include halogen such as chlorine and bromine, substituted sulfonyloxy such as p-toluenesulfonyloxy, methanesulfonyloxy and trifluoromethylsulfonyloxy,
Other symbols are the same as above)
Compound (II) can be obtained by reacting compound (IV) with compound (V). Compound (I) can be obtained by reacting the obtained compound with compound (III).

Step 1:
Compound (II) can be produced by condensing compound (IV) and compound (V) in a solvent in the presence of a base.

  As the solvent used for the condensation, any solvent can be suitably used as long as it does not affect the reaction. Examples of the solvent include ethers such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane; Hydrocarbons such as toluene, hexane, xylene; halogenohydrocarbons such as dichloromethane, chloroform, 1,2-dichloroethane; esters such as ethyl acetate and butyl acetate; ketones such as acetone and butanone; N, N-dimethylformamide, N, Examples include amides such as N-dimethylacetamide, 1,3-dimethyl-2-imidazolidinone and N-methylpyrrolidone; sulfoxides such as dimethyl sulfoxide. The following amines can also be used as a solvent. These solvents can be used alone or in combination. A preferable solvent in this reaction is an amine such as pyridine; or a halogeno hydrocarbon such as chloroform.

As the base, a conventional base can be used. Examples of the base include, for example, alkali metal amides such as lithium diisopropylamide, sodium amide, lithium bistrimethylsilylamide; sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate Alkali metal phosphates such as sodium phosphate and potassium phosphate; amines such as triethylamine, diisopropylethylamine, pyridine and N-methylmorpholine, and preferably amines such as pyridine.
The reaction can be performed at low temperature, room temperature, or high temperature, for example, 0 ° C to 120 ° C.
In the condensation reaction, when a sulfonimide compound obtained by condensing 2 equivalents of compound (V) with 1 equivalent of compound (IV) is obtained, the sulfonimide compound is treated with tetrabutylammonium fluoride. The corresponding compound (II) can be obtained.

Step 2:
Compound (I) can be produced by condensing compound (II) and compound (III) in a solvent in the presence of a base.
As the solvent used for the condensation, any solvent can be suitably used as long as it does not affect the reaction. Examples of the solvent include ethers such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane; Hydrocarbons such as toluene, hexane, xylene; esters such as ethyl acetate and butyl acetate; ketones such as acetone and butanone; N, N-dimethylformamide, N, N-dimethylacetamide, 1,3-dimethyl-2-imidazolide Non- and amides such as N-methylpyrrolidone; sulfoxides such as dimethyl sulfoxide, and the following amines can also be used as a solvent. These solvents can be used alone or in combination. A preferred solvent in this reaction is an amide such as N, N-dimethylformamide.

As the base, a conventional base can be used. Examples of the base include, for example, alkali metal amides such as lithium diisopropylamide, sodium amide, lithium bistrimethylsilylamide; sodium carbonate, potassium carbonate, cesium carbonate, sodium hydrogen carbonate, Examples include alkali metal carbonates such as potassium hydrogen carbonate; alkali metal phosphates such as sodium phosphate and potassium phosphate; amines such as triethylamine, diisopropylethylamine, pyridine, and N-methylmorpholine, and preferably alkali carbonates such as potassium carbonate. It is a metal.
The reaction can be carried out at low temperature, room temperature or high temperature, for example at -20 ° C to 80 ° C.

（上記のスキームにおいて、記号は、上記と同様である） Scheme 2:

(In the above scheme, the symbols are the same as above)

Compound (II) can be obtained by reacting compound (IV) with compound (V). Compound (I) can be obtained by reacting the obtained compound with compound (VI).
Step 1:
Compound (II) can be produced according to the method described in Scheme 1, Step 1.

Step 2:
Compound (I) can be produced by subjecting compound (II) and compound (VI) to Mitsunobu reaction in a solvent.
The Mitsunobu reaction can be carried out in a suitable solvent in the presence of a phosphine and an azodicarboxylic acid compound.

  Examples of phosphines are triphenylphosphine, diphenyl (2-pyridyl) phosphine, (4-dimethylaminophenyl) diphenylphosphine, isopropyldiphenylphosphine, diethylphenylphosphine, dicyclohexylphenylphosphine, tributylphosphine, trit-butylphosphine, tricyclohexyl. A phosphine is mentioned. Examples of the azodicarboxylic acid compound include diethyl azodicarboxylate, diisopropyl azodicarboxylate, dibutyl azodicarboxylate, azodicarbonyldipiperazine, and tetramethylazodicarboxamide. Alternatively, the reaction can be carried out in the presence of cyanomethylene tributylphosphorane instead of the phosphine and azodicarboxylic acid compound.

  Any solvent can be suitably used as long as it does not affect the reaction. Examples of the solvent include ethers such as tetrahydrofuran, 1,4-dioxane and 1,2-dimethoxyethane; toluene, hexane Hydrocarbons such as xylene; esters such as ethyl acetate and butyl acetate; ketones such as acetone and butanone; N, N-dimethylformamide, N, N-dimethylacetamide, 1,3-dimethyl-2-imidazolidinone and N -Amides such as methyl pyrrolidone; and sulfoxides such as dimethyl sulfoxide. These solvents can be used alone or in combination. A preferred solvent in this reaction is an ether such as tetrahydrofuran.

  The reaction can be carried out at low temperature, room temperature or high temperature, for example at -20 ° C to 80 ° C.

（上記のスキームにおいて、記号は、上記と同様である） Scheme 3:

(In the above scheme, the symbols are the same as above)

Compound (VII) can be obtained by reacting compound (VIII) with compound (IX). Compound (I) can be obtained by reacting the obtained compound with compound (V).
Step 1:
Compound (VII) can be produced by condensing compound (VIII) and compound (IX) in the presence of a base in a solvent or without a solvent.

  As the solvent used for the condensation, any solvent can be suitably used as long as it does not affect the reaction. Examples of the solvent include ethers such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane; Hydrocarbons such as toluene, hexane, xylene; esters such as ethyl acetate and butyl acetate; ketones such as acetone and butanone; N, N-dimethylformamide, N, N-dimethylacetamide, 1,3-dimethyl-2-imidazolide Non- and amides such as N-methylpyrrolidone; and sulfoxides such as dimethyl sulfoxide. These solvents can be used alone or in combination. In this reaction, no solvent is preferable.

  As the base, a conventional base can be used. Examples of the base include, for example, alkali metal amides such as lithium diisopropylamide, sodium amide, lithium bistrimethylsilylamide; sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate And alkali metals such as sodium phosphate and potassium phosphate; and amines such as triethylamine, diisopropylethylamine, pyridine and N-methylmorpholine. An excess amount of compound (IX) can also be used as a base. A preferred base in this reaction is an excess amount of compound (IX).

  The reaction can be performed at a high temperature, for example, 100 ° C. to 250 ° C., and can be preferably performed by microwave irradiation.

Step 2:
Compound (I) can be produced according to the method described in Scheme 1, Step 1.

Further, the compound (I) produced by the above production method or the intermediate compound obtained during the production of the compound (I) may be subjected to interconversion by a conventional method.
Compound (I) in which ring B is indole and its intermediate compound can be produced by oxidizing compound (I) and its intermediate compound in which corresponding ring B is indoline, respectively.
The oxidation reaction can be performed in a suitable solvent in the presence of an oxidizing agent.

  Examples of the oxidizing agent include 2,3-dichloro-5,6-dicyano-p-benzoquinone. The solvent can be selected from any that does not interfere with the reaction. Examples of the solvent include aromatic hydrocarbons such as toluene and xylene; tetrahydrofuran, 1,2-dimethoxyethane and 1,4-dioxane. Ethers; halogenohydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane. These solvents can be used alone or in combination.

Compound (I) and its intermediate compound (hereinafter referred to as the substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d ) Each of the corresponding substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is halogen (especially Compound (I) which is bromine, iodine) and an intermediate compound thereof (hereinafter also referred to as a halogen-containing compound) are converted to Ar ¹ B (OH) ₂ or a cyclic borate ester thereof, Ar ¹ BF ₃ K or Ar ¹ Sn. (n-Bu) 3 prepared by _(wherein, Ar ¹ denotes phenyl which may be substituted, n-Bu is that meaning butyl) is such coupling Rukoto can.

  The coupling reaction is a conventional aryl coupling reaction, such as the Suzuki coupling method (for reference, Suzuki et al., Synth. Commun. 11: 513 (1981); Suzuki, Pure and Appl. Chem. 57: 1749 -1758 (1985); Suzuki et al., Chem. Rev. 95: 2457-2483 (1995); Shieh et al., J. Org. Chem. 57: 379-381 (1992); Martin et al., Acta Chemica Scand inavica 47: 221-230 (1993); Wallace et al., Tetrahedron Lett. 43: 6987-6990 (2002) and Molander et al., J. Org. Chem. 68: 4302-4314 (2003)) And Stille coupling methods (for reference, Still, Angew. Chem. Int. Ed. Engl. 25: 508-524 (1986) and Liebeskind et al., J. Org. Chem. 59: 5905-5911 (1994)).

  The coupling reaction can be carried out in the presence of a palladium catalyst in a suitable solvent with or without ligand, base and additives.

  Examples of palladium catalysts are tetrakis (triphenylphosphine) palladium (0), palladium (II) acetate, bis (acetonitrile) dichloropalladium (II), dichlorobis (triphenylphosphine) palladium (II), [1,1′- Bis (diphenylphosphino) ferrocene] dichloropalladium (II) with dichloromethane, tris (dibenzylidene-acetone) dipalladium (0) -chloroform adduct and palladium (II) chloride. Examples of bases include, for example, alkali metal carbonates such as cesium carbonate, potassium carbonate, sodium carbonate and sodium bicarbonate; alkali metal phosphates such as tribasic potassium phosphate, sodium phosphate and sodium hydrogen phosphate; N , N-diisopropylethylamine and the like; alkali metal fluorides such as cesium fluoride and potassium fluoride; and alkali metal alkoxides such as sodium t-butoxide and potassium t-butoxide. Examples of ligands include triphenylphosphine, tributylphosphine, tri-t-butylphosphonium tetrafluoroborate, 1,3-bis (diphenylphosphino) propane, 2,2′-bis (diphenylphosphino) -1,1 ′. -Binaphthyl, 1,1'-bis (diphenylphosphino) ferrocene, 2- (di-tert-butylphosphino) biphenyl, 2-dicyclohexylphosphino-2 '-(N, N-dimethylamino) biphenyl, 2- (Dicyclohexylphosphino) biphenyl, di (1-adamantyl) butylphosphine. Examples of the additive include copper (I) iodide.

  The solvent can be selected from any that does not interfere with the coupling reaction, and examples of solvents include, for example, aromatic hydrocarbons such as toluene and xylene; tetrahydrofuran, 1,2-dimethoxyethane and 1,4-dioxane. Ethers such as N, N-dimethylformamide, N, N-dimethylacetamide, amides such as 1,3-dimethyl-2-imidazolidinone and N-methylpyrrolidone; alcohols such as methanol, ethanol and 2-propanol; water Is mentioned. These solvents can be used alone or in combination.

  The coupling reaction can be performed at room temperature or high temperature, for example, 20 ° C to 150 ° C.

The substituent R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d may be substituted monocyclic aromatic heterocyclic group or may be substituted monocyclic The compound (I), which is a non-aromatic heterocyclic group of the formula, and an intermediate compound thereof have the corresponding substituents R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d , respectively. Compound (I), which is a halogen (especially bromine, iodine) and its intermediate compound, are converted to Ar ² B (OH) ₂ , Ar ² BF ₃ K or Ar ² Sn (n-Bu) ₃ (wherein Ar ² is A monocyclic aromatic heterocyclic group which may be substituted or a monocyclic non-aromatic heterocyclic group which may be substituted; n-Bu is as defined above) Can be manufactured by That.
This reaction can be carried out according to the above-described coupling reaction method for producing a compound having phenyl which may be substituted from a compound having halogen.

The substituent R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d may be a monocyclic non-aromatic heterocyclic ring which may be substituted and contains a nitrogen atom A compound (I) and an intermediate compound thereof, which are bonded to ring A or ring B at the nitrogen atom, are represented by corresponding substituents R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , respectively. Compound (I) wherein R ^3b , R ^3c or R ^3d is halogen (especially bromine or iodine) and its intermediate compound are converted to a corresponding monocyclic non-aromatic heterocyclic group in which the nitrogen atom is replaced with hydrogen. It can be manufactured by coupling.
This reaction can be carried out by a conventional amination method, for example, the Buchwald-Hartwig amination method (for reference, Yang, BH; Buchwald, SLJ Organomet. Chem. 576 (1999) 125-146.).
Specifically, it can be carried out according to the above coupling reaction method for producing a compound having phenyl which may be substituted from a compound having halogen.

The compound (I) in which the substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d are optionally substituted alkyls and intermediate compounds thereof are respectively Corresponding substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d are halogen (especially bromine, iodine) and intermediate compounds thereof It can be produced by alkylation.
In the alkylation reaction, the substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is halogen in a suitable solvent (eg, ether such as tetrahydrofuran). Compound (I) or an intermediate compound thereof can be treated by sequential treatment with alkyllithium (for example, butyllithium) and then corresponding halogenoalkyl (for example, iodoalkyl).

The compound (I) in which the substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is methyl and the intermediate compound thereof are each represented by the corresponding substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is halogen (especially bromine, iodine) and its intermediate compound is methylboric acid or its cyclic It can be prepared by coupling with boric acid ester, trimethylboroxine or methyl trifluoroborate potassium salt.
This reaction can be carried out according to the above-described coupling reaction method for producing a compound having phenyl which may be substituted from a compound having halogen.

Compound (I) wherein the substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d are optionally substituted C ₂ -C ₆ alkyl and intermediates thereof Compound is a compound (I) in which the corresponding substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is halogen (especially bromine, iodine) The intermediate compound is coupled with R ⁷ B (OH) ₂ or R ⁷ BF ₃ K, where R ⁷ means an optionally substituted C ₂ -C ₆ alkenyl and is substituted It may be produced by obtaining an alkenyl compound which may be present and hydrogenating it.
The reaction for producing an optionally substituted alkenyl compound can be carried out according to the above coupling reaction method for producing a compound having optionally substituted phenyl from a compound having halogen.
The hydrogenation reaction of the alkenyl compound which may be substituted can be performed in a suitable solvent in the presence of a catalyst in a hydrogen stream.
Examples of catalysts include palladium on carbon, palladium hydroxide, and platinum oxide.
The solvent can be selected from any solvent that does not interfere with the reaction. Examples of the solvent include ethers such as tetrahydrofuran, 1,2-dimethoxyethane and 1,4-dioxane; methanol, ethanol, 2-propanol and the like. Alcohols; esters such as ethyl acetate; carboxylic acids such as acetic acid. These solvents can be used alone or in combination.
The reaction can be carried out at room temperature or elevated temperature, for example 20 ° C to 80 ° C.

The compound (I) in which the substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d are cyclopropylmethyl and the intermediate compound thereof have corresponding substituents. R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is a halogen (especially bromine, iodine) and a compound (I) and its intermediate compound are coupled with allyltributyltin It can be produced by ringing and cyclopropylating the resulting allyl double bond.
The allyl compound production reaction can be performed according to the above-described coupling reaction method for producing an optionally substituted phenyl-containing compound from a halogen-containing compound.
The cyclopropylation reaction can be performed in the presence of dihalogenomethane and diethylzinc in a suitable solvent.
Examples of dihalogenomethane include chloroiodomethane and diiodomethane.
The solvent can be selected from any that does not interfere with the cyclopropylation reaction, and examples of the solvent include halogeno hydrocarbons such as dichloromethane, chloroform, and 1,2-dichloroethane. These solvents can be used alone or in combination.
The reaction can be carried out at room temperature or elevated temperature, for example 20 ° C to 80 ° C.

The compound (I) in which the substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is alkyl substituted with oxo and its intermediate compound correspond respectively Wherein the substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d are alkyls with the same carbon atom substituted with hydroxy and oxo, and The intermediate compound is N-methoxy-N-methylamidated, and the resulting amide is converted to R ⁸ Li or R ⁸ MgLG ¹ (wherein R ⁸ is a corresponding optionally substituted alkyl or a corresponding substituted means which may cycloalkyl, LG ¹ may be prepared by alkylating or cycloalkyl alkylated represents a halogen).
The N-methoxy-N-methylamidation reaction is carried out in a suitable solvent (eg, a halogeno hydrocarbon such as dichloromethane, chloroform or dichloroethane) in the presence or absence of N-hydroxybenzotriazole (eg, N, O -Dimethylhydroxyamine or N, O-dimethylhydroxyamine / hydrochloride), condensing agents (for example, carbodiimide such as 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide / hydrochloride) and bases (for example, triethylamine, etc.) In the presence of an amine).
The alkylation reaction or cycloalkylation reaction can be carried out in a suitable solvent (for example, an ether such as tetrahydrofuran, a hydrocarbon such as hexane, or a combination thereof).

Compound (I) in which the substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is an optionally substituted alkanoyl and its intermediate compound are: Compound (I) in which each of the corresponding substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is halogen (especially bromine or iodine) and its intermediate compound Is coupled with R ⁹ Sn (n-Bu) ₃ (wherein R ⁹ represents 1-alkoxy-1-alkene-1-yl and n-Bu represents butyl) to form an alkenyl ether compound. And can be produced by hydrolysis. The reaction for producing the alkenyl ether compound can be carried out according to the above-described coupling reaction method for producing a compound having phenyl which may be substituted from a halogen-containing compound.
The hydrolysis reaction is carried out in the presence of an acid (eg, an inorganic acid such as hydrogen chloride) in a suitable solvent (eg, an ether such as tetrahydrofuran; an ester such as ethyl acetate; or water, or a combination thereof). it can.

［式中、Ｒ^１０は置換されていてもよいアルキルであり、Ｍｅはメチルである。］ Alternatively, the compound (I) in which the substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is an optionally substituted alkanoyl and its intermediate compound Are compounds (I) in which the corresponding substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d are halogen (especially bromine, iodine) and intermediates thereof Can be produced by alkanoylating a body compound.
The alkanoylation reaction is performed in a suitable solvent (for example, an ether such as tetrahydrofuran or a hydrocarbon such as hexane, or a combination thereof), the substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^The compound (I) in which ^3b , R ^3c or R ^3d is halogen or an intermediate compound thereof can be sequentially treated with alkyllithium (for example, butyllithium) and a compound of the following formula.

[Wherein R ¹⁰ is an optionally substituted alkyl, and Me is methyl. ]

The compound (I) in which the substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is optionally substituted cycloalkyl and its intermediate compound are: Compound (I) in which each of the corresponding substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is halogen (especially bromine or iodine) and its intermediate compound ^the, R 11 B _{(OH) 2} or ^R 11 _BF 3 K can be prepared by coupling ^{(wherein, R 11} is meant to cycloalkyl which may be substituted).
This reaction can be carried out according to the above-described coupling reaction method for producing a compound having phenyl which may be substituted from a compound having halogen.

Alternatively, the compound (I) in which the substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is optionally substituted cycloalkyl and its intermediate compound Are compounds (I) in which the corresponding substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d are halogen (especially bromine, iodine) and intermediates thereof the body compound R ^{12 B (OH)} ₂ or R ^{12 BF} 3 K _(wherein, R ¹² means a good cycloalkenyl optionally substituted) and by coupling, good cycloalkenyl compounds may be substituted And can be produced by hydrogenation.
The production reaction of the optionally substituted cycloalkenyl compound can be carried out according to the above coupling reaction method for producing the optionally substituted phenyl-containing compound from the halogen-containing compound.
The hydrogenation reaction of the cycloalkenyl compound can be performed according to the method of hydrogenation reaction of the optionally substituted C ₂ -C ₆ alkenyl compound.

The compound (I) in which the substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is hydrogen and the intermediate compound thereof are each represented by the corresponding substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c, or R ^3d is a compound (I) in which halogen (especially bromine or iodine) and an intermediate compound thereof are reduced. be able to.
The reduction reaction can be carried out in a suitable solvent in the presence of a catalyst in a suitable solvent with or without a base.
Examples of the catalyst include palladium carbon, palladium hydroxide and platinum oxide. Examples of the base include amines such as triethylamine.
The solvent can be selected from any solvent that does not interfere with the reaction. Examples of the solvent include ethers such as tetrahydrofuran, 1,2-dimethoxyethane and 1,4-dioxane; methanol, ethanol, 2-propanol and the like. Alcohols; esters such as ethyl acetate; carboxylic acids such as acetic acid. These solvents can be used alone or in combination.
The reaction can be carried out at room temperature or elevated temperature, for example 20 ° C to 80 ° C.
Alternatively, the reduction reaction is carried out with a palladium catalyst (eg, palladium (II) acetate) with or without a ligand (eg, triphenylphosphine) in a suitable solvent (eg, a secondary alcohol such as 2-propanol). ) And a base (for example, an alkali metal carbonate such as potassium carbonate).

The compound (I) in which the substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is fluoroalkyl and the intermediate compound thereof are represented by the corresponding substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is halogen (especially iodine) and its intermediate compound is methyl fluorosulfonyldifluoroacetate, fluoro It can be produced by coupling with potassium alkylcarboxylate or fluoroalkyltrimethylsilane.
The coupling reaction can be carried out in the presence of a copper complex in a suitable solvent with or without additives.

Examples of the copper complex are cuprous bromide, cuprous iodide, or cuprous thiophene-2-carboxylate, preferably cuprous bromide and cuprous iodide. This reaction can also be carried out by adding an additive. Examples of the additive include potassium fluoride.
Any solvent can be suitably used as long as it does not affect the reaction. Examples of the solvent include ethers such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane; N, N -Amides such as dimethylformamide, N, N-dimethylacetamide, 1,3-dimethyl-2-imidazolidinone and N-methylpyrrolidone; and aprotic polar solvents such as dimethyl sulfoxide and hexamethylphosphoric triamide . These solvents can be used alone or in combination. A preferred solvent in this reaction is a combination of an amide such as N, N-dimethylformamide and an aprotic polar solvent such as hexamethylphosphoric triamide.
The reaction can be carried out at room temperature or elevated temperature, for example 20 ° C to 120 ° C.

Compound (I) wherein the substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is an alkyl having the same carbon atom difluorinated, and intermediates thereof The compound is a compound (I) in which the corresponding substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is an alkyl substituted with oxo and intermediates thereof Body compounds can be produced by difluorination.
The difluorination reaction may be performed in a suitable solvent (eg, a halogeno hydrocarbon such as dichloromethane, chloroform or dichloroethane) or without solvent, with or without a catalyst (eg, an alcohol such as methanol or ethanol). (Eg, diethylaminosulfur trifluoride or bis (2-methoxyethyl) aminosulfur trifluoride).
This reaction can be suitably carried out at 0 ° C to 100 ° C, particularly 20 ° C to 80 ° C.

The compound (I) in which the substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d are alkyl substituted with alkoxy and the intermediate compounds thereof correspond respectively. A compound (I) in which R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c, or R ^3d is alkyl substituted with hydroxy is substituted with R 1 ¹³ LG ² (wherein R ¹³ represents alkyl, and LG ² represents a leaving group, for example, halogen such as bromine and iodine; p-toluenesulfonyloxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, And substituted sulfonyloxy such as alkoxysulfonyloxy) and the like.
The alkylation reaction can be carried out in the presence of a base in a suitable solvent.

  As the solvent used in the alkylation reaction, any solvent can be suitably used as long as it does not affect the reaction. Examples of the solvent include tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like. Ethers; hydrocarbons such as toluene, hexane, xylene; esters such as ethyl acetate and butyl acetate; N, N-dimethylformamide, N, N-dimethylacetamide, 1,3-dimethyl-2-imidazolidinone and N-methyl Examples include amides such as pyrrolidone. These solvents can be used alone or in combination, and are preferably amides such as N, N-dimethylformamide.

  Examples of the base include alkali metal hydrides such as sodium hydride and potassium hydride; alkali hydroxide metals such as sodium hydroxide and potassium hydroxide; alkaline earth metal hydroxides such as calcium hydroxide and barium hydroxide; Alkali metal alkoxides such as sodium methoxide, sodium ethoxide, potassium ethoxide, potassium t-butoxide; alkali metal amides such as lithium diisopropylamide, sodium amide, lithium bistrimethylsilylamide; sodium carbonate, potassium carbonate, sodium hydrogen carbonate, carbonic acid Examples include alkali metal carbonates such as potassium hydride, preferably alkali metal hydrides such as sodium hydride.

The substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d have the same carbon atom (a) C ₁ -C ₃ perfluoroalkyl (eg, trifluoromethyl , Pentafluoroethyl or heptafluoropropyl) and (b) hydroxy-substituted compound (I) and its intermediate compounds are represented by the corresponding substituents R ¹ , R ^2a , R ^2b , R ^2c , R, respectively. ^2d , R ^3a , R ^3b , R ^3c or R ^3d is an alkyl substituted with oxo and the intermediate compound thereof, R ¹⁴ SiMe ₃ (wherein R ¹⁴ means perfluoroalkyl, Me means methyl) and can be prepared by perfluoroalkylation.
The perfluoroalkylation reaction can be carried out in a suitable solvent (eg, an ether such as tetrahydrofuran) in the presence of a fluoride ion source (eg, tetrabutylammonium fluoride).

Two substituents selected from the substituents R ^3a , R ^3b , R ^3c and R ^3d are substituted with two substituents (a) C ₁ -C ₃ perfluoroalkyl on the same carbon atom constituting the ring B (for example, tri Fluoromethyl, pentafluoroethyl or heptafluoropropyl) and (b) hydroxy (compound (I)) and its intermediate compounds are each selected from two substituents selected from the corresponding substituents R ^3a , R ^3b , R ^3c and R ^3d Compound (I) and the intermediate compound thereof, in which the substituents are combined to form oxo, are represented by R ¹⁵ SiMe ₃ (wherein R ¹⁵ represents perfluoroalkyl and Me represents methyl). It can be produced by perfluoroalkylation.
This reaction can be carried out according to the above-described method for perfluoroalkylation of alkyl substituted with oxo.

The compound (I) in which the substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d are alkyls with the same carbon atom substituted by cycloalkyl and hydroxy, and The intermediate compound is a compound (I) in which the corresponding substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is an alkyl substituted with oxo. And an intermediate compound thereof can be produced by cycloalkylation with R ¹⁶ Li or R ¹⁶ MgLG ¹ (wherein R ¹⁶ represents cycloalkyl and LG ¹ represents halogen).
The cycloalkylation reaction can be carried out in a suitable solvent (for example, an ether such as tetrahydrofuran).

The compound (I) in which the substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is alkyl substituted with hydroxy, Corresponding substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d are alkyls substituted with oxo and intermediate compounds thereof It can manufacture by reducing.
The reduction reaction can be performed in a suitable solvent (for example, alcohol such as methanol and ethanol) in the presence of a reducing agent (for example, lithium borohydride, sodium borohydride).

The compound (I) in which the substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is alkyl and the intermediate compound thereof are each represented by the corresponding substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is an alkyl substituted with hydroxy, and the intermediate compound is produced by silane reduction can do.
The reduction reaction is carried out in a suitable solvent (eg, a halogeno hydrocarbon such as chloroform) or without solvent, with an acid (eg, a carboxylic acid such as trifluoroacetic acid) and a reducing agent (eg, a trialkylsilane such as triethylsilane). Can be done in the presence.

Substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is a substituent on the nitrogen atom constituting ring A or ring B and is substituted The compound (I), which is an alkyl which may be substituted, and the intermediate compound thereof have the corresponding substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d , respectively. Compound (I), which is hydrogen, and an intermediate compound thereof are represented by R ¹⁷ LG ² (wherein R ¹⁷ represents an optionally substituted alkyl, and LG ² represents a leaving group, for example, bromine And halogen such as iodine; substituted sulfonyloxy such as p-toluenesulfonyloxy, methanesulfonyloxy, trifluoromethanesulfonyloxy, and alkoxysulfonyloxy). It can be prepared by kill of.
The production reaction of this compound can be carried out in accordance with the above alkylation reaction method of alkyl substituted with hydroxy, and a preferable base is an alkali metal hydride such as potassium carbonate or sodium hydride such as sodium hydride. is there.

Substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is a substituent on the nitrogen atom constituting ring A or ring B and is substituted The compound (I) which is an optionally substituted cycloalkyl and its intermediate compound (hereinafter also referred to as a compound having an optionally substituted cycloalkyl) are each represented by a corresponding substituent R ¹ , R ^2a , R ^2b , Compound (I) in which R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is hydrogen and its intermediate compound (hereinafter also referred to as a compound having hydrogen on the nitrogen atom) are represented by R ¹⁸ B ( OH) ₂ or R ¹⁸ BF ₃ K (wherein R ¹⁸ means an optionally substituted cycloalkyl).
The coupling reaction may be performed with a copper catalyst (eg, with or without a ligand (eg, a diamine such as 2,2′-bipyridyl) in a suitable solvent (eg, a halogeno hydrocarbon such as 1,2-dichloroethane). , Copper (II) acetate) and a base (for example, an alkali metal carbonate such as sodium carbonate).

The compound (I) in which the substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is an optionally substituted alkoxy and its intermediate compound are: Compound (I) in which the corresponding substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d are halogen (especially bromine or iodine) and intermediates thereof The compound can be produced by alkoxylation.
The alkoxylation reaction can be carried out in a suitable solvent (for example, an ether such as tetrahydrofuran) in the presence of the corresponding alcohol and base (for example, an alkali metal hydride such as sodium hydride).

The compound (I) in which the substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is iodine and the intermediate compound thereof have the corresponding substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c, or R ^3d is bromine and can be produced by iodination.
The iodination reaction can be carried out in a suitable solvent, with or without ligand, in the presence of an iodinating agent and a catalyst.
An example of an iodinating agent is sodium iodide. Examples of the catalyst include copper (I) iodide. Examples of the ligand include diamines such as N, N′-dimethylethylenediamine and N, N′-1,2-cyclohexanediamine.
The solvent can be selected from any solvent that does not interfere with the reaction. Examples of the solvent include ethers such as tetrahydrofuran, 1,4-dioxane and 1,2-dimethoxyethane; alkyls such as acetonitrile and propionitrile. Nitriles are mentioned. These solvents can be used alone or in combination.
The reaction can be carried out at room temperature or elevated temperature, for example 20 ° C to 120 ° C.

The compound (I) in which the substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is fluorine and the intermediate compound thereof are represented by the corresponding substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d can be produced by fluorinating the compound (I) and its intermediate compound. .
The fluorination reaction is carried out by subjecting Compound (I), which is bromine or iodine, or an intermediate compound thereof to alkyl lithium (for example, an ether such as tetrahydrofuran or an aliphatic hydrocarbon such as hexane, or a combination thereof). For example, butyllithium) and a fluorinating agent (for example, N-fluorobenzenesulfonimide) can be sequentially treated.

The compound (I) in which the substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d are halogen and the intermediate compound thereof are represented by the corresponding substituent R ^1. , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d can be produced by halogenating the compound (I) and its intermediate compound.
The halogenation reaction is carried out in a suitable solvent (for example, an ether such as tetrahydrofuran, an amide such as N, N-dimethylformamide, a halogeno hydrocarbon such as dichloromethane, a carboxylic acid such as acetic acid, or a combination thereof). (For example, in the presence of N-halogenosuccinimide).

The compound (I) in which the substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is alkyl and the intermediate compound thereof are each represented by the corresponding substituent R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is an alkyl substituted with oxo, and the intermediate compound is obtained by treating with hydrazine It can be produced by reducing hydrazone.
The treatment with hydrazine can be carried out in the presence of hydrazine monohydrate in a suitable solvent (for example, alcohol such as ethanol).
The reduction reaction of hydrazone can be carried out in the presence of a base (for example, an alkali metal hydroxide such as potassium hydroxide) in a suitable solvent (for example, an alcohol such as ethylene glycol).

Alternatively, the compound (I) in which the substituents R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d are alkyl and the intermediate compound thereof each have a corresponding substituent. Silane reduction of compound (I) wherein R ¹ , R ^2a , R ^2b , R ^2c , R ^2d , R ^3a , R ^3b , R ^3c or R ^3d is alkyl substituted with oxo and its intermediate compound Can be manufactured.
The silane reduction reaction of alkyl substituted with oxo can be carried out according to the above-mentioned method of silane reduction reaction of alkyl substituted with hydroxy.

The compound (I) in which two substituents selected from the substituents R ^3a , R ^3b , R ^3c and R ^3d are two hydrogens on the same carbon atom constituting the ring B and the intermediate compound thereof correspond respectively. By performing hydrazone reduction or silane reduction of the compound (I) in which two substituents selected from the substituents R ^3a , R ^3b , R ^3c and R ^3d together form oxo and its intermediate compound Can be manufactured.
The hydrazone reduction reaction or silane reduction reaction can be carried out according to the above-described reduction reaction method for alkyl substituted with oxo.

The compound (I) in which the substituent X is carboxy and its intermediate compound are produced by hydrolyzing the compound (I) in which the substituent X is alkoxycarbonyl and the intermediate compound thereof by a conventional method. Can do.
The hydrolysis is carried out in a suitable inert solvent (eg tetrahydrofuran, 1,4-dioxane, methanol, ethanol and water, or combinations thereof) with a base (eg sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium). By treating compound (I) or an intermediate compound thereof, wherein the substituent X is alkoxycarbonyl, with methoxide and sodium ethoxide.

  Compound (I) in which substituent X is hydroxyalkyl and its intermediate compound are respectively compound (I) in which substituent X is alkoxycarbonyl or alkanoyl and its intermediate compound are combined with lithium aluminum hydride or alkylmagnesium bromide. It can be produced by reacting.

  The compound (I) in which the substituent X is an optionally substituted aminocarbonyl and its intermediate compound are the same as the compound (I) in which the corresponding substituent X is carboxy or alkoxycarbonyl, and the intermediate compound thereof. Can be prepared by amidation using a conventional method.

（上記のスキームにおいて、ＬＧ^Ａ脱離基を意味し、例えば、塩素、臭素等のハロゲン；トリフルオロメチルスルホニルオキシ等の置換スルホニルオキシが挙げられ、その他の記号は、上記と同様である） [Production of Intermediate Compound]
Compound (IV) can be produced according to the following scheme A1.
Scheme A1:

(In the above scheme, it means LG ^A leaving group, for example, halogen such as chlorine and bromine; substituted sulfonyloxy such as trifluoromethylsulfonyloxy, etc., and other symbols are the same as above)

Compound (A-2) is obtained by amination of compound (A-1). By hydrolyzing this, compound (IV) can be produced.
The amination reaction of compound (A-1) is carried out by using a ligand (for example, 2,2′-bis (diphenylphosphino) 1,1′-binaphthyl, etc.) in a suitable solvent (for example, an aromatic hydrocarbon such as toluene). In the presence of benzophenone imine, palladium catalyst (eg, tris (dibenzylideneacetone) dipalladium), and base (eg, alkali metal alkoxide such as sodium-t-butoxide) with or without phosphine) can do. The reaction can be carried out at an elevated temperature, for example from 80 ° C to 140 ° C.
Hydrolysis of compound (A-2) is carried out by treating with an acid (for example, an inorganic acid such as hydrogen chloride) in a suitable solvent (for example, an ether such as tetrahydrofuran; water, or a combination thereof). Can do. The reaction can be carried out at low temperature, room temperature or high temperature, for example from 0 ° C to 60 ° C.

（上記のスキームにおいて、記号は、上記と同様である） Moreover, the compound represented by Formula (IV-1) among compound (IV) can be manufactured according to the following scheme A2.
Scheme A2:

(In the above scheme, the symbols are the same as above)

Compound (A-4) is obtained by nitration of compound (A-3). By reducing this, compound (IV-1) can be produced.
The nitration reaction of compound (A-3) can be carried out without a solvent in the presence of a nitrating agent (for example, potassium nitrate) and an acid (for example, an inorganic acid such as sulfuric acid). The reaction can be carried out at room temperature or elevated temperature, for example 20 ° C to 100 ° C.
The reduction reaction of compound (A-4) is carried out in the presence of a reducing agent (for example, iron (0)) in a suitable solvent (for example, an alcohol such as ethanol; a carboxylic acid such as acetic acid, or a combination thereof). can do. The reaction can be carried out at an elevated temperature, for example from 60 ° C to 120 ° C.

（上記のスキームにおいて、記号は、上記と同様である） Among the compounds (IV), the compound represented by the formula (IV-2) can be produced according to the following scheme A3.
Scheme A3:

(In the above scheme, the symbols are the same as above)

Compound (A-6) is obtained by alkenylating compound (A-5). Compound (IV-2) can be produced by reducing this nitro to convert it to an amino compound and then cyclizing it.
The alkenylation reaction of compound (A-5) is carried out by subjecting the corresponding phosphonic acid ester (for example, substituted phosphonic acid diethyl ester) and base (for example, potassium t-butoxide, etc.) in a suitable solvent (for example, ether such as tetrahydrofuran). In the presence of an alkali metal alkoxide). The reaction can be carried out at room temperature or elevated temperature, for example 20 ° C to 100 ° C.

The reduction reaction of compound (A-6) can be carried out in the presence of a reducing agent (for example, tin (II) chloride) in a suitable solvent (for example, an alcohol such as ethanol). The reaction can be carried out at an elevated temperature, for example 60 ° C to 100 ° C.
The cyclization reaction of the obtained amino compound can be carried out in the presence of a base (for example, an alkali metal alkoxide such as sodium ethoxide) in a suitable solvent (for example, an alcohol such as ethanol). The reaction can be carried out at an elevated temperature, for example 60 ° C to 100 ° C.

（上記のスキームにおいて、

は、ベンゼンまたは単環式の芳香族複素環を意味し、

は、（ａ）ピリジンとベンゼンが縮合した；または（ｂ）ピリジンとベンゼンが縮合した二環式の芳香族複素環を意味し、Ｒ^１Ａは水素または置換されていてもよいアルキルを意味し、その他の記号は、上記と同様である） Among the compounds (IV), the compound represented by the formula (IV-3) can be produced according to the following scheme A4.
Scheme A4:

(In the above scheme,

Means benzene or a monocyclic aromatic heterocycle,

Means (a) a pyridine and benzene condensed; or (b) a bicyclic aromatic heterocyclic ring fused with pyridine and benzene, R ^1A means hydrogen or an optionally substituted alkyl, Other symbols are the same as above)

Compound (A-8) can be obtained by alkylating compound (A-7). By cyclizing this, compound (IV-3) in which R ^1A is alkyl which may be substituted can be produced.
In addition, compound (IV-3) in which R ^1A is hydrogen can be produced by cyclizing compound (A-7).
The alkylation reaction of compound (A-7) is carried out by subjecting the corresponding halogenoalkyl (eg, alkyl iodide or alkyl bromide) and base (eg, alkyl iodide or bromide) in a suitable solvent (eg, ether such as tetrahydrofuran; alcohol such as ethanol). In the presence of organic lithium such as butyl lithium; or alkali metal alkoxide such as sodium ethoxide. The reaction can be carried out at low temperature or room temperature, for example at -80 ° C to 20 ° C.
The cyclization reaction of compound (A-7) or compound (A-8) can be carried out in the presence of hydrogen bromide in a suitable solvent (for example, carboxylic acid such as acetic acid). The reaction can be carried out at a low temperature or at room temperature, for example, -20 ° C to 20 ° C.

（上記のスキームにおいて、Ｅ^１、Ｅ^２、Ｇ^１およびＧ^２は、それぞれ、ＣＨ，ＣＨ，Ｎ^＋Ｏ⁻およびＮを意味するか、あるいは、それぞれ、Ｎ^＋Ｏ⁻，Ｎ，ＣＨおよびＣＨを意味する） Among the compounds (VIII), the compound represented by the formula (VIII-1) can be produced according to the following scheme A5.
Scheme A5:

(In the above scheme, E ¹ , E ² , G ¹ and G ² mean CH, CH, N ⁺ O ⁻ and N, respectively, or N ⁺ O ⁻ , N, CH and CH, respectively. Means)

Compound (A-10) can be obtained by reducing compound (A-9). The compound of formula (VIII-1) can be produced by pyrrolidinating this.
The reduction reaction of compound (A-9) can be carried out in a suitable solvent (for example, a halogeno hydrocarbon such as chloroform) in the presence of a reducing agent (for example, phosphorus oxychloride). The reaction can be carried out at an elevated temperature, for example 40 ° C to 100 ° C.
The pyrrolopyridine reaction of compound (A-10) can be carried out in the presence of a vinylating agent (eg, vinylmagnesium bromide) in a suitable solvent (eg, ether such as tetrahydrofuran). The reaction can be carried out at a low temperature or room temperature, for example, -40 ° C to 20 ° C.

（上記のスキームにおいて、ＬＧ^Ｂ１はハロゲン（とりわけ、臭素またはヨウ素）を意味し、Ｒ^Ｂ１はアルキルを意味し、その他の記号は、上記と同様である） Among the compounds (VI), the compound represented by the formula (VI-1) can be produced according to the following scheme B1.
Scheme B1:

(In the above scheme, LG ^B1 means halogen (especially bromine or iodine), R ^B1 means alkyl, and other symbols are the same as above)

Compound (B-2) can be obtained by alkoxycarbonylating compound (B-1). By reducing this, compound (VI-1) can be produced.
Compound (B-3) is obtained by formylating compound (B-1). By reducing this, compound (VI-1) can be produced.
Compound (B-2) is obtained by esterifying compound (B-4). By reducing this, compound (VI-1) can be produced.
In addition, compound (VI-1) can be produced by reducing compound (B-4).

The alkoxycarbonylation reaction of compound (B-1) is carried out under a stream of carbon monoxide in a suitable solvent (for example, an amide such as N, N-dimethylformamide or N, N-dimethylacetamide). 1′-bis (diphenylphosphino) ferrocene) with or without the corresponding alcohol (R ^B1 OH), base (eg amine such as triethylamine) and palladium catalyst (eg palladium acetate) Can be implemented. The reaction can be carried out at an elevated temperature, for example, 60 ° C to 120 ° C.
The reduction reaction of compound (B-2) is carried out in a suitable solvent (for example, aromatic hydrocarbons such as toluene and xylene; ethers such as tetrahydrofuran and diethyl ether; alcohols such as methanol and ethanol, or a combination thereof). It can be carried out in the presence of an agent (eg, lithium borohydride, sodium borohydride, lithium aluminum hydride, diisobutylaluminum hydride). The reaction can be carried out at low temperature or room temperature, for example at -80 ° C to 20 ° C.

The formylation reaction of compound (B-1) is carried out by sequentially treating compound (B-1) with butyllithium and N, N-dimethylformamide in a suitable solvent (for example, ether such as tetrahydrofuran). Can do. The reaction can be carried out at low temperature or room temperature, for example at -80 ° C to 20 ° C.
The reduction reaction of compound (B-3) can be performed according to the method for the reduction reaction of compound (B-2).

The esterification reaction of compound (B-4) can be carried out in the presence of thionyl chloride using the corresponding alcohol (R ^B1 OH) as a solvent. The reaction can be carried out at a low temperature or at room temperature, for example, -20 ° C to 20 ° C.
Alternatively, the esterification reaction of compound (B-4) can be carried out by subjecting the corresponding iodoalkyl (R ^B1 I) and base (for example, potassium carbonate and the like) in a suitable solvent (for example, an amide such as N, N-dimethylformamide). In the presence of an alkali metal carbonate). The reaction can be carried out at room temperature or elevated temperature, for example 20 ° C to 60 ° C.
The reduction reaction of compound (B-4) is carried out in the presence of a reducing agent (eg, a borane complex such as borane-tetrahydrofuran complex or borane-dimethyl sulfide complex) in a suitable solvent (eg, ether such as tetrahydrofuran). be able to. The reaction can be carried out at a low temperature or at room temperature, for example, -20 ° C to 20 ° C.
Alternatively, the reduction reaction of compound (B-4) is carried out by reacting compound (B-4) with an activator (eg, N, N′-carbodiimidazole) and reduction in a suitable solvent (eg, ether such as tetrahydrofuran). It can be carried out by sequentially treating with an agent (for example, sodium borohydride). The reaction can be carried out at low temperature, room temperature or high temperature, for example at -20 ° C to 80 ° C.

（上記のスキームにおいて、記号は、上記と同様である） Among the compounds (VI), the compound represented by the formula (VI-2) can be produced according to the following scheme B2.
Scheme B2:

(In the above scheme, the symbols are the same as above)

Compound (B-6) is obtained by formylating compound (B-5). By reducing this, compound (VI-2) can be produced.
The formylation reaction of compound (B-5) is carried out by subjecting compound (B-5) to a base (for example, an alkali metal amide such as lithium diisopropylamide) and a formylating agent (for example, ether such as tetrahydrofuran). For example, it can be carried out by sequentially treating with N, N-dimethylformamide). The reaction can be carried out at low temperature or room temperature, for example at -80 ° C to 20 ° C.
The reduction reaction of compound (B-6) can be carried out according to the method for the reduction reaction of compound (B-2).

（上記のスキームにおいて、Ｒ^Ｂ２はアルキルを意味し、その他の記号は上記と同様である） Among the compounds (VI), the compound represented by the formula (VI-3) can be produced according to the following scheme B3.
Scheme B3:

(In the above scheme, R ^B2 means alkyl, and other symbols are the same as above)

Compound (B-8) can be obtained by oxidizing compound (B-7). By cyanating this, compound (B-9) can be obtained. This can be reduced to give compound (B-10). Furthermore, a compound (VI-3) can be manufactured by reducing this.
The oxidation reaction of compound (B-7) can be carried out in the presence of an oxidizing agent (for example, a percarboxylic acid such as metachloroperbenzoic acid) in a suitable solvent (for example, a halogeno hydrocarbon such as dichloromethane). . The reaction can be carried out at low temperature, room temperature or high temperature, for example, 0 ° C. to 50 ° C.
The cyanation reaction of compound (B-8) can be carried out in the presence of a cyanating agent (for example, tetrabutylammonium cyanide) in a suitable solvent (for example, a halogeno hydrocarbon such as dichloromethane). The reaction can be carried out at room temperature or elevated temperature, for example 20 ° C to 50 ° C.
The reduction reaction of compound (B-9) can be carried out in the presence of a reducing agent (eg diisobutylaluminum hydride) in a suitable solvent (eg ether such as tetrahydrofuran). The reaction can be carried out at a low temperature, for example, -80 ° C to 0 ° C.
The reduction reaction of compound (B-10) can be carried out according to the method for the reduction reaction of compound (B-2).

（上記のスキームにおいて、Ｒ^Ｂ３はアルキルを意味し、その他の記号は上記と同様である）
化合物（Ｂ−１１）をベンゾチオフェンへと変換することで、化合物（Ｂ−１２）を得る。これを還元することで、化合物（ＶＩ−４）を製造することができる。
化合物（Ｂ−１２）を加水分解することで、化合物（Ｂ−１３）を得ることができる。これのカルボン酸をＮ−メトキシ−Ｎ−メチルアミド化し、次いで、これを還元することで、化合物（Ｂ−１４）を得る。これを還元することで、化合物（ＶＩ−４）を製造することができる。
化合物（Ｂ−１３）を還元することで、化合物（ＶＩ−４）を製造することができる。
化合物（Ｂ−１１）をベンゾチオフェンへと変換する反応は、好適な溶媒（例えば、Ｎ，Ｎ−ジメチルホルムアミド等のアミド）中、対応するチオグリコール酸エステルおよび塩基（例えば、炭酸カリウム等の炭酸アルカリ金属）の存在下で実施することができる。反応は、高温、例えば、４０℃〜８０℃で行なうことができる。
化合物（Ｂ−１２）の還元反応は、上記化合物（Ｂ−２）の還元反応の方法に準じて行なうことができる。
式（Ｂ−１２）の加水分解反応は、置換基Ｘがアルコキシカルボニルである化合物（Ｉ）およびその中間体化合物を、それぞれ置換基Ｘがカルボキシである化合物（Ｉ）およびその中間体化合物へ変換する方法に準じて行なうことができる。 Among the compounds (VI), the compound represented by the formula (VI-4) can be produced according to the following scheme B4.
Scheme B4:

(In the above scheme, R ^B3 means alkyl, and other symbols are the same as above)
Compound (B-12) is obtained by converting compound (B-11) to benzothiophene. By reducing this, compound (VI-4) can be produced.
Compound (B-13) can be obtained by hydrolyzing compound (B-12). This carboxylic acid is N-methoxy-N-methylamidated and then reduced to give compound (B-14). By reducing this, compound (VI-4) can be produced.
Compound (VI-4) can be produced by reducing compound (B-13).
The reaction for converting compound (B-11) to benzothiophene is carried out in a suitable solvent (for example, an amide such as N, N-dimethylformamide) with a corresponding thioglycolic acid ester and a base (for example, a carbonate such as potassium carbonate). In the presence of an alkali metal). The reaction can be carried out at an elevated temperature, for example, 40 ° C to 80 ° C.
The reduction reaction of compound (B-12) can be carried out according to the method for the reduction reaction of compound (B-2).
The hydrolysis reaction of formula (B-12) converts compound (I) in which substituent X is alkoxycarbonyl and its intermediate compound into compound (I) in which substituent X is carboxy, respectively, and its intermediate compound. It can be performed according to the method to do.

The N-methoxy-N-methylamidation reaction of compound (B-13) is carried out using an amine (for example, N, O-dimethylhydroxyamine or N) in a suitable solvent (for example, a halogeno hydrocarbon such as dichloromethane, chloroform or dichloroethane). , O-dimethylhydroxyamine hydrochloride) and a base (for example, an organic base such as triethylamine). The next reduction reaction can be performed according to the method for the reduction reaction of the compound (B-9).
The reduction reaction of compound (B-14) can be carried out according to the method for the reduction reaction of compound (B-2).
The reduction reaction of compound (B-13) to compound (VI-4) can be carried out according to the method for the reduction reaction of compound (B-4).

（上記のスキームにおいて、ｐは１または２を意味し、

は、（ａ）ベンゼンと単環式の脂環式炭化水素が縮合した二環式の芳香族炭化水素；または（ｂ）単環式の芳香族複素環と単環式の脂環式炭化水素が縮合した二環式の芳香族複素環を意味し、その他の記号は上記と同様である） Among the compounds (VI), the compound represented by the formula (VI-5) can be produced according to the following scheme B5.
Scheme B5:

(In the above scheme, p means 1 or 2,

(A) a bicyclic aromatic hydrocarbon condensed with benzene and a monocyclic alicyclic hydrocarbon; or (b) a monocyclic aromatic heterocycle and a monocyclic alicyclic hydrocarbon. Means a bicyclic aromatic heterocyclic ring condensed with other symbols as above)

Compound (VI-5) can be produced by reducing compound (B-15).
The reduction reaction of compound (B-15) can be carried out according to the method for the reduction reaction of compound (B-2).
Alternatively, the reduction reaction of the compound (B-15) is carried out using a catalyst (for example, (2S) -1- (1,3,2-dioxaborolan-2-yloxy)-in a suitable solvent (for example, ether such as tetrahydrofuran). Boron complexes such as a reducing agent (for example, borane-tetrahydrofuran complex or borane-dimethylsulfide complex) in the presence or absence of boron-containing 5-membered ring compounds such as 3-methyl-1,1-diphenylbutan-2-amine) ) In the presence of The reaction can be carried out at a low temperature or at room temperature, for example, -40 ° C to 20 ° C.

The amino group can be protected, for example, by t-butoxycarbonylation of the amino group.
The t-butoxycarbonylation reaction of the amino group is carried out by di-t-butyl dicarbonate and a catalyst (eg, N, N-dimethyl-4-aminopyridine) in a suitable solvent (eg, a halogeno hydrocarbon such as dichloromethane). It can be carried out in the presence.
On the other hand, removal of the t-butylcarbonyl protecting group can be carried out by treatment with an acid (eg, hydrogen chloride or trifluoroacetic acid) in a suitable solvent (eg, ether such as tetrahydrofuran) or without solvent.
Alternatively, the t-butylcarbonyl protecting group can be removed by treatment at a high temperature, for example, 100 ° C. to 150 ° C. in a suitable solvent (for example, a mixed solvent of dimethyl sulfoxide and water).

Hydroxy protection can be achieved, for example, by methoxymethylating hydroxy.
The methoxymethylation of hydroxy can be carried out in the presence of chloromethyl methyl ether and a base (eg an amine such as N, N-diisopropylethylamine) in a suitable solvent (eg a halogeno hydrocarbon such as dichloromethane). .
On the other hand, removal of the methoxymethyl protecting group can be carried out by treatment with an acid (for example, hydrogen chloride) in a suitable solvent (for example, a mixed solvent of alcohol such as ethanol and water).
Other starting compounds are commercially available or can be readily prepared by conventional methods well known to those skilled in the art.

  Hereinafter, the present invention will be described more specifically with reference to examples, but the present invention is not limited thereto.

  In the following examples and tables, Me means methyl, Et means ethyl, and n-Pr means propyl. The optically active compound can be obtained by separating the racemic mixture by chiral HPLC.

（１） ４−メチルイソキノリン−３−アミン（２．００ｇ，１２．６ｍｍｏｌ）のピリジン（５０．６ｍｌ）溶液に、室温にて４−クロロスルホニル安息香酸エチル（３．３０ｇ，１３．３ｍｍｏｌ）を加えた。８０℃にて３時間撹拌後、反応液を減圧濃縮した。得られた残渣を２ｍｏｌ／Ｌ塩酸水溶液および水で希釈後、酢酸エチルで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝４：１→１：１）で精製後、ジイソプロピルエーテルで洗浄し、４−｛［（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（４．２９ｇ，９２％）を淡黄色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：３７１［Ｍ＋Ｈ］^＋．
（２） 上記化合物（８００ｍｇ，２．１６ｍｍｏｌ）のＮ，Ｎ−ジメチルホルムアミド（２１．６ｍｌ）溶液に、室温にて炭酸カリウム（３５８ｍｇ，２．５９ｍｍｏｌ）および１−（ブロモメチル）−４−（トリフルオロメトキシ）ベンゼン（４２７μｌ，２．５９ｍｍｏｌ）を加えた。同温にて終夜撹拌後、反応液に水を加え、酢酸エチルで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９：１→３：１）で精製し、４−（｛（４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（１．１２ｇ，９５％）を無色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：５４５[Ｍ＋Ｈ]^＋．
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ １．３７（３Ｈ，ｔ，Ｊ＝７．３Ｈｚ），２．４４（３Ｈ，ｓ），４．３９（２Ｈ，ｑ，Ｊ＝７．３Ｈｚ），４．４５−５．３０（２Ｈ，ｍ），７．２０（２Ｈ，ｄ，Ｊ＝８．２Ｈｚ），７．３０（２Ｈ，ｄ，Ｊ＝８．８Ｈｚ），７．７４（１Ｈ，ｔ，Ｊ＝７．３Ｈｚ），７．８１−７．８８（３Ｈ，ｍ），８．０５（１Ｈ，ｄ，Ｊ＝８．５Ｈｚ），８．１０−８．１８（３Ｈ，ｍ），９．００（１Ｈ，ｓ）． Example 1:
Preparation of ethyl 4-({(4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoate

(1) Ethyl 4-chlorosulfonylbenzoate (3.30 g, 13.3 mmol) was added to a solution of 4-methylisoquinolin-3-amine (2.00 g, 12.6 mmol) in pyridine (50.6 ml) at room temperature. added. After stirring at 80 ° C. for 3 hours, the reaction solution was concentrated under reduced pressure. The obtained residue was diluted with 2 mol / L hydrochloric acid aqueous solution and water, and extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 4: 1 → 1: 1), washed with diisopropyl ether, and 4-{[(4-methylisoquinolin-3-yl) amino]. Sulfonyl} ethyl benzoate (4.29 g, 92%) was obtained as a pale yellow powder.
APCI-MS m / z: 371 [M + H] ⁺ .
(2) To a solution of the above compound (800 mg, 2.16 mmol) in N, N-dimethylformamide (21.6 ml) at room temperature, potassium carbonate (358 mg, 2.59 mmol) and 1- (bromomethyl) -4- (tri Fluoromethoxy) benzene (427 μl, 2.59 mmol) was added. After stirring overnight at the same temperature, water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 9: 1 → 3: 1), and 4-({(4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) [Benzyl] amino} sulfonyl) ethyl benzoate (1.12 g, 95%) was obtained as a colorless powder.
APCI-MS m / z: 545 [M + H] ⁺ .
¹ H-NMR (DMSO-d ₆ ) δ 1.37 (3H, t, J = 7.3 Hz), 2.44 (3H, s), 4.39 (2H, q, J = 7.3 Hz), 4.45-5.30 (2H, m), 7.20 (2H, d, J = 8.2 Hz), 7.30 (2H, d, J = 8.8 Hz), 7.74 (1H, t , J = 7.3 Hz), 7.81-7.88 (3H, m), 8.05 (1H, d, J = 8.5 Hz), 8.10-8.18 (3H, m), 9 .00 (1H, s).

実施例１で製造した４−（｛（４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（１．１１ｇ，２．０４ｍｍｏｌ）および２ｍｏｌ／Ｌ水酸化ナトリウム水溶液（１．０２ｍｌ，２．０４ｍｍｏｌ）のエタノール（２０．４ｍｌ）懸濁液を、１時間加熱還流した。反応液を減圧濃縮し、得られた残渣をジエチルエーテルおよびペンタンで洗浄し、４−（｛（４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸ナトリウム（１．０７ｇ，９４％）を無色粉末として得た。
ＥＳＩ−ＭＳ ｍ／ｚ：５１５[Ｍ−Ｎａ]⁻．
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ ２．４６（３Ｈ，ｓ），４．４０−５．２０（２Ｈ，ｍ），７．１９（２Ｈ，ｄ，Ｊ＝８．０Ｈｚ），７．３０（２Ｈ，ｄ，Ｊ＝８．７Ｈｚ），７．５８（２Ｈ，ｄ，Ｊ＝８．３Ｈｚ），７．７２（１Ｈ，ｔ，Ｊ＝７．１Ｈｚ），７．８０−７．８５（１Ｈ，ｍ），７．９８（２Ｈ，ｄ，Ｊ＝８．７Ｈｚ），８．０４（１Ｈ，ｄ，Ｊ＝８．７Ｈｚ），８．１１（１Ｈ，ｄ，Ｊ＝８．０Ｈｚ），９．０１（１Ｈ，ｓ）． Example 2:
Preparation of sodium 4-({(4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoate

Ethyl 4-({(4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoate (1.11 g, 2.04 mmol) and 2 mol / L prepared in Example 1 A suspension of aqueous sodium hydroxide (1.02 ml, 2.04 mmol) in ethanol (20.4 ml) was heated to reflux for 1 hour. The reaction mixture was concentrated under reduced pressure, and the resulting residue was washed with diethyl ether and pentane to give 4-({(4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid. Sodium (1.07 g, 94%) was obtained as a colorless powder.
ESI-MS m / z: 515 [M-Na] ⁻ .
¹ H-NMR (DMSO-d ₆ ) δ 2.46 (3H, s), 4.40-5.20 (2H, m), 7.19 (2H, d, J = 8.0 Hz), 7. 30 (2H, d, J = 8.7 Hz), 7.58 (2H, d, J = 8.3 Hz), 7.72 (1H, t, J = 7.1 Hz), 7.80-7.85 (1H, m), 7.98 (2H, d, J = 8.7 Hz), 8.04 (1H, d, J = 8.7 Hz), 8.11 (1H, d, J = 8.0 Hz) 9.01 (1H, s).

実施例１−（１）で得られた４−｛［（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（８０ｍｇ，０．２２ｍｍｏｌ）および参考例１で得られた［３−フルオロ−４−（トリフルオロメトキシ）フェニル］メタノール（５７ｍｇ，０．２７ｍｍｏｌ）のテトラヒドロフラン（３ｍｌ）溶液に、室温にてトリフェニルホスフィン（８５ｍｇ，０．３２ｍｍｏｌ）を加えた。上記溶液を０℃に冷却しジイソプロピルアゾジカルボキシラート（６４μｌ，０．３２ｍｍｏｌ）を加え、ゆっくりと室温まで昇温し、そのまま終夜攪拌した。反応液を減圧濃縮し、得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝５：１→２：１）で精製し、４−｛［［３−フルオロ−４−（トリフルオロメトキシ）ベンジル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（５１ｍｇ，４２％）を白色固体として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：５６３[Ｍ＋Ｈ]^＋．
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ １．３６（３Ｈ，ｔ、Ｊ＝７．０Ｈｚ），２．５０（３Ｈ，ｓ），４．３９（２Ｈ，ｑ，Ｊ＝７．２Ｈｚ），４．６８−５．０１（２Ｈ，ｍ），７．１８（１Ｈ，ｄ，Ｊ＝８．５Ｈｚ），７．３３（１Ｈ，ｄｄ，Ｊ＝１０．９，１．８Ｈｚ），７．４３（１Ｈ，ｄｄ，Ｊ＝８．５，８．５Ｈｚ），７．７５（１Ｈ，ｍ），７．８３−７．８８（３Ｈ，ｍ），８．０９（１Ｈ，ｄ，Ｊ＝８．５Ｈｚ），８．１３−８．１５（３Ｈ，ｍ），９．０１（１Ｈ，ｓ）． Example 3:
4-{[[3-Fluoro-4- (trifluoromethoxy) benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} Preparation of ethyl benzoate

Example 1 Ethyl 4-{[(4-methylisoquinolin-3-yl) amino] sulfonyl} benzoate (80 mg, 0.22 mmol) obtained in (1) and [3- To a solution of fluoro-4- (trifluoromethoxy) phenyl] methanol (57 mg, 0.27 mmol) in tetrahydrofuran (3 ml) was added triphenylphosphine (85 mg, 0.32 mmol) at room temperature. The above solution was cooled to 0 ° C., diisopropyl azodicarboxylate (64 μl, 0.32 mmol) was added, the temperature was slowly raised to room temperature, and the mixture was stirred as it was overnight. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane: ethyl acetate = 5: 1 → 2: 1) to give 4-{[[3-fluoro-4- (trifluoromethoxy). [Benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} ethyl benzoate (51 mg, 42%) was obtained as a white solid.
APCI-MS m / z: 563 [M + H] ⁺ .
¹ H-NMR (DMSO-d ₆ ) δ 1.36 (3H, t, J = 7.0 Hz), 2.50 (3H, s), 4.39 (2H, q, J = 7.2 Hz), 4.68-5.01 (2H, m), 7.18 (1H, d, J = 8.5 Hz), 7.33 (1H, dd, J = 10.9, 1.8 Hz), 7.43 (1H, dd, J = 8.5, 8.5 Hz), 7.75 (1H, m), 7.83-7.88 (3H, m), 8.09 (1H, d, J = 8. 5 Hz), 8.13-8.15 (3H, m), 9.01 (1H, s).

実施例３で製造した４−｛［［３−フルオロ−４−（トリフルオロメトキシ）ベンジル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（４７ｍｇ，０．０８４ｍｍｏｌ）のエタノール（１ｍｌ）懸濁液に１ｍｏｌ／Ｌ水酸化ナトリウム水溶液（１６７μｌ，０．１６７ｍｍｏｌ）を加え室温で終夜攪拌した。反応液に水（２ｍｌ）を加えた後６ｍｏｌ／Ｌ塩酸水溶液で溶液を酸性とした。析出した固体をろ過し水で洗浄後、６０℃で減圧乾燥することにより白色固体３９．７ｍｇを得た。この固体を再度エタノール（１ｍｌ）に懸濁し１ｍｏｌ／Ｌ水酸化ナトリウム水溶液（７３μｌ，０．０７３ｍｍｏｌ）を加え攪拌し溶解後反応液を減圧濃縮し析出した固体を乾燥することにより４−｛［［３−フルオロ−４−（トリフルオロメトキシ）ベンジル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸ナトリウム（４２ｍｇ，８９％）を白色固体として得た。
ＥＳＩ−ＭＳ ｍ／ｚ：５３３[Ｍ−Ｎａ]⁻．
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ ２．５２（３Ｈ，ｓ），４．６８（１Ｈ，ｂｒｓ），４．９６（１Ｈ，ｂｒｓ），７．１８（１Ｈ，ｄ，Ｊ＝８．７Ｈｚ），７．３３（１Ｈ，ｄｄ，Ｊ＝１１．２，１．９Ｈｚ），７．４２（１Ｈ，ｄｄ，Ｊ＝８．０，８．０Ｈｚ），７．７３（１Ｈ，ｍ），７．５６（２Ｈ，ｍ），７．８４（１Ｈ，ｍ），７．９７（２Ｈ，ｍ），８．０７（１Ｈ，ｄ，Ｊ＝８．７Ｈｚ），８．１２（１Ｈ，ｄ，Ｊ＝８．０Ｈｚ），９．１１（１Ｈ，ｓ）． Example 4:
4-{[[3-Fluoro-4- (trifluoromethoxy) benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} preparation of sodium benzoate

Ethanol of 4-{[[[3-Fluoro-4- (trifluoromethoxy) benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoate (47 mg, 0.084 mmol) prepared in Example 3 A 1 mol / L aqueous sodium hydroxide solution (167 μl, 0.167 mmol) was added to the (1 ml) suspension, and the mixture was stirred overnight at room temperature. Water (2 ml) was added to the reaction solution, and the solution was acidified with a 6 mol / L hydrochloric acid aqueous solution. The precipitated solid was filtered, washed with water, and dried under reduced pressure at 60 ° C. to obtain 39.7 mg of a white solid. This solid was suspended again in ethanol (1 ml), 1 mol / L aqueous sodium hydroxide solution (73 μl, 0.073 mmol) was added, stirred and dissolved, the reaction mixture was concentrated under reduced pressure, and the precipitated solid was dried to give 4-{[[ 3-Fluoro-4- (trifluoromethoxy) benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} sodium benzoate (42 mg, 89%) was obtained as a white solid.
ESI-MS m / z: 533 [M-Na] ⁻ .
¹ H-NMR (DMSO-d ₆ ) δ 2.52 (3H, s), 4.68 (1H, brs), 4.96 (1H, brs), 7.18 (1H, d, J = 8. 7 Hz), 7.33 (1H, dd, J = 11.2, 1.9 Hz), 7.42 (1H, dd, J = 8.0, 8.0 Hz), 7.73 (1H, m), 7.56 (2H, m), 7.84 (1H, m), 7.97 (2H, m), 8.07 (1H, d, J = 8.7 Hz), 8.12 (1H, d, J = 8.0 Hz), 9.11 (1H, s).

（１） 参考例２で得られた４，７−ジクロロ−１−メチル−１Ｈ−ピロロ［２，３−ｃ］ピリジン（１５３ｍｇ，７６０μｍｏｌ）および４−（トリフルオロメトキシ）ベンジルアミン（１．４５ｇ，７．６０ｍｍｏｌ）の混合物を、マイクロ波照射下、２００℃にて６時間撹拌した。冷却後、反応液に１ｍｏｌ／Ｌクエン酸水溶液を加え、酢酸エチルで２回抽出した。有機層を合わせ、水で洗浄し、珪藻土カラムにてろ過後、減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１９：１→１：１）で精製し、４−クロロ−１−メチル−Ｎ−［４−（トリフルオロメトキシ）ベンジル］−１Ｈ−ピロロ［２，３−ｃ］ピリジン−７−アミン（１３８ｍg，５１％）を黄色粘体として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：３５６／３５８[Ｍ＋Ｈ]^＋． Example 5:
Preparation of ethyl 4-({(4-chloro-1-methyl-1H-pyrrolo [2,3-c] pyridin-7-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoate

(1) 4,7-Dichloro-1-methyl-1H-pyrrolo [2,3-c] pyridine (153 mg, 760 μmol) and 4- (trifluoromethoxy) benzylamine (1.45 g) obtained in Reference Example 2 , 7.60 mmol) was stirred at 200 ° C. for 6 hours under microwave irradiation. After cooling, a 1 mol / L citric acid aqueous solution was added to the reaction solution, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water, filtered through a diatomaceous earth column, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 19: 1 → 1: 1), and 4-chloro-1-methyl-N- [4- (trifluoromethoxy) benzyl] -1H. -Pyrrolo [2,3-c] pyridin-7-amine (138 mg, 51%) was obtained as a yellow viscous body.
APCI-MS m / z: 356/358 [M + H] ⁺ .

(2) To a solution of the above compound (136 mg, 381 μmol) in pyridine (1.91 ml), ethyl 4-chlorosulfonylbenzoate (190 mg, 763 μmol) was added at room temperature, and the mixture was stirred at 80 ° C. for 6 hours. Ethyl 4-chlorosulfonylbenzoate (379 mg, 1.53 mmol) was added, and the mixture was stirred at 80 ° C. overnight. After cooling, the reaction mixture was diluted with ethyl acetate, washed with 1 mol / L aqueous citric acid solution, water, saturated aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 19: 1 → 4: 1), and 4-({(4-chloro-1-methyl-1H-pyrrolo [2,3-c ] Pyridin-7-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) ethyl benzoate (51.1 mg, 24%) was obtained as a pale yellow gum.
APCI-MS m / z: 568/570 [M + H] ⁺ .
¹ H-NMR (DMSO-d ₆ ) δ 1.37 (3H, t, J = 7.3 Hz), 3.87 (3H, s), 4.39 (2H, q, J = 7.3 Hz), 4.59 (1H, d, J = 13.0 Hz), 5.07 (1 H, d, J = 13.0 Hz), 6.56 (1 H, d, J = 3.0 Hz), 7.20 (2H , D, J = 8.0 Hz), 7.25 (2H, d, J = 8.8 Hz), 7.66 (2H, d, J = 3.0 Hz), 7.85 (1H, d, J = 8.5 Hz), 7.97 (1 H, s), 8.16 (2 H, d, J = 8.5 Hz).

実施例５で製造した４−（｛（４−クロロ−１−メチル−１Ｈ−ピロロ［２，３−ｃ］ピリジン−７−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（５０．７ｍｇ，８９．３μｍｏｌ）を、実施例２と同様の方法で処理することにより、４−（｛（４−クロロ−１−メチル−１Ｈ−ピロロ［２，３−ｃ］ピリジン−７−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸ナトリウム（４９．４ｍｇ，９８％）を無色粉末として得た。
ＥＳＩ−ＭＳ ｍ／ｚ：５３８／５４０［Ｍ−Ｎａ］⁻．
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ ３．９０（３Ｈ，ｓ），４．５８（１Ｈ，ｄ，Ｊ＝１３．２Ｈｚ），４．９９（１Ｈ，ｄ，Ｊ＝１３．２Ｈｚ），６．５４（１Ｈ，ｄ，Ｊ＝３．２Ｈｚ），７．２０（２Ｈ，ｄ，Ｊ＝８．０Ｈｚ），７．２５（２Ｈ，ｄ，Ｊ＝８．７Ｈｚ），７．５３（２Ｈ，ｄ，Ｊ＝８．３Ｈｚ），７．６４（１Ｈ，ｄ，Ｊ＝２．９Ｈｚ），７．９６−８．００（３Ｈ，ｍ）． Example 6:
Preparation of 4-({(4-Chloro-1-methyl-1H-pyrrolo [2,3-c] pyridin-7-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) sodium benzoate

4-({(4-Chloro-1-methyl-1H-pyrrolo [2,3-c] pyridin-7-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid prepared in Example 5 Ethyl acid (50.7 mg, 89.3 μmol) was treated in the same manner as in Example 2 to give 4-({(4-chloro-1-methyl-1H-pyrrolo [2,3-c] pyridine. -7-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) sodium benzoate (49.4 mg, 98%) was obtained as a colorless powder.
ESI-MS m / z: 538/540 [M-Na] ⁻ .
¹ H-NMR (DMSO-d ₆ ) δ 3.90 (3H, s), 4.58 (1 H, d, J = 13.2 Hz), 4.99 (1 H, d, J = 13.2 Hz), 6.54 (1H, d, J = 3.2 Hz), 7.20 (2H, d, J = 8.0 Hz), 7.25 (2H, d, J = 8.7 Hz), 7.53 (2H , D, J = 8.3 Hz), 7.64 (1H, d, J = 2.9 Hz), 7.96-8.00 (3H, m).

（１） 実施例１−（１）で得られた４−｛［（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチルおよび１−ブロモ−４−（ブロモメチル）ベンゼンを、実施例１−（２）と同様の方法で処理して４−｛［（４−ブロモベンジル）（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（４６９ｍｇ，７９％）を無色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：５３９［Ｍ＋Ｈ］^＋． Example 7:
4-{[[[(4'-Fluorobiphenyl-4-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} Preparation of ethyl benzoate

(1) Ethyl 4-{[(4-methylisoquinolin-3-yl) amino] sulfonyl} benzoate and 1-bromo-4- (bromomethyl) benzene obtained in Example 1- (1) Treatment with a method similar to 1- (2) gave ethyl 4-{[(4-bromobenzyl) (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoate (469 mg, 79%) as a colorless powder. Obtained.
APCI-MS m / z: 539 [M + H] ⁺ .

(2) 1,2-dimethoxy of the above compound (110 mg, 0.2 mmol), 4-fluorophenylboric acid (33 mg, 0.22 mmol) and tetrakis (triphenylphosphine) palladium (0) (5 mg, 0.004 mmol) Sodium carbonate (33 mg, 0.3 mmol) was added to a mixed solution of ethane (2.0 ml) and water (1.0 ml), and the mixture was heated to reflux for 6 hours. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 9: 1 → 3: 1) to give 4-{[[(4′-fluorobiphenyl-4-yl) methyl] (4-methyl Isoquinolin-3-yl) amino] sulfonyl} ethyl benzoate (88.0 mg, 78%) was obtained as a colorless powder.

実施例７で製造した４−｛［［（４’−フルオロビフェニル−４−イル）メチル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（８８．０ｍｇ，０．１６ｍｍｏｌ）および１ｍｏｌ／Ｌ水酸化ナトリウム水溶液（３２０μｌ，０．３２ｍｍｏｌ）のメタノール（１．６ｍｌ）懸濁液を、室温にて終夜撹拌した後、反応液に２ｍｏｌ／Ｌ塩酸水溶液（４００μｌ）を加え、クロロホルムで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（クロロホルム：メタノール＝１０：０→９：１）で精製し、４−｛［［（４’−フルオロビフェニル−４−イル）メチル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸（６２．１ｍｇ，７４％）を無色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：５２７［Ｍ＋Ｈ］^＋．
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ ２．４９（３Ｈ，ｓ），４．５０−５．１５（２Ｈ，ｍ），７．１９−７．２８（４Ｈ，ｍ），７．５０（２Ｈ，ｄ，Ｊ＝８．４Ｈｚ），７．５８−７．６３（２Ｈ，ｍ），７．７０−７．７４（１Ｈ，ｍ），７．８０−７．８６（３Ｈ，ｍ），８．０３−８．０６（１Ｈ，ｍ），８．１１−８．１５（３Ｈ，ｍ），９．０１（１Ｈ，ｓ）． Example 8:
4-{[[((4′-Fluorobiphenyl-4-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid preparation

4-{[[((4′-Fluorobiphenyl-4-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} ethyl benzoate (88.0 mg, 0.16 mmol) prepared in Example 7 And a 1 mol / L aqueous solution of sodium hydroxide (320 μl, 0.32 mmol) in methanol (1.6 ml) was stirred overnight at room temperature, then a 2 mol / L aqueous hydrochloric acid solution (400 μl) was added to the reaction solution, and chloroform was added. And extracted twice. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform: methanol = 10: 0 → 9: 1), and 4-{[[(4′-fluorobiphenyl-4-yl) methyl] (4-methylisoquinoline). -3-yl) amino] sulfonyl} benzoic acid (62.1 mg, 74%) was obtained as a colorless powder.
APCI-MS m / z: 527 [M + H] ⁺ .
¹ H-NMR (DMSO-d ₆ ) δ 2.49 (3H, s), 4.50-5.15 (2H, m), 7.19-7.28 (4H, m), 7.50 ( 2H, d, J = 8.4 Hz), 7.58-7.63 (2H, m), 7.70-7.74 (1H, m), 7.80-7.86 (3H, m), 8.03-8.06 (1H, m), 8.11-8.15 (3H, m), 9.01 (1H, s).

（１） １−ブロモ−４−メチルイソキノリン−３−アミン、４−クロロスルホニル安息香酸エチルおよび１−（ブロモメチル）−４−（トリフルオロメトキシ）ベンゼンを、実施例１−（１）、（２）と同様の方法で処理して４−（｛（１−ブロモ−４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチルを無色固体として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：６２３／６２５［Ｍ＋Ｈ］^＋． Example 9:
Preparation of 4-({(1-cyclopropyl-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) ethyl benzoate

(1) 1-Bromo-4-methylisoquinolin-3-amine, ethyl 4-chlorosulfonylbenzoate and 1- (bromomethyl) -4- (trifluoromethoxy) benzene were mixed with Examples 1- (1), (2 ) To give ethyl 4-({(1-bromo-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoate as a colorless solid. .
APCI-MS m / z: 623/625 [M + H] ⁺ .

(2) Compound (100 mg, 160 μmol), cyclopropyl trifluoroborate potassium salt (45.9 mg, 321 μmol), palladium acetate (3.7 mg, 16.0 μmol), di (1-adamantyl) butylphosphine (9.1 mg) , 24.1 μmol), cesium carbonate (105 mg, 321 μmol), water (80 μl) and toluene (802 μl) were heated to reflux for 3 hours under an argon atmosphere. After cooling, the reaction solution was diluted with ethyl acetate, filtered through a diatomaceous earth column, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 19: 1 → 17: 3), and 4-({(1-cyclopropyl-4-methylisoquinolin-3-yl) [4- (Trifluoromethoxy) benzyl] amino} sulfonyl) ethyl benzoate (93.0 mg, 99%) was obtained as a pale yellow solid.
APCI-MS m / z: 585 [M + H] ⁺ .
¹ H-NMR (DMSO-d ₆ ) δ 0.25-0.95 (4H, m), 1.37 (3H, t, J = 7.3 Hz), 2.38 (3H, s), 2. 73-2.82 (1H, m), 4.40 (2H, q, J = 7.3 Hz), 4.46-5.12 (2H, m), 7.20 (2H, d, J = 8) .2 Hz), 7.26 (2H, d, J = 8.8 Hz), 7.69-7.75 (1H, m), 7.77-7.84 (3H, m), 8.01 (1H) , D, J = 8.2 Hz), 8.14 (2H, d, J = 8.5 Hz), 8.49 (1H, d, J = 8.2 Hz).

実施例９で製造した４−（｛（１−シクロプロピル−４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）−ベンジル］アミノ｝スルホニル）安息香酸エチル（９２．０ｍｇ，１５７μｍｏｌ）、２ｍｏｌ／Ｌ水酸化ナトリウム水溶液（７９μｌ，１５７μｍｏｌ）およびエタノール（１．５７ｍｌ）の混合物を、１時間加熱還流した。反応液を減圧濃縮し、得られた残渣をジエチルエーテルおよびペンタンで洗浄し、４−（｛（１−シクロプロピル−４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸ナトリウム（８６．６ｍｇ，９５％）を無色粉末として得た。
ＥＳＩ−ＭＳ ｍ／ｚ：５５５［Ｍ−Ｎａ］⁻．
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ ０．４５−０．９５（４Ｈ，ｍ），２．４１（３Ｈ，ｓ），２．７６−２．８３（１Ｈ，ｍ），４．４０−５．１０（２Ｈ，ｍ），７．１９（２Ｈ，ｄ，Ｊ＝８．０Ｈｚ），７．２７（２Ｈ，ｄ，Ｊ＝８．７Ｈｚ），７．５３（２Ｈ，ｄ，Ｊ＝８．７Ｈｚ），７．６８−７．７３（１Ｈ，ｍ），７．７７−７．８２（１Ｈ，ｍ），７．９７−８．０２（３Ｈ，ｍ），８．４９（１Ｈ，ｄ，Ｊ＝８．３Ｈｚ）． Example 10:
Preparation of 4-({(1-cyclopropyl-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) sodium benzoate

Ethyl 4-({(1-cyclopropyl-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) -benzyl] amino} sulfonyl) benzoate (92.0 mg, 157 μmol) prepared in Example 9 A mixture of 2 mol / L aqueous sodium hydroxide solution (79 μl, 157 μmol) and ethanol (1.57 ml) was heated to reflux for 1 hour. The reaction mixture was concentrated under reduced pressure, and the resulting residue was washed with diethyl ether and pentane to give 4-({(1-cyclopropyl-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino. } Sulfonyl) sodium benzoate (86.6 mg, 95%) was obtained as a colorless powder.
ESI-MS m / z: 555 [M-Na] ⁻ .
¹ H-NMR (DMSO-d ₆ ) δ 0.45-0.95 (4H, m), 2.41 (3H, s), 2.76-2.83 (1H, m), 4.40- 5.10 (2H, m), 7.19 (2H, d, J = 8.0 Hz), 7.27 (2H, d, J = 8.7 Hz), 7.53 (2H, d, J = 8) .7 Hz), 7.68-7.73 (1H, m), 7.77-7.82 (1H, m), 7.97-8.02 (3H, m), 8.49 (1H, d) , J = 8.3 Hz).

（１） 実施例１−（１）で得られた４−｛［（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチルおよび参考例３で得られた６−（ブロモメチル）−３−フルオロ−２−ヨードピリジンを、実施例１−（２）と同様の方法で処理して４−｛［［（５−フルオロ−６−ヨードピリジン−２−イル）メチル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチルを無色粘体として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：６０６［Ｍ＋Ｈ］^＋． Example 11:
4-{[{[5-Fluoro-6- (trifluoromethyl) pyridin-2-yl] methyl} (4-methylisoquinolin-3-yl) amino] sulfonyl} Preparation of ethyl benzoate

(1) Ethyl 4-{[(4-methylisoquinolin-3-yl) amino] sulfonyl} benzoate obtained in Example 1- (1) and 6- (bromomethyl) -3 obtained in Reference Example 3 4-Fluoro-2-iodopyridine was treated in the same manner as in Example 1- (2) to give 4-{[[(5-Fluoro-6-iodopyridin-2-yl) methyl] (4-methylisoquinoline. -3-yl) amino] sulfonyl} ethyl benzoate was obtained as a colorless viscous body.
APCI-MS m / z: 606 [M + H] ⁺ .

(2) Under a stream of argon, a mixed solution of the above compound (68 mg, 0.112 mmol) in N, N-dimethylformamide (0.5 mL) and hexamethylphosphoric triamide (0.5 mL) was added at room temperature to 2, Methyl 2-difluoro-2- (fluorosulfonyl) acetate (104 μL, 0.82 mmol) and cuprous iodide (156 mg, 0.82 mmol) were added. The reaction mixture was stirred at 70 ° C. overnight, cooled to room temperature, water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 17: 3 → 3: 2), and 4-{[{[5-fluoro-6- (trifluoromethyl) pyridin-2-yl] Methyl} (4-methylisoquinolin-3-yl) amino] sulfonyl} ethyl benzoate (41 mg, 68%) was obtained as a colorless powder.
APCI-MS m / z: 548 [M + H] ⁺ .
¹ H-NMR (CDCl ₃ ) δ 1.43 (3H, t, J = 7.3 Hz) 2.73 (3H, s), 4.44 (2H, q, J = 7.3 Hz), 5.02 (2H, s), 7.44-7.49 (1H, m), 7.63-7.66 (1H, m), 7.73-7.76 (2H, m), 7.78 (2H , D, J = 8.5 Hz), 7.93 (1H, d, J = 8.3 Hz), 8.03 (1H, d, J = 8.3 Hz), 8.16 (2H, d, J = 8.5Hz), 8.82 (1H, s)

実施例１１で製造した４−｛［｛［５−フルオロ−６−（トリフルオロメチル）ピリジン−２−イル］メチル｝（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（３８ｍｇ，０．６４ｍｍｏｌ）を、実施例２と同様の方法で処理して、４−｛［｛［５−フルオロ−６−（トリフルオロメチル）ピリジン−２−イル］メチル｝（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸ナトリウム（３５ｍｇ，９３％）を無色粉末として得た。
ＥＳＩ−ＭＳ ｍ／ｚ：５１８［Ｍ−Ｎａ］⁻．
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ ２．６１（３Ｈ，ｓ），４．８５（１Ｈ，ｂｒｓ），５．１０（１Ｈ，ｂｒｓ），７．５５（２Ｈ，ｄ，Ｊ＝８．７Ｈｚ），７．７０−７．７４（１Ｈ，ｍ），７．７７−７．７９（１Ｈ，ｍ），７．８３−７．８６（１Ｈ，ｍ），７．９２−７．９５（１Ｈ，ｍ），７．９６（２Ｈ，ｄ，Ｊ＝８．３Ｈｚ），８．１０（２Ｈ，ｄ，Ｊ＝８．７Ｈｚ），８．９７（１Ｈ，ｓ）． Example 12:
4-{[{[5-Fluoro-6- (trifluoromethyl) pyridin-2-yl] methyl} (4-methylisoquinolin-3-yl) amino] sulfonyl} preparation of sodium benzoate

4-{[{[5-Fluoro-6- (trifluoromethyl) pyridin-2-yl] methyl} (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid ethyl ester prepared in Example 11 (38 mg , 0.64 mmol) in the same manner as in Example 2 to give 4-{[{[5-fluoro-6- (trifluoromethyl) pyridin-2-yl] methyl} (4-methylisoquinoline- 3-yl) amino] sulfonyl} sodium benzoate (35 mg, 93%) was obtained as a colorless powder.
ESI-MS m / z: 518 [M-Na] ⁻ .
¹ H-NMR (DMSO-d ₆ ) δ 2.61 (3H, s), 4.85 (1H, brs), 5.10 (1H, brs), 7.55 (2H, d, J = 8. 7 Hz), 7.70-7.74 (1 H, m), 7.77-7.79 (1 H, m), 7.83-7.86 (1 H, m), 7.92-7.95 ( 1H, m), 7.96 (2H, d, J = 8.3 Hz), 8.10 (2H, d, J = 8.7 Hz), 8.97 (1H, s).

（１） 実施例１−（１）で得られた４−｛［（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチルおよび４−（２，２，２−トリフルオロ−１−ヒドロキシ−１−メチルエチル）ベンジルアルコールを、実施例３と同様の方法で処理して４−（｛（４−メチルイソキノリン−３−イル）［４−（２，２，２−トリフルオロ−１−ヒドロキシ−１−メチルエチル）ベンジル］アミノ｝スルホニル）安息香酸エチルを無色粘体として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：５７３［Ｍ＋Ｈ］^＋． Example 13:
4-{[[4- (1-Ethoxy-2,2,2-trifluoro-1-methylethyl) benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} Preparation of ethyl benzoate

(1) Ethyl 4-{[(4-methylisoquinolin-3-yl) amino] sulfonyl} benzoate and 4- (2,2,2-trifluoro-1-) obtained in Example 1- (1) Hydroxy-1-methylethyl) benzyl alcohol was treated in the same manner as in Example 3 to give 4-({(4-methylisoquinolin-3-yl) [4- (2,2,2-trifluoro-1 -Hydroxy-1-methylethyl) benzyl] amino} sulfonyl) ethyl benzoate was obtained as a colorless viscous body.
APCI-MS m / z: 573 [M + H] ⁺ .

(2) Sodium hydride (10.5 mg, 0.26 mmol) was added to a solution of the above compound (100 mg, 0.18 mmol) in N, N-dimethylformamide (2 ml) at 0 ° C. After stirring at 0 ° C. for 30 minutes, iodoethane (42 μl, 0.52 mmol) was added at the same temperature. After stirring overnight at room temperature, water was added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, washed twice with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 10: 0 → 7: 3) to give 4-{[[4- (1-ethoxy-2,2,2-trifluoro-1 -Methylethyl) benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} ethyl benzoate (103 mg, 98%) was obtained as a colorless liquid.
APCI-MS m / z: 601 [M + H] ⁺ .
¹ H-NMR (400 MHz, DMSO-d ₆ ) δ 1.00-1.13 (3H, m), 1.37 (3H, t, J = 7.0 Hz), 1.66 (3H, s), 2 .39 (3H, s), 2.89-3.05 (1H, m), 3.29-3.41 (1H, m), 4.39 (2H, q, J = 7.0 Hz), 4 .48-5.16 (2H, m), 7.22 (2H, d, J = 8.5 Hz), 7.34 (2H, d, J = 8.2 Hz), 7.73 (1H, t, J = 7.3 Hz), 7.82 (1H, d, J = 8.5 Hz), 7.86 (2H, d, J = 8.5 Hz), 8.03 (1H, d, J = 8.5 Hz) ), 8.12-8.15 (3H, m), 9.11 (1H, s).

実施例１３で製造した４−｛［［４−（１−エトキシ−２，２，２−トリフルオロ−１−メチルエチル）ベンジル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（１０２ｍｇ，０．１７ｍｍｏｌ）のエタノール（１ｍＬ）およびテトラヒドロフラン（１ｍＬ）の混合溶液に、室温にて２ｍｏｌ／Ｌ水酸化ナトリウム水溶液（３４０μＬ，０．６８ｍｍｏｌ）を加えた。反応液を室温にて終夜撹拌した後、反応液に２ｍｏｌ／Ｌ塩酸水溶液（１ｍｌ）を加え、クロロホルムで３回抽出した。有機層を合わせ、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（クロロホルム：メタノール＝１０：０→１０：１）で精製し、４−｛［［４−（１−エトキシ−２，２，２−トリフルオロ−１−メチルエチル）ベンジル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸（８２ｍｇ，８５％）を無色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：５７３［Ｍ＋Ｈ］^＋．
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ １．００−１．１４（３Ｈ，ｍ），１．６６（３Ｈ，ｓ），２．３９（３Ｈ，ｓ），２．８９−３．０５（１Ｈ，ｍ），３．１７−３．５１（１Ｈ，ｍ），４．４９−５．２８（２Ｈ，ｍ），７．２２（２Ｈ，ｄ，Ｊ＝８．５Ｈｚ），７．３４（２Ｈ，ｄ，Ｊ＝８．２Ｈｚ），７．７３（１Ｈ，ｔ，Ｊ＝７．３Ｈｚ），７．８１−７．８５（３Ｈ，ｍ），８．０３（１Ｈ，ｄ，Ｊ＝８．８Ｈｚ），８．１１−８．１４（３Ｈ，ｍ），９．０２（１Ｈ，ｓ），１２．７１−１４．５９（１Ｈ，ｍ） Example 14:
4-{[[4- (1-Ethoxy-2,2,2-trifluoro-1-methylethyl) benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid

4-{[[4- (1-Ethoxy-2,2,2-trifluoro-1-methylethyl) benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid prepared in Example 13 To a mixed solution of ethyl (102 mg, 0.17 mmol) in ethanol (1 mL) and tetrahydrofuran (1 mL) was added 2 mol / L aqueous sodium hydroxide solution (340 μL, 0.68 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight, 2 mol / L aqueous hydrochloric acid solution (1 ml) was added to the reaction mixture, and the mixture was extracted 3 times with chloroform. The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform: methanol = 10: 0 → 10: 1) to give 4-{[[4- (1-ethoxy-2,2,2-trifluoro-1- Methylethyl) benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid (82 mg, 85%) was obtained as a colorless powder.
APCI-MS m / z: 573 [M + H] ⁺ .
¹ H-NMR (DMSO-d ₆ ) δ 1.00-1.14 (3H, m), 1.66 (3H, s), 2.39 (3H, s), 2.89-3.05 ( 1H, m), 3.17-3.51 (1H, m), 4.49-5.28 (2H, m), 7.22 (2H, d, J = 8.5 Hz), 7.34 ( 2H, d, J = 8.2 Hz), 7.73 (1H, t, J = 7.3 Hz), 7.81-7.85 (3H, m), 8.03 (1H, d, J = 8) .8 Hz), 8.11-8.14 (3H, m), 9.02 (1 H, s), 12.71-14.59 (1 H, m)

Examples 15-37
The corresponding starting material compounds were treated in the same manner as in Examples 1, 2, and / or 8 to obtain the compounds shown in Table 1 below. In addition, a carboxylic acid compound or a salt thereof can be converted into each other by a conventional salt formation treatment or desalting treatment.

Examples 38-87
The corresponding starting material compounds were treated in the same manner as in Examples 3, 4 and / or 8, to obtain the compounds shown in Table 2 below. In addition, a carboxylic acid compound or a salt thereof can be converted into each other by a conventional salt formation treatment or desalting treatment.

Examples 88-91
The corresponding starting material compounds were treated in the same manner as in Examples 7, 8 and / or 2 to obtain the compounds shown in Table 3 below. In addition, a carboxylic acid compound or a salt thereof can be converted into each other by a conventional salt formation treatment or desalting treatment.

Examples 92-95
The corresponding starting material compounds were treated in the same manner as in Example 9 and / or 10 to obtain the compounds shown in Table 4 below. In addition, a carboxylic acid compound or a salt thereof can be converted into each other by a conventional salt formation treatment or desalting treatment.

Example 96
The corresponding starting compounds were treated in the same manner as in Examples 13 and 14 to give the compounds shown in Table 5 below. In addition, a carboxylic acid compound or a salt thereof can be converted into each other by a conventional salt formation treatment or desalting treatment.

（１） 実施例９−（１）で合成した４−（｛（１−ブロモ−４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（９３．５ｍｇ，０．１５ｍｍｏｌ）および１−プロペニルボロン酸を実施例７−（２）と同様の方法で処理することにより、４−（｛｛４−メチル−１−［（１Ｅ）−プロプ−１−エン−１−イル］イソキノリン−３−イル｝［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（８６．９ｍｇ，９９％）を薄黄色の粘体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ５８５［Ｍ＋Ｈ］^＋
（２） 上記化合物（８６．９ｍｇ，０．１４９ｍｍｏｌ）のテトラヒドロフラン（５ｍＬ）溶液に酸化プラチナ（３．４ｍｇ，０．０１４９ｍｍｏｌ）を加え、水素気流下、室温で３時間攪拌した。酢酸エチルを用いて珪藻土ろ過を行い、ろ液を減圧濃縮することにより、粗４−（｛（４−メチル−１−プロピルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチルを得た。
（３）上記粗生成物を実施例１４と同様の方法で処理することにより、４−（｛（４−メチル−１−プロピルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸（７０．３ｍｇ，８４％，二段階収率）を白色粉末として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ５５９［Ｍ＋Ｈ］^＋ Example 97
Preparation of 4-({(4-Methyl-1-propylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid

(1) Ethyl 4-({(1-bromo-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoate (93) synthesized in Example 9- (1) .5 mg, 0.15 mmol) and 1-propenylboronic acid in the same manner as in Example 7- (2) to give 4-({{4-methyl-1-[(1E) -prop-1 -En-1-yl] isoquinolin-3-yl} [4- (trifluoromethoxy) benzyl] amino} sulfonyl) ethyl benzoate (86.9 mg, 99%) was obtained as a pale yellow gum.
APCI-MS: m / z 585 [M + H] ⁺
(2) Platinum oxide (3.4 mg, 0.0149 mmol) was added to a tetrahydrofuran (5 mL) solution of the above compound (86.9 mg, 0.149 mmol), and the mixture was stirred at room temperature for 3 hours in a hydrogen stream. Diatomaceous earth filtration was performed using ethyl acetate, and the filtrate was concentrated under reduced pressure to give crude 4-({(4-methyl-1-propylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino}. Sulfonyl) ethyl benzoate was obtained.
(3) The crude product is treated in the same manner as in Example 14 to give 4-({(4-methyl-1-propylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino. } Sulfonyl) benzoic acid (70.3 mg, 84%, two step yield) was obtained as a white powder.
APCI-MS: m / z 559 [M + H] ⁺

アルゴン気流下、実施例９−（１）で合成した４−（｛（１−ブロモ−４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（９３．５ｍｇ，０．１５ｍｍｏｌ）、ピロリジン（０．０１５ｍＬ，０．１８ｍｍｏｌ）、２，２’−ビス（ジフェニルホスフィノ）−１，１’−ビナフチル（９．３ｍｇ，０．０１５ｍｍｏｌ）、トリスジベンジリデンアセトンジパラジウム（６．９ｍｇ、０．００７５ｍｍｏｌ）およびナトリウムｔ−ブトキシド（２０．２ｍｇ，０．２１ｍｍｏｌ）のトルエン（２ｍＬ）混合物を、１００℃にて４時間攪拌した。室温まで冷却した後、ろ過を行い、ろ液を減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（酢酸エチル／ヘキサン＝１０％→２５％）で精製し、４−（｛（４−メチル−１−ピロリジン−１−イルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（２２．４ｍｇ，２４％）を黄色粘体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ６１４［Ｍ＋Ｈ］^＋ Example 98:
Preparation of 4-({(4-Methyl-1-pyrrolidin-1-ylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) ethyl benzoate

Ethyl 4-({(1-bromo-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoate synthesized in Example 9- (1) under an argon stream ( 93.5 mg, 0.15 mmol), pyrrolidine (0.015 mL, 0.18 mmol), 2,2′-bis (diphenylphosphino) -1,1′-binaphthyl (9.3 mg, 0.015 mmol), trisuji A toluene (2 mL) mixture of benzylideneacetone dipalladium (6.9 mg, 0.0075 mmol) and sodium t-butoxide (20.2 mg, 0.21 mmol) was stirred at 100 ° C. for 4 hours. After cooling to room temperature, filtration was performed and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (ethyl acetate / hexane = 10% → 25%), and 4-({(4-methyl-1-pyrrolidin-1-ylisoquinolin-3-yl) [4- (Trifluoromethoxy) benzyl] amino} sulfonyl) ethyl benzoate (22.4 mg, 24%) was obtained as a yellow viscous body.
APCI-MS: m / z 614 [M + H] ⁺

実施例９８で製造した４−（｛（４−メチル−１−ピロリジン−１−イルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（２２．４ｍｇ，０．０３６５ｍｍｏｌ）を実施例１４と同様の方法で処理することにより、４−（｛（４−メチル−１−ピロリジン−１−イルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸（２０．８ｍｇ，９７％）を黄色粉末として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ５８６［Ｍ＋Ｈ］^＋ Example 99:
Preparation of 4-({(4-Methyl-1-pyrrolidin-1-ylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid

4-({(4-Methyl-1-pyrrolidin-1-ylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid ethyl ester (22.4 mg, prepared in Example 98) 0.0365 mmol) was treated in the same manner as Example 14 to give 4-({(4-methyl-1-pyrrolidin-1-ylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] Amino} sulfonyl) benzoic acid (20.8 mg, 97%) was obtained as a yellow powder.
APCI-MS: m / z 586 [M + H] ⁺

アルゴン気流下、実施例９−（１）で製造した４−（｛（１−ブロモ−４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（９３．５ｍｇ、０．１５ｍｍｏｌ）、水素化ナトリウム（６０．０ｍｇ、１．５ｍｍｏｌ）のテトラヒドロフラン（２ｍＬ）懸濁液に２−プロパノール（０．１１５ｍＬ、１．５ｍｍｏｌ）を加え、４時間加熱還流した。２ｍｏｌ／Ｌ塩酸により中和し、クロロホルムを加えて攪拌した後、分液し、有機層を減圧濃縮し、残渣をシリカゲルカラムクロマトグラフィー（メタノール／クロロホルム＝２％→１０％）で精製し、４−（｛（１−イソプロポキシ−４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸（５３．１ｍｇ，５８％）を茶色粉末として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ５７５［Ｍ＋Ｈ］^＋ Example 100:
Preparation of 4-({(1-Isopropoxy-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid

4-({(1-Bromo-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid ethyl benzoate prepared in Example 9- (1) under an argon stream To a suspension of 93.5 mg, 0.15 mmol) and sodium hydride (60.0 mg, 1.5 mmol) in tetrahydrofuran (2 mL) was added 2-propanol (0.115 mL, 1.5 mmol) and heated to reflux for 4 hours. . After neutralizing with 2 mol / L hydrochloric acid, adding chloroform and stirring, the mixture was separated, the organic layer was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (methanol / chloroform = 2% → 10%). -({(1-Isopropoxy-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid (53.1 mg, 58%) was obtained as a brown powder.
APCI-MS: m / z 575 [M + H] ⁺

（１） 参考例２１で得られた１−ブロモ−５−クロロイソキノリン−３−アミン（２５８ｍｇ，１ｍｍｏｌ）、４−クロロスルホニル安息香酸エチルおよび１−（ブロモメチル）−４−（トリフルオロメトキシ）ベンゼンを実施例１−（１）および（２）と同様の方法で処理することにより、４−（｛（１−ブロモ−５−クロロイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチルを茶色固体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ６４３／６４５／６４７［Ｍ＋Ｈ］^＋
（２） アルゴン気流下、上記化合物（１９３ｍｇ，０．３ｍｍｏｌ）、酢酸パラジウム（３．４ｍｇ，０．０１５ｍｍｏｌ）、トリフェニルホスフィン（１５．７ｍｇ，０．０６ｍｍｏｌ）および炭酸カリウム（８２．９ｍｇ，０．６ｍｍｏｌ）の２−プロパノール（２ｍＬ）混合物を、６時間加熱還流した。反応液を室温まで冷却し、酢酸エチルを加えてろ過し、不溶物を除去した。ろ液を減圧濃縮した後、シリカゲルカラムクロマトグラフィー（酢酸エチル／ヘキサン＝１０％→３０％）で精製し、４−（｛（５−クロロイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸イソプロピル（８１．２ｍｇ，４７％）を薄黄色粘体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ５７９／５８１［Ｍ＋Ｈ］^＋ Example 101:
Preparation of 4-({(5-chloroisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) isopropyl benzoate

(1) 1-Bromo-5-chloroisoquinolin-3-amine (258 mg, 1 mmol), ethyl 4-chlorosulfonylbenzoate and 1- (bromomethyl) -4- (trifluoromethoxy) benzene obtained in Reference Example 21 Is treated in a manner similar to Example 1- (1) and (2) to give 4-({(1-bromo-5-chloroisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl]. Amino} sulfonyl) ethyl benzoate was obtained as a brown solid.
APCI-MS: m / z 643/645/647 [M + H] ⁺
(2) Under an argon stream, the above compound (193 mg, 0.3 mmol), palladium acetate (3.4 mg, 0.015 mmol), triphenylphosphine (15.7 mg, 0.06 mmol) and potassium carbonate (82.9 mg, 0 .6 mmol) of 2-propanol (2 mL) was heated to reflux for 6 hours. The reaction solution was cooled to room temperature, ethyl acetate was added and filtered to remove insoluble matters. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (ethyl acetate / hexane = 10% → 30%) to give 4-({(5-chloroisoquinolin-3-yl) [4- (trifluoromethoxy). [Benzyl] amino} sulfonyl) isopropyl benzoate (81.2 mg, 47%) was obtained as a pale yellow gum.
APCI-MS: m / z 579/581 [M + H] ⁺

実施例１０１で製造した４−（｛（５−クロロイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸イソプロピル（４２．２ｍｇ，０．０７２９ｍｍｏｌ）を実施例１４と同様の方法で処理することにより、４−（｛（５−クロロイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸（３５．８ｍｇ，９１％）を白色粉末として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ５３７／５３９［Ｍ＋Ｈ］^＋ Example 102:
Preparation of 4-({(5-chloroisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid

4-({(5-Chloroisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) isopropyl benzoate (42.2 mg, 0.0729 mmol) prepared in Example 101 was used in Example 14. 4-({(5-chloroisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid (35.8 mg, 91%) was treated in the same manner as Obtained as a powder.
APCI-MS: m / z 537/539 [M + H] ⁺

実施例１５３で製造した４−（｛（４−ブロモイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（６５．０ｍｇ，０．１０７ｍｍｏｌ）、シクロプロピルボロン酸（２７．０ｍｇ，０．３２１ｍｍｏｌ）、酢酸パラジウム（２．５ｍｇ，０．０１１ｍｍｏｌ）、トリシクロヘキシルホスフィン（５．９ｍｇ，０．０２１ｍｍｏｌ）およびリン酸三カリウム（７９．０ｍｇ，０．３７５ｍｍｏｌ）の水（０．０２７ｍＬ）およびトルエン（０．５４ｍＬ）混合物を、アルゴン雰囲気下、１００℃にて５時間撹拌した。冷却後、反応液を酢酸エチルで希釈し、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９５：５→６５：３５）で精製し、４−（｛（４−シクロプロピルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（４６．７ｍｇ，７８％）を白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：５７１［Ｍ＋Ｈ］^＋． Example 103:
Preparation of 4-({(4-cyclopropylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) ethyl benzoate

4-({(4-Bromoisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid ethyl ester prepared in Example 153 (65.0 mg, 0.107 mmol), cyclopropyl boron Of acid (27.0 mg, 0.321 mmol), palladium acetate (2.5 mg, 0.011 mmol), tricyclohexylphosphine (5.9 mg, 0.021 mmol) and tripotassium phosphate (79.0 mg, 0.375 mmol). A mixture of water (0.027 mL) and toluene (0.54 mL) was stirred at 100 ° C. for 5 hours under an argon atmosphere. After cooling, the reaction mixture was diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 95: 5 → 65: 35), and 4-({(4-cyclopropylisoquinolin-3-yl) [4- (trifluoromethoxy )] Benzyl] amino} sulfonyl) ethyl benzoate (46.7 mg, 78%) was obtained as a white powder.
APCI-MS m / z: 571 [M + H] ⁺ .

実施例１０３で製造した４−（｛（４−シクロプロピルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（４６．０ｍｇ，０．０８１ｍｍｏｌ）を実施例１４と同様の方法で処理することにより、４−（｛（４−シクロプロピルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸（４１．１ｍｇ，９１％）を白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：５４３［Ｍ＋Ｈ］^＋． Example 104:
Preparation of 4-({(4-cyclopropylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid

4-({(4-Cyclopropylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid ethyl ester (46.0 mg, 0.081 mmol) prepared in Example 103 4-({(4-cyclopropylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid (41.1 mg, 91%) Was obtained as a white powder.
APCI-MS m / z: 543 [M + H] ⁺ .

（１） イソキノリン−３−アミンおよび４−クロロスルホニル安息香酸エチルを実施例１−（１）と同様の方法で処理することにより、４−［（イソキノリン−３−イルアミノ）スルホニル］安息香酸エチルを白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：３５７［Ｍ＋Ｈ］^＋．
（２） 上記化合物（３５６．０ｍｇ，１．００ｍｍｏｌ）およびＮ−ヨードコハク酸イミド（３３７．０ｍｇ，１．５０ｍｍｏｌ）の酢酸（５ｍＬ）混合物を、アルゴン雰囲気下、８０℃にて８時間撹拌した。反応液を冷却後、減圧濃縮した。残渣を酢酸エチルで希釈し、炭酸水素ナトリウム水溶液および飽和食塩水で洗浄した後、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１９：１→３：２）で精製し、４−｛［（４−ヨードイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（２５０．０ｍｇ，５２％）を淡赤色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：４８３［Ｍ＋Ｈ］^＋．
（３） 上記化合物（９６．０ｍｇ，０．２０ｍｍｏｌ）を実施例１−（２）と同様の方法で処理することにより、４−（｛（４−ヨードイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（１２２．０ｍｇ，９３％）を白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：６５７［Ｍ＋Ｈ］^＋．
（４） 上記化合物（１１６．０ｍｇ，０．１８ｍｍｏｌ）を実施例１１−（２）と同様の方法で処理することにより、４−（｛［４−（トリフルオロメトキシ）ベンジル］［４−（トリフルオロメチル）イソキノリン−３−イル］アミノ｝スルホニル）安息香酸エチル（９５．０ｍｇ，９０％）を白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：５９９［Ｍ＋Ｈ］^＋． Example 105:
Preparation of ethyl 4-({[4- (trifluoromethoxy) benzyl] [4- (trifluoromethyl) isoquinolin-3-yl] amino} sulfonyl) benzoate

(1) By treating isoquinolin-3-amine and ethyl 4-chlorosulfonylbenzoate in the same manner as in Example 1- (1), ethyl 4-[(isoquinolin-3-ylamino) sulfonyl] benzoate was obtained. Obtained as a white powder.
APCI-MS m / z: 357 [M + H] ⁺ .
(2) A mixture of the above compound (356.0 mg, 1.00 mmol) and N-iodosuccinimide (337.0 mg, 1.50 mmol) in acetic acid (5 mL) was stirred at 80 ° C. for 8 hours under an argon atmosphere. The reaction mixture was cooled and concentrated under reduced pressure. The residue was diluted with ethyl acetate, washed with aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 19: 1 → 3: 2), and ethyl 4-{[(4-iodoisoquinolin-3-yl) amino] sulfonyl} benzoate ( 250.0 mg, 52%) was obtained as a pale red powder.
APCI-MS m / z: 483 [M + H] ⁺ .
(3) The above compound (96.0 mg, 0.20 mmol) was treated in the same manner as in Example 1- (2) to give 4-({(4-iodoisoquinolin-3-yl) [4- ( Trifluoromethoxy) benzyl] amino} sulfonyl) ethyl benzoate (122.0 mg, 93%) was obtained as a white powder.
APCI-MS m / z: 657 [M + H] ⁺ .
(4) The above compound (116.0 mg, 0.18 mmol) was treated in the same manner as in Example 11- (2) to give 4-({[4- (trifluoromethoxy) benzyl] [4- ( Trifluoromethyl) isoquinolin-3-yl] amino} sulfonyl) ethyl benzoate (95.0 mg, 90%) was obtained as a white powder.
APCI-MS m / z: 599 [M + H] ⁺ .

実施例１０５で製造した４−（｛［４−（トリフルオロメトキシ）ベンジル］［４−（トリフルオロメチル）イソキノリン−３−イル］アミノ｝スルホニル）安息香酸エチル（９３．０ｍｇ，０．１６ｍｍｏｌ）を実施例１４と同様の方法で処理することにより、４−（｛［４−（トリフルオロメトキシ）ベンジル］［４−（トリフルオロメチル）イソキノリン−３−イル］アミノ｝スルホニル）安息香酸（７７．７ｍｇ，８８％）を白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：５７１［Ｍ＋Ｈ］^＋． Example 106:
Preparation of 4-({[4- (trifluoromethoxy) benzyl] [4- (trifluoromethyl) isoquinolin-3-yl] amino} sulfonyl) benzoic acid

4-({[4- (Trifluoromethoxy) benzyl] [4- (trifluoromethyl) isoquinolin-3-yl] amino} sulfonyl) benzoic acid ethyl ester (93.0 mg, 0.16 mmol) prepared in Example 105 Was treated in the same manner as in Example 14 to give 4-({[4- (trifluoromethoxy) benzyl] [4- (trifluoromethyl) isoquinolin-3-yl] amino} sulfonyl) benzoic acid (77 0.7 mg, 88%) was obtained as a white powder.
APCI-MS m / z: 571 [M + H] ⁺ .

（１） 実施例９−（１）で製造した４−（｛（１−ブロモ−４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（９３．５ｍｇ，０．１５ｍｍｏｌ）を参考例３−（１）と同様の方法で処理することにより、４−（｛（１−ヨード−４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（７３．７ｍｇ，７３％）を白色固体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ６７１［Ｍ＋Ｈ］^＋
（２） 上記化合物（７３．７ｍｇ，０．１１ｍｍｏｌ）を実施例１１−（２）と同様の方法で処理することにより、４−（｛［４−メチル−１−（トリフルオロメチル）イソキノリン−３−イル］［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（５２．７ｍｇ，７８％）を白色固体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ６１３［Ｍ＋Ｈ］^＋ Example 107:
Preparation of 4-({[4-Methyl-1- (trifluoromethyl) isoquinolin-3-yl] [4- (trifluoromethoxy) benzyl] amino} sulfonyl) ethyl benzoate

(1) Ethyl 4-({(1-bromo-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoate (93) prepared in Example 9- (1) .5 mg, 0.15 mmol) was treated in the same manner as in Reference Example 3- (1) to give 4-({(1-iodo-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy )] Benzyl] amino} sulfonyl) ethyl benzoate (73.7 mg, 73%) was obtained as a white solid.
APCI-MS: m / z 671 [M + H] ⁺
(2) By treating the above compound (73.7 mg, 0.11 mmol) in the same manner as in Example 11- (2), 4-({[4-methyl-1- (trifluoromethyl) isoquinoline- 3-ethyl] [4- (trifluoromethoxy) benzyl] amino} sulfonyl) ethyl benzoate (52.7 mg, 78%) was obtained as a white solid.
APCI-MS: m / z 613 [M + H] ⁺

実施例１０７で製造した４−（｛［４−メチル−１−（トリフルオロメチル）イソキノリン−３−イル］［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（５２．７ｍｇ，０．０８６ｍｍｏｌ）を実施例１４と同様の方法で処理することにより、４−（｛［４−メチル−１−（トリフルオロメチル）イソキノリン−３−イル］［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸（４７．８ｍｇ，９５％）を白色粉末として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ５８５［Ｍ＋Ｈ］^＋ Example 108:
Preparation of 4-({[4-Methyl-1- (trifluoromethyl) isoquinolin-3-yl] [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid

4-({[4-Methyl-1- (trifluoromethyl) isoquinolin-3-yl] [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid ethyl ester (52.7 mg, prepared in Example 107) 0.086 mmol) in the same manner as in Example 14 to give 4-({[4-methyl-1- (trifluoromethyl) isoquinolin-3-yl] [4- (trifluoromethoxy) benzyl] Amino} sulfonyl) benzoic acid (47.8 mg, 95%) was obtained as a white powder.
APCI-MS: m / z 585 [M + H] ⁺

（１） 参考例２５で得られた４−ヨード−１−イソプロピルイソキノリン−３−アミン、４−クロロスルホニル安息香酸エチルおよび１−（ブロモメチル）−４−（トリフルオロメトキシ）ベンゼンを、実施例１−（１）および（２）と同様の方法で処理することにより、４−（｛（４−ヨード−１−イソプロピルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチルを白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：６９９［Ｍ＋Ｈ］^＋．
（２） 上記化合物を実施例１１−（２）と同様の方法で処理することにより、４−（｛［１−イソプロピル−４−（トリフルオロメチル）イソキノリン−３−イル］［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチルを白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：６４１［Ｍ＋Ｈ］^＋． Example 109:
Preparation of 4-({[1-Isopropyl-4- (trifluoromethyl) isoquinolin-3-yl] [4- (trifluoromethoxy) benzyl] amino} sulfonyl) ethyl benzoate

(1) 4-Iodo-1-isopropylisoquinolin-3-amine, ethyl 4-chlorosulfonylbenzoate and 1- (bromomethyl) -4- (trifluoromethoxy) benzene obtained in Reference Example 25 were 4-({(4-Iodo-1-isopropylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) by treatment in the same manner as (1) and (2) Ethyl benzoate was obtained as a white powder.
APCI-MS m / z: 699 [M + H] ⁺ .
(2) The above compound was treated in the same manner as in Example 11- (2) to give 4-({[1-isopropyl-4- (trifluoromethyl) isoquinolin-3-yl] [4- (tri Fluoromethoxy) benzyl] amino} sulfonyl) ethyl benzoate was obtained as a white powder.
APCI-MS m / z: 641 [M + H] ⁺ .

実施例１０９で製造した４−（｛［１−イソプロピル−４−（トリフルオロメチル）イソキノリン−３−イル］［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチルを実施例１４と同様の方法で処理することにより、４−（｛［１−イソプロピル−４−（トリフルオロメチル）イソキノリン−３−イル］［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸を白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：６１３［Ｍ＋Ｈ］^＋． Example 110:
Preparation of 4-({[1-Isopropyl-4- (trifluoromethyl) isoquinolin-3-yl] [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid

The ethyl 4-({[1-isopropyl-4- (trifluoromethyl) isoquinolin-3-yl] [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoate prepared in Example 109 was By treating in a similar manner, 4-({[1-isopropyl-4- (trifluoromethyl) isoquinolin-3-yl] [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid is obtained as a white powder. Got as.
APCI-MS m / z: 613 [M + H] ⁺ .

実施例１５３で製造した４−（｛（４−ブロモイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（１２２．０ｍｇ，０．２０ｍｍｏｌ）、トリブチル（１−エトキシビニル）スズ（９４．０ｍｇ，０．２６ｍｍｏｌ）およびジクロロビス（トリフェニルホスフィン）パラジウム（ＩＩ）（１４．０ｍｇ，０．０２ｍｍｏｌ）の１，４−ジオキサン（１ｍＬ）混合物を、アルゴン雰囲気下、１６時間加熱還流した。冷却後、反応液を酢酸エチルで希釈し、フッ化カリウム水溶液に注いで６時間撹拌した。不溶物をろ別した後、ろ液を酢酸エチルで抽出し、有機層を水で洗浄した。水洗した有機層に２ｍｏｌ／Ｌ塩酸を加えて３日間撹拌後、有機層を分離して水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１９：１→３：２）で精製し、４−（｛（４−アセチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（５３．４ｍｇ，４７％）を白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：５７３［Ｍ＋Ｈ］^＋． Example 111:
Preparation of ethyl 4-({(4-acetylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoate

4-({(4-Bromoisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid ethyl ester (122.0 mg, 0.20 mmol) prepared in Example 153, tributyl (1 -Ethoxyvinyl) tin (94.0 mg, 0.26 mmol) and dichlorobis (triphenylphosphine) palladium (II) (14.0 mg, 0.02 mmol) in a 1,4-dioxane (1 mL) mixture under an argon atmosphere. Heated to reflux for 16 hours. After cooling, the reaction solution was diluted with ethyl acetate, poured into an aqueous potassium fluoride solution, and stirred for 6 hours. The insoluble material was filtered off, the filtrate was extracted with ethyl acetate, and the organic layer was washed with water. To the organic layer washed with water, 2 mol / L hydrochloric acid was added and stirred for 3 days. The organic layer was separated, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 19: 1 → 3: 2), and 4-({(4-acetylisoquinolin-3-yl) [4- (trifluoromethoxy) [Benzyl] amino} sulfonyl) ethyl benzoate (53.4 mg, 47%) was obtained as a white powder.
APCI-MS m / z: 573 [M + H] ⁺ .

実施例１１１で製造した４−（｛（４−アセチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（５１．０ｍｇ，０．０８９ｍｍｏｌ）を実施例１４と同様の方法で処理することにより、４−（｛（４−アセチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸（３６．９ｍｇ，７６％）を白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：５４５［Ｍ＋Ｈ］^＋． Example 112:
Preparation of 4-({(4-acetylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid

Ethyl 4-({(4-acetylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoate (51.0 mg, 0.089 mmol) prepared in Example 111 was used in Example 14. 4-({(4-acetylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid (36.9 mg, 76%) was treated in the same manner as Obtained as a powder.
APCI-MS m / z: 545 [M + H] ⁺ .

実施例１１２で製造した４−（｛（４−アセチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸（２０．０ｍｇ，０．０３６ｍｍｏｌ）のエタノール（１ｍＬ）溶液に水素化ホウ素ナトリウム（１０．０ｍｇ，０．２６４ｍｍｏｌ）を加え、室温で３時間撹拌した。反応液に１ｍｏｌ／Ｌ塩酸を加え、反応液を減圧濃縮した後、酢酸エチルで希釈して、水、および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（クロロホルム：メタノール＝１０：０→９：１）で精製し、４−（｛［４−（１−ヒドロキシエチル）イソキノリン−３−イル］［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸（１７．１ｍｇ，８７％）を白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：５４７［Ｍ＋Ｈ］^＋． Example 113:
Preparation of 4-({[4- (1-hydroxyethyl) isoquinolin-3-yl] [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid

4-({(4-Acetylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid (20.0 mg, 0.036 mmol) prepared in Example 112 in ethanol (1 mL) Sodium borohydride (10.0 mg, 0.264 mmol) was added to the solution and stirred at room temperature for 3 hours. 1 mol / L hydrochloric acid was added to the reaction solution, and the reaction solution was concentrated under reduced pressure, diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform: methanol = 10: 0 → 9: 1) to give 4-({[4- (1-hydroxyethyl) isoquinolin-3-yl] [4- ( Trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid (17.1 mg, 87%) was obtained as a white powder.
APCI-MS m / z: 547 [M + H] ⁺ .

（１） アルゴン気流下、実施例９−（１）で合成した４−（｛（１−ブロモ−４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（９３．５ｍｇ，０．１５ｍｍｏｌ）、トリブチル（１−エトキシビニル）スズ（０．０６１ｍＬ、０．１８ｍｍｏｌ）およびジクロロビス（トリフェニルホスフィン）パラジウム（ＩＩ）（５．３ｍｇ，０．００７５ｍｍｏｌ）の１，４−ジオキサン（２ｍＬ）混合物を、８０℃にて４時間攪拌した。反応液を減圧濃縮し、残渣をシリカゲルクロマトグラフィー（酢酸エチル：ヘキサン＝１：９→３：７）で精製することにより、粗４−（｛［１−（１−エトキシビニル）−４−メチルイソキノリン−３−イル］［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（１５２ｍｇ）を薄黄色の粘体として得た。
（２） 上記粗生成物のテトラヒドロフラン（５ｍＬ）溶液に、６ｍｏｌ／Ｌ塩酸（０．５ｍＬ）を加え、室温にて２４時間攪拌した。反応液を水で希釈した後、酢酸エチルで３回抽出した。有機層をあわせ、飽和炭酸水素ナトリウム水溶液で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮し、粗４−（｛（１−アセチル−４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチルを得た。
（３） 上記粗生成物のエタノール（５ｍＬ）溶液に、０℃にて水素化ホウ素ナトリウム（１１．３ｍｇ，０．３ｍｍｏｌ）を加え、同温にて３０分攪拌した。飽和塩化アンモニウム水溶液を加え、エタノールを減圧濃縮した後、酢酸エチルで３回抽出した。有機層を無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（酢酸エチル：ヘキサン＝１：３→１：１）で精製し、４−（｛［１−（１−ヒドロキシエチル）−４−メチルイソキノリン−３−イル］［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（８３．０ｍｇ，９４％，三段階収率）を無色の粘体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ５８９［Ｍ＋Ｈ］^＋ Example 114:
Preparation of 4-({[1- (1-hydroxyethyl) -4-methylisoquinolin-3-yl] [4- (trifluoromethoxy) benzyl] amino} sulfonyl) ethyl benzoate

(1) 4-({(1-Bromo-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid synthesized in Example 9- (1) under an argon stream Of ethyl acetate (93.5 mg, 0.15 mmol), tributyl (1-ethoxyvinyl) tin (0.061 mL, 0.18 mmol) and dichlorobis (triphenylphosphine) palladium (II) (5.3 mg, 0.0075 mmol) The 1,4-dioxane (2 mL) mixture was stirred at 80 ° C. for 4 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (ethyl acetate: hexane = 1: 9 → 3: 7) to give crude 4-({[1- (1-ethoxyvinyl) -4-methyl. Isoquinolin-3-yl] [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid ethyl ester (152 mg) was obtained as a pale yellow viscous body.
(2) To a solution of the above crude product in tetrahydrofuran (5 mL) was added 6 mol / L hydrochloric acid (0.5 mL), and the mixture was stirred at room temperature for 24 hours. The reaction mixture was diluted with water and extracted three times with ethyl acetate. The organic layers were combined, washed with a saturated aqueous solution of sodium bicarbonate, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and crude 4-({(1-acetyl-4-methylisoquinolin-3-yl) [4- (trifluoro Methoxy) benzyl] amino} sulfonyl) ethyl benzoate was obtained.
(3) Sodium borohydride (11.3 mg, 0.3 mmol) was added to a solution of the above crude product in ethanol (5 mL) at 0 ° C., and the mixture was stirred at the same temperature for 30 minutes. Saturated aqueous ammonium chloride solution was added, ethanol was concentrated under reduced pressure, and extracted three times with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (ethyl acetate: hexane = 1: 3 → 1: 1) to give 4-({[1- (1-hydroxyethyl) -4-methylisoquinolin-3-yl]. [4- (Trifluoromethoxy) benzyl] amino} sulfonyl) ethyl benzoate (83.0 mg, 94%, three step yield) was obtained as a colorless gum.
APCI-MS: m / z 589 [M + H] ⁺

実施例１１４で製造した４−（｛［１−（１−ヒドロキシエチル）−４−メチルイソキノリン−３−イル］［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸エチル（８３．０ｍｇ，０．１４１ｍｍｏｌ）を実施例１４と同様の方法で処理することにより、４−（｛［１−（１−ヒドロキシエチル）−４−メチルイソキノリン−３−イル］［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸（７６．０ｍｇ，９６％）を白色粉末として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ５６１［Ｍ＋Ｈ］^＋ Example 115:
Preparation of 4-({[1- (1-hydroxyethyl) -4-methylisoquinolin-3-yl] [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid

4-({[1- (1-hydroxyethyl) -4-methylisoquinolin-3-yl] [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid ethyl ester (83.0 mg) prepared in Example 114 , 0.141 mmol) in the same manner as in Example 14 to give 4-({[1- (1-hydroxyethyl) -4-methylisoquinolin-3-yl] [4- (trifluoromethoxy). [Benzyl] amino} sulfonyl) benzoic acid (76.0 mg, 96%) was obtained as a white powder.
APCI-MS: m / z 561 [M + H] ⁺

（１） ６−（ヒドロキシメチル）−１Ｈ−インドール−１−カルボン酸 ｔｅｒｔ−ブチル（７７０ｍｇ，３．１ｍｍｏｌ）および実施例１−（１）で得られた４−｛［（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（８８７ｍｇ，２．４ｍｍｏｌ）を実施例３と同様の方法で処理することにより、６−｛［｛［４−（エトキシカルボニル）フェニル］スルホニル｝（４−メチルイソキノリン−３−イル）アミノ］メチル｝−１Ｈ−インドール−１−カルボン酸 ｔｅｒｔ−ブチル（７８９ｍｇ，５５％）を無色の油状物として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ６００［Ｍ＋Ｈ］^＋
（２） 上記化合物（７８９ｍｇ，１．３２ｍｍｏｌ）のジメチルスルホキシド（５．２ｍＬ）溶液に室温にて水（２．６ｍＬ）を加え、１２０℃で５時間撹拌した。反応液を室温まで冷却し、水を加え酢酸エチルで２回抽出した。有機層を合わせ、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１９：１→２：１）で精製し、４−｛［（１Ｈ−インドール−６−イルメチル）（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（５３５ｍｇ，８１％）を白色固体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ５００［Ｍ＋Ｈ］^＋ Example 116:
4-{[(1H-Indol-6-ylmethyl) (4-methylisoquinolin-3-yl) amino] sulfonyl} Preparation of ethyl benzoate

(1) 6- (Hydroxymethyl) -1H-indole-1-carboxylic acid tert-butyl (770 mg, 3.1 mmol) and 4-{[(4-methylisoquinoline-) obtained in Example 1- (1) 3-yl) amino] sulfonyl} ethyl benzoate (887 mg, 2.4 mmol) was treated in the same manner as in Example 3 to give 6-{[{[4- (ethoxycarbonyl) phenyl] sulfonyl} (4 -Methylisoquinolin-3-yl) amino] methyl} -1H-indole-1-carboxylate tert-butyl (789 mg, 55%) was obtained as a colorless oil.
APCI-MS: m / z 600 [M + H] ⁺
(2) To a solution of the above compound (789 mg, 1.32 mmol) in dimethyl sulfoxide (5.2 mL) was added water (2.6 mL) at room temperature, and the mixture was stirred at 120 ° C. for 5 hours. The reaction mixture was cooled to room temperature, water was added, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 19: 1 → 2: 1) to give 4-{[(1H-indol-6-ylmethyl) (4-methylisoquinolin-3-yl ) Amino] sulfonyl} ethyl benzoate (535 mg, 81%) was obtained as a white solid.
APCI-MS: m / z 500 [M + H] ⁺

実施例１１６で製造した４−｛［（１Ｈ−インドール−６−イルメチル）（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（６２ｍｇ，０．１３ｍｍｏｌ）を実施例８と同様の方法で処理することにより、４−｛［（１Ｈ−インドール−６−イルメチル）（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸（２８ｍｇ，４８％）を白色固体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ４７２［Ｍ＋Ｈ］^＋ Example 117:
Preparation of 4-{[(1H-indol-6-ylmethyl) (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid

Ethyl 4-{[(1H-indol-6-ylmethyl) (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoate (62 mg, 0.13 mmol) prepared in Example 116 was used in the same manner as in Example 8. Treatment with the method gave 4-{[(1H-indol-6-ylmethyl) (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid (28 mg, 48%) as a white solid.
APCI-MS: m / z 472 [M + H] ⁺

（１） 参考例５２で得られた（１−メチル−２，３−ジヒドロ−１Ｈ−インドール−６−イル）メタノール（２４５ｍｇ，１．５０ｍｍｏｌ）および実施例１−（１）で得られた４−｛［（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（４２７ｍｇ，１．１５ｍｍｏｌ）を実施例３と同様の方法で処理することにより、４−｛［［（１−メチル−２，３−ジヒドロ−１Ｈ−インドール−６−イル）メチル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（１２７ｍｇ，２１％）を白色固体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ５１６［Ｍ＋Ｈ］^＋
（２） 上記化合物（１２５ｍｇ，０．２４ｍｍｏｌ）の１，４−ジオキサン（１２ｍＬ）溶液に、室温にて２，３−ジクロロ−５，６−ジシアノ−ｐ−ベンゾキノン（６１ｍｇ，０．２６ｍｍｏｌ）を加え、同温で３日間撹拌した。反応液に飽和重曹水を加え、３時間撹拌した後、珪藻土ろ過を行い、不溶物をろ別した。このろ液を酢酸エチルで２回抽出した。有機層を合わせ、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９：１→３：１）で精製することにより、４−｛［［（１−メチル−１Ｈ−インドール−６−イル）メチル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（８７ｍｇ，７０％）を白色固体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ５１４［Ｍ＋Ｈ］^＋ Example 118
4-{[[[(1-Methyl-1H-indol-6-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} Preparation of ethyl benzoate

(1) (1-Methyl-2,3-dihydro-1H-indol-6-yl) methanol (245 mg, 1.50 mmol) obtained in Reference Example 52 and 4 obtained in Example 1- (1) -{[(4-Methylisoquinolin-3-yl) amino] sulfonyl} ethyl benzoate (427 mg, 1.15 mmol) was treated in the same manner as in Example 3 to give 4-{[[(1-methyl -2,3-Dihydro-1H-indol-6-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} ethyl benzoate (127 mg, 21%) was obtained as a white solid.
APCI-MS: m / z 516 [M + H] ⁺
(2) 2,3-Dichloro-5,6-dicyano-p-benzoquinone (61 mg, 0.26 mmol) was added to a 1,4-dioxane (12 mL) solution of the above compound (125 mg, 0.24 mmol) at room temperature. In addition, the mixture was stirred at the same temperature for 3 days. Saturated sodium hydrogen carbonate solution was added to the reaction liquid, and after stirring for 3 hours, diatomaceous earth filtration was performed and the insoluble matter was separated by filtration. The filtrate was extracted twice with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 9: 1 → 3: 1) to give 4-{[[(1-methyl-1H-indol-6-yl) methyl] ( Ethyl 4-methylisoquinolin-3-yl) amino] sulfonyl} benzoate (87 mg, 70%) was obtained as a white solid.
APCI-MS: m / z 514 [M + H] ⁺

実施例１１８で製造した４−｛［［（１−メチル−１Ｈ−インドール−６−イル）メチル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（８３ｍｇ，０．１６ｍｍｏｌ）を実施例８と同様の方法で処理することにより、４−｛［［（１−メチル−１Ｈ−インドール−６−イル）メチル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸（６５ｍｇ，８３％）を白色固体として得た。
ＭＳ：４８６［Ｍ＋Ｈ］^＋，ＡＰＣＩ Example 119:
Preparation of 4-{[[[(1-Methyl-1H-indol-6-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid

4-{[[((1-Methyl-1H-indol-6-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} ethyl benzoate prepared in Example 118 (83 mg, 0.16 mmol) Was treated in the same manner as in Example 8 to give 4-{[[((1-methyl-1H-indol-6-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid. (65 mg, 83%) was obtained as a white solid.
MS: 486 [M + H] ⁺ , APCI

実施例１１６で製造した４−｛［（１Ｈ−インドール−６−イルメチル）（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（１７７ｍｇ，０．３６ｍｍｏｌ）のテトラヒドロフラン（１．８ｍＬ）溶液に、室温にてＮ−クロロコハク酸イミド（５７ｍｇ，０．４３ｍｍｏｌ）を加え１７時間撹拌した。反応液を減圧濃縮し、得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝５：１→１：１）で精製し、４−｛［［（３−クロロ−１Ｈ−インドール−６−イル）メチル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（１２４ｍｇ，６５％）を白色固体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ５３４／５３６［Ｍ＋Ｈ］^＋ Example 120:
4-{[[[(3-Chloro-1H-indol-6-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} Preparation of ethyl benzoate

4-{[(1H-Indol-6-ylmethyl) (4-methylisoquinolin-3-yl) amino] sulfonyl} ethyl benzoate (177 mg, 0.36 mmol) prepared in Example 116 in tetrahydrofuran (1.8 mL) To the solution, N-chlorosuccinimide (57 mg, 0.43 mmol) was added at room temperature and stirred for 17 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (hexane: ethyl acetate = 5: 1 → 1: 1) to give 4-{[[(3-chloro-1H-indole-6 Iyl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} ethyl benzoate (124 mg, 65%) was obtained as a white solid.
APCI-MS: m / z 534/536 [M + H] ⁺

実施例１２０で製造した４−｛［［（３−クロロ−１Ｈ−インドール−６−イル）メチル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（３２ｍｇ，０．０６ｍｍｏｌ）を実施例８と同様の方法で処理することにより、４−｛［［（３−クロロ−１Ｈ−インドール−６−イル）メチル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸（８ｍｇ，２８％）を白色固体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ５０６／５０８［Ｍ＋Ｈ］^＋ Example 121:
Preparation of 4-{[[[(3-Chloro-1H-indol-6-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid

4-{[[((3-Chloro-1H-indol-6-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} ethyl benzoate (32 mg, 0.06 mmol) prepared in Example 120 Was treated in the same manner as in Example 8 to give 4-{[[(3-chloro-1H-indol-6-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid. (8 mg, 28%) was obtained as a white solid.
APCI-MS: m / z 506/508 [M + H] ⁺

（１） 実施例１２０で製造した４−｛［［（３−クロロ−１Ｈ−インドール−６−イル）メチル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（８１ｍｇ，０．１５ｍｍｏｌ）のＮ，Ｎ−ジメチルホルムアミド（１ｍＬ）溶液に、０℃にて水素化ナトリウム（９ｍｇ，０．２２ｍｍｏｌ）を加え、同温にて３０分間撹拌した。反応液にヨウ化メチル（２９μＬ，０．４６ｍｍｏｌ）を加え、室温にて１８時間撹拌した。反応液に水を加え酢酸エチルで２回抽出した。有機層を合わせ、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９：１→２：１）で精製し、粗４−｛［［（３−クロロ−１−メチル−１Ｈ−インドール−６−イル）メチル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸エチル（５３．０ｍｇ）を無色粉末として得た。
（２） 上記粗生成物を実施例８と同様の方法で処理することにより、４−｛［［（３−クロロ−１−メチル−１Ｈ−インドール−６−イル）メチル］（４−メチルイソキノリン−３−イル）アミノ］スルホニル｝安息香酸（３８ｍｇ，４８％，二段階収率）を白色固体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ５２０／５２２［Ｍ＋Ｈ］^＋ Example 122:
4-{[[(3-Chloro-1-methyl-1H-indol-6-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid

(1) 4-{[[[(3-Chloro-1H-indol-6-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} ethyl benzoate (81 mg, 0) prepared in Example 120 .15 mmol) in N, N-dimethylformamide (1 mL) was added sodium hydride (9 mg, 0.22 mmol) at 0 ° C. and stirred at the same temperature for 30 minutes. Methyl iodide (29 μL, 0.46 mmol) was added to the reaction solution, and the mixture was stirred at room temperature for 18 hours. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 9: 1 → 2: 1), and crude 4-{[[(3-chloro-1-methyl-1H-indol-6-yl). Methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} ethyl benzoate (53.0 mg) was obtained as a colorless powder.
(2) The above crude product is treated in the same manner as in Example 8 to give 4-{[[(3-chloro-1-methyl-1H-indol-6-yl) methyl] (4-methylisoquinoline. -3-yl) amino] sulfonyl} benzoic acid (38 mg, 48%, two step yield) was obtained as a white solid.
APCI-MS: m / z 520/522 [M + H] ⁺

実施例２で製造した４−（｛（４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸ナトリウム（１００ｍｇ，０．１８６ｍｍｏｌ）、塩化アンモニウム（５０ｍｇ，０．９２９ｍｍｏｌ）およびＮ，Ｎ−ジイソプロピルエチルアミン（１６２μＬ，０．９２９ｍｍｏｌ）のＮ，Ｎ−ジメチルアセトアミド（１．８ｍＬ）溶液に、０℃にて２−（１Ｈ−７−アザベンゾトリアゾール−１−イル）−１，１，３，３−テトラメチルウロニウムヘキサフルオロホスフェートメタンアミニウム（８５ｍｇ，０．２２３ｍｍｏｌ）を加え、室温にて終夜撹拌した。反応液に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルで３回抽出し、有機層を合わせ水にて２回洗浄し、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（クロロホルム：メタノール＝１００：０→９１：９）で精製することにより、４−（｛（４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）ベンズアミド（２６ｍｇ，２７％）を無色粉末として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ５１６［Ｍ＋Ｈ］^＋ Example 123:
Preparation of 4-({(4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzamide

4-({(4-Methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid sodium salt (100 mg, 0.186 mmol), ammonium chloride (50 mg, prepared in Example 2) 0.9 (29 mmol) and N, N-diisopropylethylamine (162 μL, 0.929 mmol) in N, N-dimethylacetamide (1.8 mL) at 0 ° C. at 2- (1H-7-azabenzotriazole-1- Yl) -1,1,3,3-tetramethyluronium hexafluorophosphate methanaminium (85 mg, 0.223 mmol) was added and stirred at room temperature overnight. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, washed twice with water, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform: methanol = 100: 0 → 91: 9) to give 4-({(4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) [Benzyl] amino} sulfonyl) benzamide (26 mg, 27%) was obtained as a colorless powder.
APCI-MS: m / z 516 [M + H] ⁺

実施例２で製造した４−（｛（４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）安息香酸ナトリウム（１０７．７ｍｇ，０．２００ｍｍｏｌ）のクロロホルム（１ｍＬ）懸濁液に、二塩化オキサリル（２１μＬ，０．２４０ｍｍｏｌ）を加え、室温で２時間撹拌した後、再度、二塩化オキサリル（２１μＬ，０．２４ｍｍｏｌ）を加え、室温で１時間撹拌した。反応液を減圧濃縮した後、得られた残渣をクロロホルム（１ｍＬ）に懸濁し、Ｏ−メチルヒドロキシルアミン塩酸塩（５０．１ｍｇ、０．６００ｍｍｏｌ）およびトリエチルアミン（１３９μＬ，１．００ｍｍｏｌ）のクロロホルム（１ｍＬ）懸濁液に滴下して、室温で１時間撹拌した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝３：１→０：１０）で精製し、Ｎ−メトキシ−４−（｛（４−メチルイソキノリン−３−イル）［４−（トリフルオロメトキシ）ベンジル］アミノ｝スルホニル）ベンズアミド（８８．１ｍｇ，８１％）を白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：５４６［Ｍ＋Ｈ］^＋． Example 124:
Preparation of N-methoxy-4-({(4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzamide

4-({(4-Methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid sodium salt (107.7 mg, 0.200 mmol) prepared in Example 2 in chloroform (1 mL ) Oxalyl dichloride (21 μL, 0.240 mmol) was added to the suspension and stirred at room temperature for 2 hours. Oxalyl dichloride (21 μL, 0.24 mmol) was added again and stirred at room temperature for 1 hour. After the reaction solution was concentrated under reduced pressure, the obtained residue was suspended in chloroform (1 mL), and O-methylhydroxylamine hydrochloride (50.1 mg, 0.600 mmol) and triethylamine (139 μL, 1.00 mmol) in chloroform (1 mL). ) Dropped into the suspension and stirred at room temperature for 1 hour. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 3: 1 → 0: 10), and N-methoxy-4-({(4-methylisoquinolin-3-yl) [4- ( Trifluoromethoxy) benzyl] amino} sulfonyl) benzamide (88.1 mg, 81%) was obtained as a white powder.
APCI-MS m / z: 546 [M + H] ⁺ .

実施例１５２で製造した４−アセチル−Ｎ−（４−メチルイソキノリン−３−イル）−Ｎ−［４−（トリフルオロメトキシ）ベンジル］ベンゼンスルホンアミド（９８ｍｇ，０．１９０ｍｍｏｌ）のジエチルエーテル（２ｍＬ）溶液に、０℃にてメチルマグネシウムブロミド（テトラヒドロフラン溶液、３ｍｏｌ／Ｌ，０．２２９ｍｍｏｌ）を加え、室温にて終夜撹拌した。反応液に１ｍｏｌ／Ｌ塩酸を加え、酢酸エチルで３回抽出し、有機層を合わせて減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝８０：２０→４０：６０）で精製することにより、（１−ヒドロキシ−１−メチルエチル）−Ｎ−（４−メチルイソキノリン−３−イル）−Ｎ−［４−（トリフルオロメトキシ）ベンジル］ベンゼンスルホンアミド（８３ｍｇ，８２％）を無色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：５３１［Ｍ＋Ｈ］^＋． Example 125:
Preparation of 4- (1-hydroxy-1-methylethyl) -N- (4-methylisoquinolin-3-yl) -N- [4- (trifluoromethoxy) benzyl] benzenesulfonamide

4-Acetyl-N- (4-methylisoquinolin-3-yl) -N- [4- (trifluoromethoxy) benzyl] benzenesulfonamide (98 mg, 0.190 mmol) prepared in Example 152 in diethyl ether (2 mL) ) To the solution was added methylmagnesium bromide (tetrahydrofuran solution, 3 mol / L, 0.229 mmol) at 0 ° C., and the mixture was stirred at room temperature overnight. 1 mol / L hydrochloric acid was added to the reaction solution, followed by extraction three times with ethyl acetate, and the organic layers were combined and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 80: 20 → 40: 60) to give (1-hydroxy-1-methylethyl) -N- (4-methylisoquinoline-3- Yl) -N- [4- (trifluoromethoxy) benzyl] benzenesulfonamide (83 mg, 82%) was obtained as a colorless powder.
APCI-MS m / z: 531 [M + H] ⁺ .

Examples 126-158
The corresponding starting material compounds were treated in the same manner as in Examples 1, 2, and / or 8 to obtain the compounds shown in Table 6 below. In addition, a carboxylic acid compound or a salt thereof can be converted into each other by a conventional salt formation treatment or desalting treatment.

Examples 159-210
The corresponding starting material compounds were treated in the same manner as in Examples 3, 4 and / or 8, to obtain the compounds shown in Table 7 below. In addition, a carboxylic acid compound or a salt thereof can be converted into each other by a conventional salt formation treatment or desalting treatment.

Examples 211-212
The corresponding starting material compounds were treated in the same manner as in Examples 5, 6 and / or 8 to obtain the compounds described in Table 8 below. In addition, a carboxylic acid compound or a salt thereof can be converted into each other by a conventional salt formation treatment or desalting treatment.

Examples 213-218
The corresponding starting material compounds were treated in the same manner as in Examples 8, 9 and / or 10 to obtain the compounds shown in Table 9 below. In addition, a carboxylic acid compound or a salt thereof can be converted into each other by a conventional salt formation treatment or desalting treatment.

Examples 219-224
The corresponding starting material compounds were treated in the same manner as in Examples 8, 13, and / or 14 to obtain the compounds described in Table 10 below. In addition, a carboxylic acid compound or a salt thereof can be converted into each other by a conventional salt formation treatment or desalting treatment.

Examples 225-227
The corresponding starting compounds were treated in the same manner as in Example 97 to give the compounds as shown in Table 11 below. In addition, a carboxylic acid compound or a salt thereof can be converted into each other by a conventional salt formation treatment or desalting treatment.

Examples 228-229
The corresponding starting material compounds were treated in the same manner as in Example 100 to give the compounds shown in Table 12 below. In addition, a carboxylic acid compound or a salt thereof can be converted into each other by a conventional salt formation treatment or desalting treatment.

Example 230
The corresponding starting materials were treated in the same manner as in Examples 101 and 102 to give the compounds shown in Table 13 below. In addition, a carboxylic acid compound or a salt thereof can be converted into each other by a conventional salt formation treatment or desalting treatment.

Examples 231 to 232
The corresponding starting compounds were treated in the same manner as in Examples 103 and 104 to obtain the compounds shown in Table 14 below. In addition, a carboxylic acid compound or a salt thereof can be converted into each other by a conventional salt formation treatment or desalting treatment.

Examples 233-235
The corresponding starting materials were treated in the same manner as in Examples 105 and 106 to obtain the compounds shown in Table 15 below. In addition, a carboxylic acid compound or a salt thereof can be converted into each other by a conventional salt formation treatment or desalting treatment.

Examples 236-237
The corresponding starting material compounds were treated in the same manner as in Examples 120, 121 and / or 122 to give the compounds described in Table 16 below. In addition, a carboxylic acid compound or a salt thereof can be converted into each other by a conventional salt formation treatment or desalting treatment.

Examples 238-240
The corresponding starting material compound was treated in the same manner as in Example 123 to give the compounds shown in Table 17 below.

Examples 241 to 242
The corresponding starting materials were treated in the same manner as in Example 124 to give the compounds as shown in Table 18 below.

（１） ３−フルオロ−４−（トリフルオロメトキシ）安息香酸（１．００ｇ，４．４６ｍｍｏｌ）のエタノール（１０ｍｌ）溶液に、０℃にてチオニルクロリド（１．３３ｇ，１１．２ｍｍｏｌ）を加えた。反応溶液をゆっくり室温まで昇温し、そのまま終夜攪拌した。反応溶液を飽和重曹水にあけ酢酸エチルで２回抽出した。有機層を合わせ、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１０：０→９：１）で精製することにより３−フルオロ−４−（トリフルオロメトキシ）安息香酸エチル（０．７２ｇ，６４％）を無色透明の油状物として得た。
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ １．３３（３Ｈ，ｔ，Ｊ＝７．１Ｈｚ），４．３５（２Ｈ，ｑ，Ｊ＝７．１Ｈｚ），７．７７−７．７３（１Ｈ，ｍ），７．９２−７．９０（１Ｈ，ｍ），８．００（１Ｈ，ｄｄ，Ｊ＝１０．６，１．９Ｈｚ）．
（２） 上記化合物（６９８ｍｇ，２．７７ｍｍｏｌ）のテトラヒドロフラン（７ｍｌ）溶液に、０℃にて水素化アルミニウムリチウム（７９ｍｇ，２．０８ｍｍｏｌ）を加えた。同温にて３０分撹拌後、室温で５時間攪拌した。反応液を０℃に冷却後ジエチルエーテル、および１ｍｏｌ／Ｌ水酸化ナトリウム水溶液（１０ｍｌ）を加え同温で１５分間攪拌した。反応液をジエチルエーテルで２回抽出した。有機層を合わせ、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝６：１→２：１）で精製し、標記化合物、［３−フルオロ−４−（トリフルオロメトキシ）フェニル］メタノール（０．５２ｇ，９０％）を無色透明の油状物として得た。
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ ４．５３（２Ｈ，ｄ，Ｊ＝５．４Ｈｚ），５．４４（１Ｈ，ｔ，Ｊ＝５．７Ｈｚ），７．２６（１Ｈ，ｍ），７．４０（１Ｈ，ｄｄ，Ｊ＝１１．５，１．５Ｈｚ），７．５３−７．４９（１Ｈ，ｍ）． Reference example 1:
Production of [3-fluoro-4- (trifluoromethoxy) phenyl] methanol

(1) To a solution of 3-fluoro-4- (trifluoromethoxy) benzoic acid (1.00 g, 4.46 mmol) in ethanol (10 ml) was added thionyl chloride (1.33 g, 11.2 mmol) at 0 ° C. It was. The reaction solution was slowly warmed to room temperature and stirred as it was overnight. The reaction solution was poured into saturated aqueous sodium hydrogen carbonate and extracted twice with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 10: 0 → 9: 1) to give ethyl 3-fluoro-4- (trifluoromethoxy) benzoate (0.72 g, 64% ) Was obtained as a colorless and transparent oil.
¹ H-NMR (DMSO-d ₆ ) δ 1.33 (3H, t, J = 7.1 Hz), 4.35 (2H, q, J = 7.1 Hz), 7.77-7.73 (1H M), 7.92-7.90 (1H, m), 8.00 (1H, dd, J = 10.6, 1.9 Hz).
(2) To a solution of the above compound (698 mg, 2.77 mmol) in tetrahydrofuran (7 ml) was added lithium aluminum hydride (79 mg, 2.08 mmol) at 0 ° C. The mixture was stirred at the same temperature for 30 minutes and then at room temperature for 5 hours. The reaction mixture was cooled to 0 ° C., diethyl ether and 1 mol / L aqueous sodium hydroxide solution (10 ml) were added, and the mixture was stirred at the same temperature for 15 min. The reaction solution was extracted twice with diethyl ether. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 6: 1 → 2: 1) to give the title compound, [3-fluoro-4- (trifluoromethoxy) phenyl] methanol (0.52 g). , 90%) as a clear and colorless oil.
¹ H-NMR (DMSO-d ₆ ) δ 4.53 (2H, d, J = 5.4 Hz), 5.44 (1H, t, J = 5.7 Hz), 7.26 (1H, m), 7.40 (1H, dd, J = 11.5, 1.5 Hz), 7.53-7.49 (1H, m).

（１） ２，５−ジクロロ−３−ニトロピリジン（５．００ｇ，２５．９ｍｍｏｌ）のテトラヒドロフラン（１６４ｍｌ）溶液に、−７８℃にて１ｍｏｌ/Ｌビニルマグネシウムブロミドテトラヒドロフラン溶液（８２．９ｍｌ，８２．９ｍｍｏｌ）を加えた。−２０℃にて終夜撹拌後、反応液に飽和塩化アンモニウム水溶液を加え、酢酸エチルで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１９：１→７：３）で精製後、ジイソプロピルエーテルで洗浄し、４，７−ジクロロ−１Ｈ−ピロロ［２，３−ｃ］ピリジン（１．１２ｇ，２３％）を淡黄色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１８７／１８９［Ｍ＋Ｈ］^＋．
（２） 上記化合物（１５０ｍｇ，８０２μｍｏｌ）のジメチルスルホキシド（４．０１ｍｌ）溶液に、室温にて炭酸カリウム（２２８ｍｇ，１．６０ｍｍｏｌ）およびヨードメタン（１００μｌ，１．６０ｍｍｏｌ）を加えた。同温にて終夜撹拌後、反応液に水を加え、酢酸エチルで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、珪藻土カラムにてろ過後、減圧濃縮し、標記化合物、４，７−ジクロロ−１−メチル−１Ｈ−ピロロ［２，３−ｃ］ピリジン（１５６ｍｇ，９７％）を黄色固体として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２０１／２０３［Ｍ＋Ｈ］^＋． Reference example 2:
Preparation of 4,7-dichloro-1-methyl-1H-pyrrolo [2,3-c] pyridine

(1) To a solution of 2,5-dichloro-3-nitropyridine (5.00 g, 25.9 mmol) in tetrahydrofuran (164 ml) at −78 ° C., a 1 mol / L vinylmagnesium bromide tetrahydrofuran solution (82.9 ml, 82. 9 mmol) was added. After stirring at −20 ° C. overnight, a saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 19: 1 → 7: 3), washed with diisopropyl ether, and 4,7-dichloro-1H-pyrrolo [2,3-c]. Pyridine (1.12 g, 23%) was obtained as a pale yellow powder.
APCI-MS m / z: 187/189 [M + H] ⁺ .
(2) To a solution of the above compound (150 mg, 802 μmol) in dimethyl sulfoxide (4.01 ml), potassium carbonate (228 mg, 1.60 mmol) and iodomethane (100 μl, 1.60 mmol) were added at room temperature. After stirring overnight at the same temperature, water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, filtered through a diatomaceous earth column, and concentrated under reduced pressure to give the title compound, 4,7-dichloro-1-methyl-1H-pyrrolo [2,3-c] pyridine ( 156 mg, 97%) was obtained as a yellow solid.
APCI-MS m / z: 201/203 [M + H] ⁺ .

（１） アルゴン気流下、２−ブロモ−３−フルオロ−６−メチルピリジン（１０００ｍｇ，５．２６ｍｍｏｌ）の１，４−ジオキサン（１６ｍＬ）溶液に、ヨウ化ナトリウム（１５８０ｍｇ，１０．５２ｍｍｏｌ）、ヨウ化第一銅（１５０ｍｇ，０．２６ｍｍｏｌ）、Ｎ，Ｎ’−ジメチルエチレンジアミン（６２μＬ，０．５８ｍｍｏｌ）を加えた。反応液を４時間加熱還流し、室温まで冷却後、反応液に水を加え、酢酸エチルで２回抽出した。有機層を合わせ、クエン酸水溶液および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮することにより３−フルオロ−２−ヨード−６−メチルピリジン（１１６９ｍｇ，９４％）を白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２３８［Ｍ＋Ｈ］^＋．
（２） 上記化合物（１００ｍｇ，０．４２ｍｍｏｌ）の１，２−ジクロロエタン（２ｍＬ）溶液に、Ｎ−ブロモコハク酸イミド（８６ｍｇ，０．４９ｍｍｏｌ）および２，２’−アゾビスイソブチロニトリル（３ｍｇ，０．０１５ｍｍｏｌ）を加え、７５℃にて終夜撹拌した。室温まで冷却後、反応液に飽和重曹水を加え、酢酸エチルで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９７：３→９：１）で精製し、標記化合物、６−（ブロモメチル）−３−フルオロ−２−ヨードピリジンを得た。これを次の工程に更に精製せずに使用した。 Reference Example 3:
Preparation of 6- (bromomethyl) -3-fluoro-2-iodopyridine

(1) Under a stream of argon, a solution of 2-bromo-3-fluoro-6-methylpyridine (1000 mg, 5.26 mmol) in 1,4-dioxane (16 mL) was added sodium iodide (1580 mg, 10.52 mmol), iodine Cuprous chloride (150 mg, 0.26 mmol) and N, N′-dimethylethylenediamine (62 μL, 0.58 mmol) were added. The reaction solution was heated to reflux for 4 hours, cooled to room temperature, water was added to the reaction solution, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with aqueous citric acid solution and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 3-fluoro-2-iodo-6-methylpyridine (1169 mg, 94%) as a white powder. Obtained.
APCI-MS m / z: 238 [M + H] ⁺ .
(2) To a solution of the above compound (100 mg, 0.42 mmol) in 1,2-dichloroethane (2 mL), N-bromosuccinimide (86 mg, 0.49 mmol) and 2,2′-azobisisobutyronitrile (3 mg) , 0.015 mmol) and stirred at 75 ° C. overnight. After cooling to room temperature, saturated aqueous sodium hydrogen carbonate was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 97: 3 → 9: 1) to obtain the title compound, 6- (bromomethyl) -3-fluoro-2-iodopyridine. This was used in the next step without further purification.

（１） ４−（２−メトキシエトキシ）安息香酸（１００ｍｇ，０．５１ｍｍｏｌ）のＮ，Ｎ−ジメチルホルムアミド（２ｍＬ）溶液に、室温にて炭酸カリウム（２８２ｍｇ，２．０４ｍｍｏｌ）およびヨードメタン（７９μＬ，１．２７ｍｍｏｌ）を加えた。同温にて終夜撹拌後、反応液に水を加え、酢酸エチルで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を、テトラヒドロフラン（３ｍＬ）に溶解し、０℃にて水素化ホウ素リチウム（５３ｍｇ，２．４５ｍｍｏｌ）を加えた。反応溶液をゆっくり室温まで昇温し、３日間攪拌した。反応液に水を加え、酢酸エチルで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮することにより［４−（２−メトキシエトキシ）フェニル］メタノール（６１ｍｇ，６８％）を無色透明の油状物として得た．
ＡＰＣＩ−ＭＳ ｍ／ｚ：２００［Ｍ＋ＮＨ_４］^＋．
（２） 上記化合物（５８ｍｇ，０．３２ｍｍｏｌ）のジクロロメタン（１．５ｍＬ）溶液に、０℃にて塩化ｐ−トルエンスルホニル（７９ｍｇ，０．４１ｍｍｏｌ）、Ｎ，Ｎ−ジイソプロピルエチルアミン（１６２μＬ，０．９５ｍｍｏｌ）、およびＮ，Ｎ−ジメチル−４−アミノピリジン（８ｍｇ，０．０６４ｍｍｏｌ）を加えた。反応溶液をゆっくり室温まで昇温し、７時間攪拌した。反応液に水を加え、酢酸エチルで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮して、標記化合物、４−メチルベンゼンスルホン酸 ４−（２−メトキシエトキシ）ベンジルを得た。これを次の工程に更に精製せずに使用した。 Reference example 4:
4-Methylbenzenesulfonic acid 4- (2-methoxyethoxy) benzyl production

(1) To a solution of 4- (2-methoxyethoxy) benzoic acid (100 mg, 0.51 mmol) in N, N-dimethylformamide (2 mL) at room temperature, potassium carbonate (282 mg, 2.04 mmol) and iodomethane (79 μL, 1.27 mmol) was added. After stirring overnight at the same temperature, water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was dissolved in tetrahydrofuran (3 mL), and lithium borohydride (53 mg, 2.45 mmol) was added at 0 ° C. The reaction solution was slowly warmed to room temperature and stirred for 3 days. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give [4- (2-methoxyethoxy) phenyl] methanol (61 mg, 68%) as a colorless transparent oil. Obtained as
APCI-MS m / z: 200 [M + NH ₄ ] ⁺ .
(2) To a solution of the above compound (58 mg, 0.32 mmol) in dichloromethane (1.5 mL) at 0 ° C., p-toluenesulfonyl chloride (79 mg, 0.41 mmol), N, N-diisopropylethylamine (162 μL,. 95 mmol), and N, N-dimethyl-4-aminopyridine (8 mg, 0.064 mmol). The reaction solution was slowly warmed to room temperature and stirred for 7 hours. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the title compound, 4- (2-methoxyethoxy) benzyl 4-methylbenzenesulfonate. This was used in the next step without further purification.

（１） アルゴン気流下、Ｎ，Ｎ−ジイソプロピルアミン（６８０μＬ，５．１９ｍｍｏｌ）のテトラヒドロフラン（５ｍｌ）溶液に、−７８℃にて１．６７ｍｏｌ/Ｌ ｎ−ブチルリチウムヘキサン溶液（３．１１ｍｌ，５．１９ｍｍｏｌ）を滴下し、同温にて１５分撹拌した。反応溶液を０℃までゆっくり昇温し、２０分撹拌した後に−４０℃に冷却し、３−ブロモ−２−（トリフルオロメチル）チオフェン（１０００ｍｇ，４．３３ｍｍｏｌ）のテトラヒドロフラン溶液（１５ｍｌ）を滴下した。同温にて２０分撹拌し、反応溶液を−１０℃までゆっくり昇温した後に５分撹拌した。反応溶液を−４０℃に冷却し、Ｎ，Ｎ−ジメチルホルムアミド（１ｍＬ）を滴下した後に、０℃までゆっくり昇温し、終夜撹拌した。反応液に水を加え、酢酸エチルで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１０：０→９：１）で精製し、４−ブロモ−５−（トリフルオロメチル）チオフェン−２−カルバルデヒド（５２７ｍｇ，４７％）を黄色の油状物として得た。
^１Ｈ−ＮＭＲ（ＣＤＣｌ_３） δ ７．７１（１Ｈ，ｍ），９．９３（１Ｈ，ｓ）．
（２） 上記化合物（５２０ｍｇ，２．０１ｍｍｏｌ）のエタノール（１０ｍＬ）溶液に、０℃にて水素化ホウ素ナトリウム（１５２ｍｇ，４．０２ｍｍｏｌ）を加えた。同温にて１時間撹拌後、反応液に水を加え、酢酸エチルで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮することにより［４−ブロモ−５−（トリフルオロメチル）−２−チエニル］メタノール（４３２ｍｇ，８２％）を淡黄色の油状物として得た。
^１Ｈ−ＮＭＲ（ＣＤＣｌ_３） δ ２．０１（１Ｈ，t，Ｊ＝６．０Ｈｚ），４．８４（２Ｈ，ｄ，Ｊ＝６．０Ｈｚ），６．９６（１Ｈ，ｓ）． Reference example 5:
Production of [4-fluoro-5- (trifluoromethyl) -2-thienyl] methanol

(1) A solution of N, N-diisopropylamine (680 μL, 5.19 mmol) in tetrahydrofuran (5 ml) under a stream of argon at 1.78 mol / L n-butyllithium hexane solution (3.11 ml, 5) at −78 ° C. .19 mmol) was added dropwise and stirred at the same temperature for 15 minutes. The reaction solution was slowly warmed to 0 ° C., stirred for 20 minutes, cooled to −40 ° C., and a tetrahydrofuran solution (15 ml) of 3-bromo-2- (trifluoromethyl) thiophene (1000 mg, 4.33 mmol) was added dropwise. did. The mixture was stirred at the same temperature for 20 minutes, and the reaction solution was slowly warmed to −10 ° C. and then stirred for 5 minutes. The reaction solution was cooled to −40 ° C., N, N-dimethylformamide (1 mL) was added dropwise, and then the temperature was slowly raised to 0 ° C. and stirred overnight. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 10: 0 → 9: 1) to give 4-bromo-5- (trifluoromethyl) thiophene-2-carbaldehyde (527 mg, 47%). Was obtained as a yellow oil.
¹ H-NMR (CDCl ₃ ) δ 7.71 (1H, m), 9.93 (1H, s).
(2) Sodium borohydride (152 mg, 4.02 mmol) was added to a solution of the above compound (520 mg, 2.01 mmol) in ethanol (10 mL) at 0 ° C. After stirring at the same temperature for 1 hour, water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give [4-bromo-5- (trifluoromethyl) -2-thienyl] methanol (432 mg, 82%). Was obtained as a pale yellow oil.
¹ H-NMR (CDCl ₃ ) δ 2.01 (1H, t, J = 6.0 Hz), 4.84 (2H, d, J = 6.0 Hz), 6.96 (1H, s).

(3) To a solution of the above compound (427 mg, 1.64 mmol) in dichloromethane (6 mL), chloromethyl methyl ether (311 μL, 4.09 mmol) and N, N-diisopropylethylamine (1289 μL, 7.38 mmol) were added at room temperature. It was. After stirring at the same temperature for 3 days, water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 10: 0 → 9: 1) to give 3-bromo-5-[(methoxymethoxy) methyl] -2- (trifluoromethyl) thiophene ( 363 mg, 73%) was obtained as a colorless and transparent oil.
¹ H-NMR (CDCl ₃ ) δ 3.41 (3H, s), 4.70 (2H, s), 4.72 (2H, s), 6.97 (1H, s).

(4) A 1.67 mol / L n-butyllithium hexane solution (0.84 ml, 1.41 mmol) was added to a tetrahydrofuran (4 mL) solution of the above compound (358 mg, 1.17 mmol) at −78 ° C. under an argon stream. It was dripped. After stirring at the same temperature for 90 minutes, a solution of N-fluorobenzenesulfonimide (553 mg, 1.76 mmol) in tetrahydrofuran (6 mL) was added. The reaction was slowly warmed to room temperature and stirred overnight. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 10: 0 → 19: 1) to give 3-fluoro-5-[(methoxymethoxy) methyl] -2- (trifluoromethyl) thiophene and An approximately 1: 1 mixture of 2-[(methoxymethoxy) methyl] -5- (trifluoromethyl) thiophene was obtained. This was dissolved in ethanol (2 mL), and 6 mol / L hydrochloric acid aqueous solution (1 mL) was added at room temperature. After stirring overnight at the same temperature, the reaction solution was made alkaline by adding saturated aqueous sodium hydrogen carbonate, and then extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 4: 1 → 3: 2) to give the title compound [4-fluoro-5- (trifluoromethyl) -2-thienyl] methanol (34 mg). 15%) was obtained as a colorless and transparent oil.
¹ H-NMR (CDCl ₃ ) δ 2.01 (1H, t, J = 6.0 Hz), 4.81 (2H, d, J = 6.0 Hz), 6.76 (1H, s).

（１） アルゴン気流下、１−ブロモ−４−（シクロプロポキシ）ベンゼン（４９２ｍｇ，２．３１ｍｍｏｌ）のテトラヒドロフラン（１０ｍｌ）溶液に−７８℃にて２．６６ｍｏｌ／Ｌ ｎ−ブチルリチウムヘキサン溶液（０．９５５ｍｌ，２．５４ｍｍｏｌ）を滴下し、２．５時間攪拌した。同温にてＮ，Ｎ−ジメチルホルムアミド（０．３５８ｍｌ，４．６２ｍｍｏｌ）を滴下し、室温までゆっくりと昇温しながら３．５時間攪拌した。反応液に飽和塩化アンモニウム水溶液を加え攪拌した後、酢酸エチルで３回抽出した。有機層を合わせ、無水硫酸ナトリウムで乾燥後、減圧濃縮することにより、粗４−（シクロプロポキシ）ベンズアルデヒドを薄黄色の液体として得た。これを次の工程に更に精製せずに使用した。 Reference Example 6:
Production of [4- (cyclopropoxy) phenyl] methanol

(1) A solution of 1-bromo-4- (cyclopropoxy) benzene (492 mg, 2.31 mmol) in tetrahydrofuran (10 ml) under a stream of argon at 2.78 mol / L n-butyllithium hexane solution (0 .955 ml, 2.54 mmol) was added dropwise and stirred for 2.5 hours. N, N-dimethylformamide (0.358 ml, 4.62 mmol) was added dropwise at the same temperature, and the mixture was stirred for 3.5 hours while slowly warming to room temperature. Saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was stirred and extracted three times with ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain crude 4- (cyclopropoxy) benzaldehyde as a pale yellow liquid. This was used in the next step without further purification.

(2) A solution of the above crude product in methanol (5 ml) was cooled to 0 ° C., sodium borohydride (175 mg, 4.62 mmol) was added, and the mixture was stirred for 1 hour. After adding saturated brine, the reaction solution was concentrated under reduced pressure. The obtained residue was dissolved in ethyl acetate and washed with saturated brine, and the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained crude product was purified by silica gel column chromatography (hexane: ethyl acetate = 9: 1 → 3: 2), and the title compound, [4- (cyclopropoxy) phenyl] methanol (216 mg, 57%, 2 Step yield) was obtained as a white solid.
APCI-MS m / z: 182 [M + NH 4] +.

１−ブロモ−４−（シクロプロピルメチル）ベンゼンを参考例６−（１）および（２）に記載の方法と同様に処理することにより、標記化合物を得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１８０［Ｍ＋ＮＨ_４］^＋． Reference example 7:
Production of [4- (cyclopropylmethyl) phenyl] methanol

The title compound was obtained by treating 1-bromo-4- (cyclopropylmethyl) benzene in the same manner as described in Reference Examples 6- (1) and (2).
APCI-MS m / z: 180 [M + NH ₄ ] ⁺ .

ＷＯ２００６/０１３０４８Ａ１記載の方法により製造した１，１−ジメチルインダン−５−カルバルデヒドを、参考例６−（２）と同様の方法で処理することにより、標記化合物を得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１９４［Ｍ＋ＮＨ_４］^＋． Reference Example 8:
Production of (1,1-dimethyl-2,3-dihydro-1H-inden-5-yl) methanol

The title compound was obtained by treating 1,1-dimethylindane-5-carbaldehyde produced by the method described in WO2006 / 013048A1 in the same manner as in Reference Example 6- (2).
APCI-MS m / z: 194 [M + NH 4] +.

ＵＳ２００９/１０５２０９記載の方法により製造した３，３−ジメチル−２，３−ジヒドロ−１−ベンゾフラン−６−カルボン酸メチル（４４ｍｇ，０．２１ｍｍｏｌ）のテトラヒドロフラン（１．５ｍＬ）溶液に０℃にて水素化ホウ素リチウム（２３ｍｇ，１．０７ｍｍｏｌ）、およびメタノール（４３μＬ，１．０７ｍｍｏｌ）を加え、室温にて１時間撹拌した。反応液に水を加え、酢酸エチルで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮することにより表題化合物（３８ｍｇ，１００％）を無色透明の油状物として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１９６［Ｍ＋ＮＨ_４］^＋． Reference Example 9:
Production of (3,3-dimethyl-2,3-dihydro-1-benzofuran-6-yl) methanol

To a solution of methyl 3,3-dimethyl-2,3-dihydro-1-benzofuran-6-carboxylate (44 mg, 0.21 mmol) prepared in accordance with the method described in US2009 / 105209 in tetrahydrofuran (1.5 mL) at 0 ° C. Lithium borohydride (23 mg, 1.07 mmol) and methanol (43 μL, 1.07 mmol) were added, and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the title compound (38 mg, 100%) as a colorless transparent oil.
APCI-MS m / z: 196 [M + NH 4] +.

ＵＳ２０１０/１９７５９１Ａ１記載の方法により製造した５−ブロモ−１，１−ジメチル−１，３−ジヒドロ−２−ベンゾフランを、参考例６−（１）および（２）と同様の方法で処理することにより、標記化合物を得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１９６［Ｍ＋ＮＨ_４］^＋． Reference Example 10:
Production of (1,1-dimethyl-1,3-dihydro-2-benzofuran-5-yl) methanol

By treating 5-bromo-1,1-dimethyl-1,3-dihydro-2-benzofuran produced by the method described in US2010 / 197591A1 in the same manner as in Reference Examples 6- (1) and (2) To give the title compound.
APCI-MS m / z: 196 [M + NH 4] +.

ＵＳ４９５２７２２記載の方法により製造した２，２−ジメチルインダン−５−カルバルデヒドを、参考例６−（２）と同様の方法で処理することにより、標記化合物を得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１９４［Ｍ＋ＮＨ_４］^＋． Reference Example 11:
Production of (2,2-dimethyl-2,3-dihydro-1H-inden-5-yl) methanol

The title compound was obtained by treating 2,2-dimethylindane-5-carbaldehyde produced by the method described in US Pat. No. 4,952,722 in the same manner as in Reference Example 6- (2).
APCI-MS m / z: 194 [M + NH 4] +.

（１） ２，４−ジクロロ−３−メチルキノリン（１．０８ｇ，５．１ｍｍｏｌ）、トリス（ジベンジリデンアセトン）ジパラジウム（１２ｍｇ，０．００２５ｍｍｏｌ）、２，２’−ビス（ジフェニルホスフィノ）−１，１’−ビナフチル（３２ｍｇ，０．０１ｍｍｏｌ）、及びナトリウム−ｔ−ブトキシド（７３５ｍｇ，７．６ｍｍｏｌ）のトルエン（５１ｍＬ）溶液を室温にて５分間撹拌した。上記溶液にベンゾフェノイミン（８５２μＬ，５．１ｍｍｏｌ）を加え、１００℃にて４時間撹拌した。上記反応液を室温まで冷却した後、ジエチルエーテル（１０ｍＬ）を加え１０分間撹拌した。この溶液を珪藻土ろ過後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン→ヘキサン：酢酸エチル＝１０：１）で精製し、粗４−クロロ−Ｎ−（ジフェニルメチレン）−３−メチルキノリン−２−アミン（９１０ｍｇ，５０％）を黄色固体として得た。
（２） 上記粗化合物（９１０ｍｇ，２．６ｍｍｏｌ）をテトラヒドロフラン（１０ｍＬ）に溶解し、１ｍｏｌ／Ｌ塩酸水溶液（２ｍＬ）を加え室温にて１時間撹拌した。更に１ｍｏｌ／Ｌ塩酸水溶液（１ｍＬ）を追加した後、３０分間撹拌した。この溶液に飽和重曹水を加え、酢酸エチルで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝３：１→１：１）で精製し、４−クロロ−３−メチルキノリン−２−アミン（２６１ｍｇ，５３％）を白色固体として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１９３／１９５［Ｍ＋Ｈ］^＋． Reference Example 12:
Preparation of 4-chloro-3-methylquinolin-2-amine

(1) 2,4-dichloro-3-methylquinoline (1.08 g, 5.1 mmol), tris (dibenzylideneacetone) dipalladium (12 mg, 0.0025 mmol), 2,2′-bis (diphenylphosphino) A solution of -1,1′-binaphthyl (32 mg, 0.01 mmol) and sodium-t-butoxide (735 mg, 7.6 mmol) in toluene (51 mL) was stirred at room temperature for 5 minutes. Benzophenoimine (852 μL, 5.1 mmol) was added to the above solution and stirred at 100 ° C. for 4 hours. After the reaction solution was cooled to room temperature, diethyl ether (10 mL) was added and stirred for 10 minutes. The solution was filtered through diatomaceous earth and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane → hexane: ethyl acetate = 10: 1), and crude 4-chloro-N- (diphenylmethylene) -3-methylquinolin-2-amine (910 mg, 50%). ) Was obtained as a yellow solid.
(2) The crude compound (910 mg, 2.6 mmol) was dissolved in tetrahydrofuran (10 mL), 1 mol / L aqueous hydrochloric acid solution (2 mL) was added, and the mixture was stirred at room temperature for 1 hr. Further, a 1 mol / L hydrochloric acid aqueous solution (1 mL) was added, followed by stirring for 30 minutes. To this solution was added saturated aqueous sodium hydrogen carbonate, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 3: 1 → 1: 1) to obtain 4-chloro-3-methylquinolin-2-amine (261 mg, 53%) as a white solid. It was.
APCI-MS m / z: 193/195 [M + H] ⁺ .

（１） アルゴン気流下、６−クロロ−７−ヨード−１Ｈ−ピロロ［３，２−ｃ］ピリジン（６００ｍｇ，２．１５ｍｍｏｌ）のＮ，Ｎ−ジメチルホルムアミド（８ｍＬ）溶液に６０％水素化ナトリウム（１３０ｍｇ，３．２５ｍｍｏｌ）を加え、室温にて１時間撹拌した。反応液を０℃に冷却し、硫酸ジメチル（２５０μＬ，２．６４ｍｍｏｌ）を滴下した後、室温にて３時間撹拌した。反応液に水を加え、酢酸エチルで３回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９７：３→７５：２５）で精製し、６−クロロ−７−ヨード−１−メチル−１Ｈ−ピロロ［３，２−ｃ］ピリジン（５４０ｍｇ，８６％）を無色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２９３／２９５［Ｍ＋Ｈ］^＋．
（２） アルゴン気流下、上記化合物（６５０ｍｇ，２．２２ｍｍｏｌ）のテトラヒドロフラン（１３ｍＬ）溶液に、−７８℃にて１．６５ｍｏｌ／Ｌ ｎ−ブチルリチウムヘキサン溶液（１．７５ｍＬ，２．８９ｍｍｏｌ）を滴下した。同温にて２時間撹拌後、ヨードメタン（１８０μＬ，２．８９ｍｍｏｌ）のテトラヒドロフラン（４ｍＬ）溶液を滴下し、同温にて１時間攪拌した。反応液を１０℃までゆっくり昇温した後、反応液に水を加え、酢酸エチルで３回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９５：５→６５：３５）で精製し、６−クロロ−１，７−ジメチル−１Ｈ−ピロロ［３，２−ｃ］ピリジン（２０４ｍｇ，５１％）を無色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１８１／１８３［Ｍ＋Ｈ］^＋．
（３） 上記化合物（２００ｍｇ，１．１１ｍｍｏｌ）、ベンゾフェノンイミン（５６０μＬ，３．３５ｍｍｏｌ）、トリス（ジベンジリデンアセトン）ジパラジウム（１００ｍｇ，０．１１ｍｍｏｌ）、２，２’−ビス（ジフェニルホスフィノ）−１，１’−ビナフチル（１４０ｍｇ，０．２２ｍｍｏｌ）、ナトリウムｔ−ブトキシド（３２０ｍｇ，３．３３ｍｍｏｌ）のトルエン（１０ｍＬ）懸濁液を、マイクロ波照射下、１１０℃にて１５時間撹拌した。冷却後、反応液に水を加え、酢酸エチルで３回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９８：２→４０：６０）で精製し、Ｎ−（ジフェニルメチレン）−１，７−ジメチル−１Ｈ−ピロロ［３，２−ｃ］ピリジン−６−アミン（２４４ｍｇ，６８％）を黄色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：３２６［Ｍ＋Ｈ］^＋．
（４） 上記化合物（２４０ｍｇ，０．７４ｍｍｏｌ）のテトラヒドロフラン（１０ｍＬ）溶液に１ｍｏｌ／Ｌ塩酸水溶液（３．７０ｍＬ，３．７０ｍｍｏｌ）を加え、室温で２時間攪拌した。反応液に飽和炭酸水素ナトリウム水溶液を加え溶液をアルカリ性とした後、塩化ナトリウムを加えて酢酸エチルで６回抽出した。有機層を合わせ、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ＮＨ−シリカゲル，クロロホルム：メタノール＝１００：０→９５：５）で精製し、１，７−ジメチル−１Ｈ−ピロロ［３，２−ｃ］ピリジン−６−アミン（１０６ｍｇ，９０％）を薄黄色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１６２［Ｍ＋Ｈ］^＋． Reference Example 13:
Preparation of 1,7-dimethyl-1H-pyrrolo [3,2-c] pyridin-6-amine

(1) 60% sodium hydride in a solution of 6-chloro-7-iodo-1H-pyrrolo [3,2-c] pyridine (600 mg, 2.15 mmol) in N, N-dimethylformamide (8 mL) under an argon stream (130 mg, 3.25 mmol) was added and stirred at room temperature for 1 hour. The reaction solution was cooled to 0 ° C., dimethyl sulfate (250 μL, 2.64 mmol) was added dropwise, and the mixture was stirred at room temperature for 3 hours. Water was added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 97: 3 → 75: 25), and 6-chloro-7-iodo-1-methyl-1H-pyrrolo [3,2-c] pyridine. (540 mg, 86%) was obtained as a colorless powder.
APCI-MS m / z: 293/295 [M + H] ⁺ .
(2) A 1.65 mol / L n-butyllithium hexane solution (1.75 mL, 2.89 mmol) was added to a tetrahydrofuran (13 mL) solution of the above compound (650 mg, 2.22 mmol) at −78 ° C. under an argon stream. It was dripped. After stirring at the same temperature for 2 hours, a solution of iodomethane (180 μL, 2.89 mmol) in tetrahydrofuran (4 mL) was added dropwise and stirred at the same temperature for 1 hour. After the temperature of the reaction solution was raised slowly to 10 ° C., water was added to the reaction solution and extracted three times with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 95: 5 → 65: 35) to give 6-chloro-1,7-dimethyl-1H-pyrrolo [3,2-c] pyridine (204 mg). , 51%) as a colorless powder.
APCI-MS m / z: 181/183 [M + H] ⁺ .
(3) The above compound (200 mg, 1.11 mmol), benzophenone imine (560 μL, 3.35 mmol), tris (dibenzylideneacetone) dipalladium (100 mg, 0.11 mmol), 2,2′-bis (diphenylphosphino) A suspension of -1,1′-binaphthyl (140 mg, 0.22 mmol) and sodium t-butoxide (320 mg, 3.33 mmol) in toluene (10 mL) was stirred at 110 ° C. for 15 hours under microwave irradiation. After cooling, water was added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 98: 2 → 40: 60), and N- (diphenylmethylene) -1,7-dimethyl-1H-pyrrolo [3,2-c]. Pyridin-6-amine (244 mg, 68%) was obtained as a yellow powder.
APCI-MS m / z: 326 [M + H] ⁺ .
(4) A 1 mol / L aqueous hydrochloric acid solution (3.70 mL, 3.70 mmol) was added to a solution of the above compound (240 mg, 0.74 mmol) in tetrahydrofuran (10 mL), and the mixture was stirred at room temperature for 2 hours. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture to make the solution alkaline, sodium chloride was added, and the mixture was extracted 6 times with ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (NH-silica gel, chloroform: methanol = 100: 0 → 95: 5), and 1,7-dimethyl-1H-pyrrolo [3,2-c] pyridine-6- Amine (106 mg, 90%) was obtained as a pale yellow powder.
APCI-MS m / z: 162 [M + H] ⁺ .

（１） ４−メトキシイソキノリン（１３０ｍｇ，０．８２ｍｍｏｌ）の９８％硫酸（０．６１ｍＬ）溶液に、硝酸カリウム（９１ｍｇ，０．９０ｍｍｏｌ）を加え、６０℃に加熱して２時間撹拌した。反応液を冷却後、氷に加えて粉末をろ取し、酢酸エチルに溶解した。溶液を炭酸水素ナトリウム水溶液および飽和食塩水で洗浄した後、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９：１→２：８）で精製し、４−メトキシ−３−ニトロイソキノリン（５８．３ｍｇ，３５％）を淡黄色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２０５［Ｍ＋Ｈ］^＋．
（２） 上記化合物（６７．０ｍｇ，０．３３ｍｍｏｌ）の酢酸（３．３ｍＬ）およびエタノール（３．３ｍＬ）の混合溶液に還元鉄（１８３．０ｍｇ，３．２８ｍｍｏｌ）を加え、アルゴン雰囲気下、２時間加熱還流した。反応液を冷却後、酢酸エチルで希釈して、飽和炭酸水素ナトリウム水溶液で洗浄した後、不溶をろ別した。ろ液を飽和食塩水で洗浄した後、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝３：１→１：３）で精製し、４−メトキシイソキノリン−３−アミン（４８．１ｍｇ，８４％）を白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１７５［Ｍ＋Ｈ］^＋． Reference Example 14:
Preparation of 4-methoxyisoquinolin-3-amine

(1) To a 98% sulfuric acid (0.61 mL) solution of 4-methoxyisoquinoline (130 mg, 0.82 mmol), potassium nitrate (91 mg, 0.90 mmol) was added, heated to 60 ° C. and stirred for 2 hours. After cooling the reaction solution, it was added to ice and the powder was collected by filtration and dissolved in ethyl acetate. The solution was washed with aqueous sodium hydrogen carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 9: 1 → 2: 8) to give 4-methoxy-3-nitroisoquinoline (58.3 mg, 35%) as a pale yellow powder. It was.
APCI-MS m / z: 205 [M + H] ⁺ .
(2) Reduced iron (183.0 mg, 3.28 mmol) was added to a mixed solution of the above compound (67.0 mg, 0.33 mmol) in acetic acid (3.3 mL) and ethanol (3.3 mL). Heated to reflux for 2 hours. The reaction mixture was cooled, diluted with ethyl acetate, washed with a saturated aqueous sodium hydrogen carbonate solution, and insolubles were filtered off. The filtrate was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 3: 1 → 1: 3) to obtain 4-methoxyisoquinolin-3-amine (48.1 mg, 84%) as a white powder. .
APCI-MS m / z: 175 [M + H] ⁺ .

（１） ジエチル（１−シアノエチル）ホスホン酸エステル（１．２６ｇ，８．５ｍｍｏｌ）のテトラヒドロフラン（２０ｍＬ）溶液を０℃に冷却し、カリウム−ｔ−ブトキシド（７４４ｍｇ，８．５ｍｍｏｌ）を加え同温にて１０分間撹拌した。２−クロロ−６−ニトロベンズアルデヒド（９４８ｍｇ，６．６ｍｍｏｌ）を加えた後、６０℃で５時間撹拌した。上記反応液を室温まで冷却した後、反応液に飽和重曹水を加え、酢酸エチルで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン→ヘキサン：酢酸エチル＝３：１）で精製し、３−（２−クロロ−６−ニトロフェニル）−２−メチルアクリロニトリル（０．９８ｇ，８６％）を黄色の油状物として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２４０／２４２［Ｍ＋ＮＨ_４］^＋．
（２） 上記化合物（２．０ｇ，９ｍｍｏｌ）のエタノール（１８０ｍＬ）溶液に、室温にて塩化スズ（ＩＩ）２水和物（１２．２ｇ，５４ｍｍｏｌ）を加え、４５分間加熱還流した。上記溶液を室温まで冷却し、飽和塩酸水（１５ｍＬ）を加え、６時間加熱還流した。この溶液を室温まで冷却し、飽和重曹水にゆっくりと滴下した。この懸濁液を珪藻土ろ過し、得られた溶液をクロロホルムで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣のエタノール（５０ｍＬ）溶液に、室温にてナトリウムエトキシド（５３５ｍｇ，１３．５ｍｍｏｌ）を加えた後、４時間加熱還流した。ナトリウムエトキシド（３５７ｍｇ，９ｍｍｏｌ）追加した後、更に１７時間加熱還流した。上記反応液を室温まで冷却した後、反応液に水を加え、酢酸エチルで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝３：１→１：１）で精製し、５−クロロ−３−メチルキノリン−２−アミン（４５７ｍｇ，２６％）を淡茶色固体として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１９３／１９５［Ｍ＋Ｈ］^＋． Reference Example 15:
Preparation of 5-chloro-3-methylquinolin-2-amine

(1) A solution of diethyl (1-cyanoethyl) phosphonate (1.26 g, 8.5 mmol) in tetrahydrofuran (20 mL) was cooled to 0 ° C., potassium-t-butoxide (744 mg, 8.5 mmol) was added, and the temperature was the same. For 10 minutes. 2-Chloro-6-nitrobenzaldehyde (948 mg, 6.6 mmol) was added, followed by stirring at 60 ° C. for 5 hours. The reaction solution was cooled to room temperature, saturated aqueous sodium hydrogen carbonate was added to the reaction solution, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane → hexane: ethyl acetate = 3: 1) to give 3- (2-chloro-6-nitrophenyl) -2-methylacrylonitrile (0.98 g, 86%). Was obtained as a yellow oil.
APCI-MS m / z: 240/242 [M + NH ₄ ] ⁺ .
(2) To a solution of the above compound (2.0 g, 9 mmol) in ethanol (180 mL) was added tin (II) chloride dihydrate (12.2 g, 54 mmol) at room temperature, and the mixture was heated to reflux for 45 minutes. The solution was cooled to room temperature, saturated aqueous hydrochloric acid (15 mL) was added, and the mixture was heated to reflux for 6 hr. The solution was cooled to room temperature and slowly added dropwise to saturated aqueous sodium bicarbonate. This suspension was filtered through diatomaceous earth, and the resulting solution was extracted twice with chloroform. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Sodium ethoxide (535 mg, 13.5 mmol) was added to a solution of the obtained residue in ethanol (50 mL) at room temperature, and the mixture was heated to reflux for 4 hours. After adding sodium ethoxide (357 mg, 9 mmol), the mixture was further heated to reflux for 17 hours. The reaction solution was cooled to room temperature, water was added to the reaction solution, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 3: 1 → 1: 1) to give 5-chloro-3-methylquinolin-2-amine (457 mg, 26%) as a light brown solid. Obtained.
APCI-MS m / z: 193/195 [M + H] ⁺ .

（１） アルゴン気流下、ナトリウムエトキシド（８．７６ｍＬ，２３．５ｍｍｏｌ、２１ｗｔ％エタノール溶液）のエタノール（１０ｍＬ）溶液を０℃に冷却し、３−ブロモ−２−（シアノメチル）ベンゾニトリル（４．３３ｇ，１９．６ｍｍｏｌ）およびヨードメタン（１．４６ｍＬ，２３．５ｍｍｏｌ）のテトラヒドロフラン溶液（１０ｍＬ）を３０分かけて滴下、その後室温で６．５時間攪拌した。減圧濃縮した後、残渣を２ｍｏｌ／Ｌ塩酸で中和し、酢酸エチルで３回抽出した。有機層をあわせ、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（酢酸エチル／ヘキサン＝１０％→４０％）で精製し、３−ブロモ−２−（１−シアノエチル）ベンゾニトリル（３．１１ｇ，６７％）を黄色粘体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ２５２／２５４［Ｍ＋ＮＨ_４］^＋
（２） アルゴン気流下、上記化合物（３．１１ｇ，１３．２ｍｍｏｌ）、トリメチルボロキシン（１．８５ｍＬ，１３．２ｍｍｏｌ）、テトラキス（トリフェニルホスフィン）パラジウム（０）（３０６ｍｇ，０．２６５ｍｍｏｌ）、炭酸カリウム（５．４９ｇ，３９．７ｍｍｏｌ）をＮ，Ｎ−ジメチルホルムアミド（１０ｍＬ）中、１２０℃で６時間攪拌した。室温まで冷却した後、水を加えて撹拌し、酢酸エチルで３回抽出した。有機層をあわせ、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（酢酸エチル／ヘキサン＝１０％→４０％）で精製し、２−（１−シアノエチル）−３−メチルベンゾニトリル（１．９９ｇ，８９％）を褐色固体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ １８８［Ｍ＋ＮＨ_４］^＋
（３） 上記化合物（１．９９ｇ，１１．７ｍｍｏｌ）の酢酸（１ｍＬ）懸濁液を０℃に冷却し、臭化水素（５ｍＬ、２５％酢酸溶液）を加え、室温まで昇温しながら２時間攪拌した。ジイソプロピルエーテルで希釈し、生成する固体をろ別した。得られた固体に飽和炭酸水素ナトリウム水溶液を加えて攪拌し、固体をろ別、乾燥することにより粗生成物を得た。ジイソプロピルエーテルで懸濁洗浄し、固体をろ別、その後乾燥することにより、１−ブロモ−４，５−ジメチルイソキノリン−３−アミン（８４３ｍｇ，２９％）を黄色粉末として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ２５１／２５３［Ｍ＋Ｈ］^＋
（４） 上記化合物（８４３ｍｇ，３．３６ｍｍｏｌ）のメタノール−テトラヒドロフラン（１：１、１０ｍＬ）溶液に１０％パラジウム炭素（４２．２ｍｇ）、トリエチルアミン（０．５６１ｍＬ，４．０３ｍｍｏｌ）を加え、水素気流下、室温で２時間攪拌した。酢酸エチルを用いて珪藻土ろ過を行い、ろ液を減圧濃縮した。残渣を酢酸エチルに溶かし、飽和炭酸水素ナトリウム水溶液で洗浄、有機層を無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（酢酸エチル／ヘキサン＝２５％→５０％）で精製し、４，５−ジメチルイソキノリン−３−アミン（４５６ｍｇ，７９％）を黄色粉末として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ １７３［Ｍ＋Ｈ］^＋ Reference Example 16:
Production of 4,5-dimethylisoquinolin-3-amine

(1) Under an argon stream, a solution of sodium ethoxide (8.76 mL, 23.5 mmol, 21 wt% ethanol solution) in ethanol (10 mL) was cooled to 0 ° C., and 3-bromo-2- (cyanomethyl) benzonitrile (4 .33 g, 19.6 mmol) and a tetrahydrofuran solution (10 mL) of iodomethane (1.46 mL, 23.5 mmol) were added dropwise over 30 minutes, and then stirred at room temperature for 6.5 hours. After concentration under reduced pressure, the residue was neutralized with 2 mol / L hydrochloric acid and extracted three times with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (ethyl acetate / hexane = 10% → 40%) to give 3-bromo-2- (1-cyanoethyl) benzonitrile (3.11 g, 67%) as a yellow viscous body. Obtained.
APCI-MS: m / z 252/254 [M + NH ₄ ] ⁺
(2) Under an argon stream, the above compound (3.11 g, 13.2 mmol), trimethylboroxine (1.85 mL, 13.2 mmol), tetrakis (triphenylphosphine) palladium (0) (306 mg, 0.265 mmol), Potassium carbonate (5.49 g, 39.7 mmol) was stirred in N, N-dimethylformamide (10 mL) at 120 ° C. for 6 hours. After cooling to room temperature, water was added and the mixture was stirred and extracted three times with ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (ethyl acetate / hexane = 10% → 40%) to give 2- (1-cyanoethyl) -3-methylbenzonitrile (1.99 g, 89%) as a brown solid. Obtained.
APCI-MS: m / z 188 [M + NH ₄ ] ⁺
(3) A suspension of the above compound (1.99 g, 11.7 mmol) in acetic acid (1 mL) was cooled to 0 ° C., hydrogen bromide (5 mL, 25% acetic acid solution) was added, Stir for hours. Diluted with diisopropyl ether and the resulting solid was filtered off. A saturated aqueous sodium hydrogen carbonate solution was added to the obtained solid and stirred, and the solid was filtered and dried to obtain a crude product. The solid was suspended and washed with diisopropyl ether, and the solid was filtered off and then dried to obtain 1-bromo-4,5-dimethylisoquinolin-3-amine (843 mg, 29%) as a yellow powder.
APCI-MS: m / z 251/253 [M + H] ⁺
(4) To a solution of the above compound (843 mg, 3.36 mmol) in methanol-tetrahydrofuran (1: 1, 10 mL) was added 10% palladium carbon (42.2 mg) and triethylamine (0.561 mL, 4.03 mmol), and a hydrogen stream The mixture was stirred at room temperature for 2 hours. Diatomaceous earth filtration was performed using ethyl acetate, and the filtrate was concentrated under reduced pressure. The residue was dissolved in ethyl acetate, washed with saturated aqueous sodium hydrogen carbonate solution, the organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (ethyl acetate / hexane = 25% → 50%) to obtain 4,5-dimethylisoquinolin-3-amine (456 mg, 79%) as a yellow powder.
APCI-MS: m / z 173 [M + H] ⁺

４−ブロモ−２−（シアノメチル）ベンゾニトリルを、参考例１６−（１）〜（４）と同様の方法で処理することにより、４，６−ジメチルイソキノリン−３−アミンを薄黄色固体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ １７３［Ｍ＋Ｈ］^＋ Reference Example 17:
Production of 4,6-dimethylisoquinolin-3-amine

By treating 4-bromo-2- (cyanomethyl) benzonitrile in the same manner as in Reference Examples 16- (1) to (4), 4,6-dimethylisoquinolin-3-amine is obtained as a light yellow solid. It was.
APCI-MS: m / z 173 [M + H] ⁺

２−（シアノメチル）−５−メチルベンゾニトリルを、参考例１６−（１）、（３）および（４）と同様の方法で処理することにより、４，７−ジメチルイソキノリン−３−アミンを黄色粉末として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ １７３［Ｍ＋Ｈ］^＋ Reference Example 18:
Production of 4,6-dimethylisoquinolin-3-amine

By treating 2- (cyanomethyl) -5-methylbenzonitrile in the same manner as in Reference Example 16- (1), (3) and (4), 4,7-dimethylisoquinolin-3-amine is converted to yellow. Obtained as a powder.
APCI-MS: m / z 173 [M + H] ⁺

２−（シアノメチル）−６−メチルベンゾニトリルを参考例１６−（１）、（３）および（４）と同様の方法で処理することにより、４，８−ジメチルイソキノリン−３−アミンを黄色粉末として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ １７３［Ｍ＋Ｈ］^＋ Reference Example 19:
Production of 4,8-dimethylisoquinolin-3-amine

By treating 2- (cyanomethyl) -6-methylbenzonitrile in the same manner as in Reference Example 16- (1), (3) and (4), 4,8-dimethylisoquinolin-3-amine is converted into a yellow powder. Got as.
APCI-MS: m / z 173 [M + H] ⁺

３−クロロ−２−（シアノメチル）ベンゾニトリルを、参考例１６−（１）および（３）と同様の方法で処理することにより、１−ブロモ−５−クロロ−４−メチルイソキノリン−３−アミンを得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ２７１／２７３［Ｍ＋Ｈ］^＋ Reference Example 20:
Preparation of 1-bromo-5-chloro-4-methylisoquinolin-3-amine

By treating 3-chloro-2- (cyanomethyl) benzonitrile in the same manner as in Reference Examples 16- (1) and (3), 1-bromo-5-chloro-4-methylisoquinolin-3-amine is obtained. Got.
APCI-MS: m / z 271/273 [M + H] ⁺

３−クロロ−２−（シアノメチル）ベンゾニトリル（８８３ｇ，５ｍｍｏｌ）を、参考例１６−（３）と同様の方法で処理することにより、１−ブロモ−５−クロロイソキノリン−３−アミン（７１７ｍｇ，５６％）を黄色粉末として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ２５７／２５９［Ｍ＋Ｈ］^＋ Reference Example 21:
Preparation of 1-bromo-5-chloroisoquinolin-3-amine

3-Chloro-2- (cyanomethyl) benzonitrile (883 g, 5 mmol) was treated in the same manner as in Reference Example 16- (3) to give 1-bromo-5-chloroisoquinolin-3-amine (717 mg, 56%) as a yellow powder.
APCI-MS: m / z 257/259 [M + H] ⁺

（１） アルゴン気流下、３−（シアノメチル）ピリジン−２−カルボニトリル（Ｓｙｎｔｈｅｓｉｓ １９７３， ４７記載の方法により合成、５３０ｍｇ，３．７０ｍｍｏｌ）のテトラヒドロフラン（１４ｍＬ）溶液に、−７８℃にて１．６５ｍｏｌ／Ｌ ｎ−ブチルリチウムヘキサン溶液（２．６０ｍＬ，４．２９ｍｍｏｌ）を滴下した。同温にて３０分撹拌後、ヨードメタン（３００μＬ，４．８１ｍｍｏｌ）のテトラヒドロフラン（７ｍＬ）溶液を滴下し、同温にて１時間攪拌した。反応液を室温までゆっくり昇温した後、反応液に水を加え、酢酸エチルで４回抽出した。有機層を合わせ、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９５：５→５０：５０）で精製し、３−（１−シアノエチル）ピリジン−２−カルボニトリル（５１４ｍｇ，８８％）を黄色の油状物として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１７５［Ｍ＋ＮＨ_４］^＋．
（２） 上記化合物を参考例１６−（３）および（４）と同様の方法で処理することにより、５−メチル−１，７−ナフチリジン−６−アミンを得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１６０［Ｍ＋Ｈ］^＋． Reference Example 22:
Preparation of 5-methyl-1,7-naphthyridin-6-amine

(1) Synthesis in a tetrahydrofuran (14 mL) solution of 3- (cyanomethyl) pyridine-2-carbonitrile (Synthesis 1973, 47, 530 mg, 3.70 mmol) at −78 ° C. in an argon stream at 1.78 ° C. A 65 mol / L n-butyllithium hexane solution (2.60 mL, 4.29 mmol) was added dropwise. After stirring at the same temperature for 30 minutes, a solution of iodomethane (300 μL, 4.81 mmol) in tetrahydrofuran (7 mL) was added dropwise and stirred at the same temperature for 1 hour. The reaction mixture was slowly warmed to room temperature, water was added to the reaction mixture, and the mixture was extracted 4 times with ethyl acetate. The organic layers were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 95: 5 → 50: 50) to give 3- (1-cyanoethyl) pyridine-2-carbonitrile (514 mg, 88%) as a yellow oil. Obtained as a thing.
APCI-MS m / z: 175 [M + NH 4] +.
(2) The above compound was treated in the same manner as in Reference Example 16- (3) and (4) to give 5-methyl-1,7-naphthyridin-6-amine.
APCI-MS m / z: 160 [M + H] ⁺ .

（１） オキシ塩化リン（６．４０μＬ，７３．２１ｍｍｏｌ）のクロロホルム（６１．２ｍＬ）溶液に２，５−ジクロロ−４−ニトロピリジン １−オキシド（３．０６ｇ，１４．６４ｍｍｏｌ）を加え、還流条件にて終夜撹拌した。反応液を氷に加え、飽和炭酸水素ナトリウム水溶液にて溶液をｐＨ７〜８に調節し、クロロホルムで３回抽出した。有機層を合わせPhase-separator（Varian Inc.）にてろ過後、減圧濃縮し、粗２，５−ジクロロ−４−ニトロピリジン（２．９８ｇ，ｑｕａｎｔ．）を黄色の油状物として得た。
（２） ビニルマグネシウムブロミド（５４．０４ｍｍｏｌ）のテトラヒドロフラン（１０４ｍＬ）溶液に上記粗化合物（２．９８ｇ，１５．４４ｍｍｏｌ）のテトラヒドロフラン（１００ｍＬ）溶液を０℃にて４０分かけて加え、室温にて１時間撹拌した。反応液に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルで３回抽出した。有機層を合わせPhase-separator（Varian Inc.）にてろ過後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝８０：２０→５０：５０）で精製することにより、４，７−ジクロロ−１Ｈ−ピロロ［３，２−ｃ］ピリジン（０．７４ｇ，２７％）を薄黄色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１８７／１８９［Ｍ＋Ｈ］^＋．
（３） 上記化合物（３００ｍｇ，１．６０ｍｍｏｌ）のＮ，Ｎ−ジメチルホルムアミド（３ｍＬ）溶液に炭酸カリウム（４４３ｍｇ，３．２１ｍｍｏｌ）およびヨードメタン（１５０μＬ，２．４１ｍｍｏｌ）を加え、室温にて終夜撹拌した。反応液に水を加え、酢酸エチルで３回抽出した後、有機層を合わせ水にて２回洗浄した。有機層をPhase-separator（Varian Inc.）にてろ過後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１００：０→７０：３０）で精製することにより、４，７−ジクロロ−１−メチル−１Ｈ−ピロロ［３，２−ｃ］ピリジン（２４０ｍｇ，７５％）を無色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２０１／２０３［Ｍ＋Ｈ］^＋． Reference Example 23:
Preparation of 4,7-dichloro-1-methyl-1H-pyrrolo [3,2-c] pyridine

(1) 2,5-dichloro-4-nitropyridine 1-oxide (3.06 g, 14.64 mmol) was added to a solution of phosphorus oxychloride (6.40 μL, 73.21 mmol) in chloroform (61.2 mL) and refluxed. Stir overnight at conditions. The reaction solution was added to ice, the solution was adjusted to pH 7-8 with a saturated aqueous sodium hydrogen carbonate solution, and extracted three times with chloroform. The organic layers were combined and filtered through a Phase-separator (Varian Inc.), followed by concentration under reduced pressure to obtain crude 2,5-dichloro-4-nitropyridine (2.98 g, quant.) As a yellow oil.
(2) A solution of the above crude compound (2.98 g, 15.44 mmol) in tetrahydrofuran (100 mL) was added to a solution of vinylmagnesium bromide (54.04 mmol) in tetrahydrofuran (104 mL) at 0 ° C. over 40 minutes, and at room temperature. Stir for 1 hour. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, filtered through Phase-separator (Varian Inc.), and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 80: 20 → 50: 50) to give 4,7-dichloro-1H-pyrrolo [3,2-c] pyridine (0.74 g). 27%) as a pale yellow powder.
APCI-MS m / z: 187/189 [M + H] ⁺ .
(3) To a solution of the above compound (300 mg, 1.60 mmol) in N, N-dimethylformamide (3 mL) was added potassium carbonate (443 mg, 3.21 mmol) and iodomethane (150 μL, 2.41 mmol), and the mixture was stirred at room temperature overnight. did. Water was added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined and washed twice with water. The organic layer was filtered through Phase-separator (Varian Inc.) and then concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0 → 70: 30) to give 4,7-dichloro-1-methyl-1H-pyrrolo [3,2-c] pyridine. (240 mg, 75%) was obtained as a colorless powder.
APCI-MS m / z: 201/203 [M + H] ⁺ .

（１） １−ブロモイソキノリン−３−アミンおよびイソプロペニルボロン酸ピナコールエステルを実施例９７−（１）および（２）と同様の方法で処理することにより、１−イソプロピルイソキノリン−３−アミンを白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１８７［Ｍ＋Ｈ］^＋．
（２）上記化合物（１８６．０ｍｇ，１．００ｍｍｏｌ）およびＮ−ブロモコハク酸イミド（２１４．０ｍｇ，１．２０ｍｍｏｌ）のメタノール溶液を室温で１時間撹拌した。反応液を減圧濃縮し、得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１０：０→３：１）で精製し、４−ブロモ−１−イソプロピルイソキノリン−３−アミン（１５５．１ｍｇ，５８％）を白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２６５／２６７［Ｍ＋Ｈ］^＋． Reference Example 24:
Preparation of 4-bromo-1-isopropylisoquinolin-3-amine

(1) By treating 1-bromoisoquinolin-3-amine and isopropenylboronic acid pinacol ester in the same manner as in Example 97- (1) and (2), 1-isopropylisoquinolin-3-amine was converted to white. Obtained as a powder.
APCI-MS m / z: 187 [M + H] ⁺ .
(2) A methanol solution of the above compound (186.0 mg, 1.00 mmol) and N-bromosuccinimide (214.0 mg, 1.20 mmol) was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 10: 0 → 3: 1) to give 4-bromo-1-isopropylisoquinolin-3-amine (155. 1 mg, 58%) was obtained as a white powder.
APCI-MS m / z: 265/267 [M + H] ⁺ .

（１） １−ブロモイソキノリン−３−アミンをおよびイソプロペニルボロン酸ピナコールエステルを実施例９７−（１）および（２）と同様の方法で処理することにより、１−イソプロピルイソキノリン−３−アミンを白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１８７［Ｍ＋Ｈ］^＋．
（２） 上記化合物（１４６．０ｍｇ，０．７８４ｍｍｏｌ）のエタノール溶液に、ヨウ素（２１９．０ｍｇ，０．８６２ｍｍｏｌ）および硫酸銀（２６９．０ｍｇ，０．８６２ｍｍｏｌ）を加え、室温で４時間撹拌した。反応液を酢酸エチルで希釈し、不溶物をろ別した後、ろ液を減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１０：０→１７：３）で精製し、４−ヨード−１−イソプロピルイソキノリン−３−アミン（７８．７ｍｇ，３２％）を淡黄色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：３１３［Ｍ＋Ｈ］^＋． Reference Example 25:
Preparation of 4-iodo-1-isopropylisoquinolin-3-amine

(1) By treating 1-bromoisoquinolin-3-amine and isopropenylboronic acid pinacol ester in the same manner as in Example 97- (1) and (2), 1-isopropylisoquinolin-3-amine is obtained. Obtained as a white powder.
APCI-MS m / z: 187 [M + H] ⁺ .
(2) Iodine (219.0 mg, 0.862 mmol) and silver sulfate (269.0 mg, 0.862 mmol) were added to an ethanol solution of the above compound (146.0 mg, 0.784 mmol), and the mixture was stirred at room temperature for 4 hours. . The reaction mixture was diluted with ethyl acetate, insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 10: 0 → 17: 3), and 4-iodo-1-isopropylisoquinolin-3-amine (78.7 mg, 32%) was palely added. Obtained as a yellow powder.
APCI-MS m / z: 313 [M + H] ⁺ .

参考例２４で得られた４−ブロモ−１−イソプロピルイソキノリン−３−アミンおよびイソプロペニルボロン酸ピナコールエステルを実施例９７−（１）および（２）と同様の方法で処理することにより、１，４−ジイソプロピルイソキノリン−３−アミンを白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２２９［Ｍ＋Ｈ］^＋． Reference Example 26:
Production of 1,4-diisopropylisoquinolin-3-amine

By treating 4-bromo-1-isopropylisoquinolin-3-amine and isopropenylboronic acid pinacol ester obtained in Reference Example 24 in the same manner as in Example 97- (1) and (2), 1, 4-Diisopropylisoquinolin-3-amine was obtained as a white powder.
APCI-MS m / z: 229 [M + H] ⁺ .

（１） １−ブロモイソキノリン−３−アミンを実施例９−（２）と同様の方法で処理することにより、１−シクロプロピルイソキノリン−３−アミンを白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１８５［Ｍ＋Ｈ］^＋
（２） 上記化合物を参考例２４−（２）と同様の方法で処理することにより、４−ブロモ−１−シクロプロピルイソキノリン−３−アミンを白色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２６３／２６５［Ｍ＋Ｈ］^＋． Reference Example 27:
Preparation of 4-bromo-1-cyclopropylisoquinolin-3-amine

(1) 1-Bromoisoquinolin-3-amine was treated in the same manner as in Example 9- (2) to give 1-cyclopropylisoquinolin-3-amine as a white powder.
APCI-MS m / z: 185 [M + H] ⁺
(2) By treating the above compound in the same manner as in Reference Example 24- (2), 4-bromo-1-cyclopropylisoquinolin-3-amine was obtained as a white powder.
APCI-MS m / z: 263/265 [M + H] ⁺ .

４−ブロモイソキノリン−３−アミンを実施例１０３と同様の方法で処理することにより、４−シクロプロピルイソキノリン−３−アミンを淡黄色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１８５［Ｍ＋Ｈ］^＋． Reference Example 28:
Preparation of 4-cyclopropylisoquinolin-3-amine

By treating 4-bromoisoquinolin-3-amine in the same manner as in Example 103, 4-cyclopropylisoquinolin-3-amine was obtained as a pale yellow powder.
APCI-MS m / z: 185 [M + H] ⁺ .

（１） アルゴン気流下、４−ブロモ−２−フルオロ安息香酸メチル（４２４ｍｇ，１．８２ｍｍｏｌ）、アリルトリブチルスズ（０．８４６ｍＬ，２．７３ｍｍｏｌ）、テトラキス（トリフェニルホスフィン）パラジウム（０）（１０５ｍｇ，０．０９１ｍｍｏｌ）、フッ化セシウム（４１５ｍｇ，２．７３ｍｍｏｌ）を１，４−ジオキサン（１０ｍＬ）中で７時間加熱還流した。室温まで冷却した後、酢酸エチルを用いて珪藻土ろ過を行い、ろ液を減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィー（酢酸エチル／ヘキサン＝２％→１０％）で精製し、４−アリル−２−フルオロ安息香酸メチル（３３３ｍｇ，９４％）を薄黄色粘体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ １９５［Ｍ＋Ｈ］^＋
（２） アルゴン気流下、上記化合物（３３３ｍｇ，１．７１ｍｍｏｌ）の１，２−ジクロロエタン（１０ｍＬ）溶液にクロロヨードメタン（１．２５ｍＬ，１７．１ｍｍｏｌ）を加え、続いてジエチル亜鉛（８．５７ｍＬ，８．５７ｍｍｏｌ、ヘキサン溶液）をゆっくり滴下し、室温で１６時間、５０℃で７時間攪拌した。室温まで冷却した後、飽和塩化アンモニウム溶液を加え、クロロホルムで３回抽出した。有機層を無水硫酸ナトリウムで乾燥した後、減圧濃縮した。得られた残渣は、マイクロカプセル化四酸化オスミウム（２１９ｍｇ，０．０８６５ｍｍｏｌ）、Ｎ−メチルモルホリン−Ｎ−オキシド（２６０ｍｇ，２．２２ｍｍｏｌ）、アセトン−アセトニトリル−水（１：１：１，６ｍＬ）中室温で２１時間攪拌した。ろ過、濃縮することにより粗生成物を得た後、シリカゲルカラムクロマトグラフィー（酢酸エチル／ヘキサン＝２％→１５％）で精製し、４−（シクロプロピルメチル）−２−フルオロ安息香酸メチル（１５５ｍｇ，４４％）を無色液体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ ２０９［Ｍ＋Ｈ］^＋
（３） アルゴン気流下、上記化合物（１５５ｍｇ，０．７４４ｍｍｏｌ）のテトラヒドロフラン（５ｍＬ）溶液に水素化ホウ素リチウム（８１．１ｍｇ，３．７２ｍｍｏｌ）及びメタノール（０．１５１ｍＬ，３．７２ｍｍｏｌ）を０℃にて加え、室温で３日間攪拌した。飽和食塩水を加え、酢酸エチルで３回抽出した後、無水硫酸ナトリウムで乾燥し、減圧濃縮した。残渣をシリカゲルカラムクロマトグラフィー（酢酸エチル／ヘキサン＝１５％→４０％）で精製し、［４−（シクロプロピルメチル）−２−フルオロフェニル］メタノール（１２６ｍｇ，９４％）を無色液体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ １９８［Ｍ＋ＮＨ_４］^＋ Reference Example 29:
Production of [4- (cyclopropylmethyl) -2-fluorophenyl] methanol

(1) Under an argon stream, methyl 4-bromo-2-fluorobenzoate (424 mg, 1.82 mmol), allyltributyltin (0.846 mL, 2.73 mmol), tetrakis (triphenylphosphine) palladium (0) (105 mg, 0.091 mmol) and cesium fluoride (415 mg, 2.73 mmol) were heated to reflux in 1,4-dioxane (10 mL) for 7 hours. After cooling to room temperature, diatomaceous earth filtration was performed using ethyl acetate, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate / hexane = 2% → 10%) to obtain methyl 4-allyl-2-fluorobenzoate (333 mg, 94%) as a pale yellow viscous body.
APCI-MS: m / z 195 [M + H] ⁺
(2) Under a stream of argon, chloroiodomethane (1.25 mL, 17.1 mmol) was added to a solution of the above compound (333 mg, 1.71 mmol) in 1,2-dichloroethane (10 mL), followed by diethylzinc (8.57 mL). , 8.57 mmol, hexane solution) was slowly added dropwise, followed by stirring at room temperature for 16 hours and at 50 ° C. for 7 hours. After cooling to room temperature, saturated ammonium chloride solution was added, and the mixture was extracted 3 times with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting residue was microencapsulated osmium tetroxide (219 mg, 0.0865 mmol), N-methylmorpholine-N-oxide (260 mg, 2.22 mmol), acetone-acetonitrile-water (1: 1: 1, 6 mL). The mixture was stirred at room temperature for 21 hours. The crude product was obtained by filtration and concentration, and then purified by silica gel column chromatography (ethyl acetate / hexane = 2% → 15%) to obtain methyl 4- (cyclopropylmethyl) -2-fluorobenzoate (155 mg). 44%) as a colorless liquid.
APCI-MS: m / z 209 [M + H] ⁺
(3) Under a stream of argon, lithium borohydride (81.1 mg, 3.72 mmol) and methanol (0.151 mL, 3.72 mmol) were added to a solution of the above compound (155 mg, 0.744 mmol) in tetrahydrofuran (5 mL) at 0 ° C. And stirred at room temperature for 3 days. Saturated brine was added, and the mixture was extracted 3 times with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate / hexane = 15% → 40%) to obtain [4- (cyclopropylmethyl) -2-fluorophenyl] methanol (126 mg, 94%) as a colorless liquid.
APCI-MS: m / z 198 [M + NH ₄ ] ⁺

４−ブロモ−３−フルオロ安息香酸メチルを参考例２９−（１）〜（３）と同様の方法で処理することにより、［４−（シクロプロピルメチル）−３−フルオロフェニル］メタノールを無色液体として得た。
ＡＰＣＩ−ＭＳ：ｍ／ｚ １９８［Ｍ＋ＮＨ_４］^＋ Reference Example 30:
Production of [4- (cyclopropylmethyl) -3-fluorophenyl] methanol

By treating methyl 4-bromo-3-fluorobenzoate in the same manner as in Reference Examples 29- (1) to (3), [4- (cyclopropylmethyl) -3-fluorophenyl] methanol was obtained as a colorless liquid. Got as.
APCI-MS: m / z 198 [M + NH ₄ ] ⁺

（１） アルゴン気流下、４−ブロモヨードベンゼン（２１５０ｍｇ，７．６０ｍｍｏｌ）のテトラヒドロフラン（２０ｍＬ）溶液に、−７８℃にて１．６７ｍｏｌ／Ｌ ｎ−ブチルリチウムヘキサン溶液（４．５０ｍＬ，７．５２ｍｍｏｌ）を滴下した。同温にて１時間撹拌後、Ｎ−メトキシ−Ｎ−メチル−１−（トリフルオロメチル）シクロプロパンカルボキサミド（Ｏｒｇａｎｉｃ Ｐｒｏｃｅｓｓ Ｒｅｓｅａｒｃｈ ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ ２００９，１３，５７６記載の方法により合成、１０００ｍｇ，５．０７ｍｍｏｌ）のテトラヒドロフラン（１０ｍＬ）溶液を滴下し、同温にて１時間撹拌した。反応液に−７８℃で飽和塩化アンモニウム水溶液を加えた後、室温まで昇温し、酢酸エチルで３回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１００：０→９５：５）で精製し、（４−ブロモフェニル）［１−（トリフルオロメチル）シクロプロピル］メタノン（７８３ｍｇ，７６％）を薄茶色の油状物として得た。
^１Ｈ−ＮＭＲ（ＣＤＣｌ_３） δ １．３６−１．５０（４Ｈ，ｍ），７．６１（２Ｈ，ｄ，Ｊ＝８．７Ｈｚ），７．７９（２Ｈ，ｄ，Ｊ＝８．７Ｈｚ）．
（２） 上記化合物（７８０ｍｇ，３．２６ｍｍｏｌ）のエタノール（１０ｍＬ）溶液に７８％ヒドラジン一水和物（１０００μＬ，１６．１ｍｍｏｌ）を加えた。反応液を終夜加熱還流し、室温まで冷却後、反応液に水を加え、酢酸エチルで３回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮することにより、粗（４−ブロモフェニル）［１−（トリフルオロメチル）シクロプロピル］メタノンヒドラゾン（７８４ｍｇ）を薄茶色の油状物として得た。これを更に精製せずに次の工程に使用した。
ＡＰＣＩ−ＭＳ ｍ／ｚ：３０７／３０９［Ｍ＋ＮＨ_４］^＋．
（３） 上記粗生成物（７７５ｍｇ）のエチレングリコール（８ｍＬ）溶液に水酸化カリウム（５８０ｍｇ，１０．３ｍｍｏｌ）を加え、１８０℃にて２時間加熱攪拌した。室温まで冷却後、反応液に水を加え、ジエチルエーテルで３回抽出した。有機層を合わせ、２ｍｏｌ／Ｌ塩酸水溶液、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン）で精製し、１−ブロモ−４−｛［１−（トリフルオロメチル）シクロプロピル］メチル｝ベンゼン（１４８ｍｇ，２１％、二段階収率）を無色の油状物として得た。
^１Ｈ−ＮＭＲ（ＣＤＣｌ_３） δ ０．４８−０．５３（２Ｈ，ｍ），０．９２−０．９７（２Ｈ，ｍ），２．９５（２Ｈ，ｓ），７．０４（２Ｈ，ｄ，Ｊ＝８．２Ｈｚ），７．４２（２Ｈ，ｄ，Ｊ＝８．２Ｈｚ）．
（４） 上記化合物（１４５ｍｇ，０．５２ｍｍｏｌ）、酢酸パラジウム（１５ｍｇ，０．０７ｍｍｏｌ）、１，１’−ビス（ジフェニルホスフィノ）フェロセン（７５ｍｇ，０．１４ｍｍｏｌ）、のＮ，Ｎ−ジメチルホルムアミド（５ｍＬ）およびメタノール（１．１ｍＬ）混合溶液に、トリエチルアミン（２００μＬ，１．４３ｍｍｏｌ）を加えた。反応液を一酸化炭素雰囲気下、９０℃にて終夜攪拌した。室温まで冷却後、反応液に水を加え、酢酸エチルで３回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９８：２→９０：１０）で精製し、４−｛［１−（トリフルオロメチル）シクロプロピル］メチル｝安息香酸メチル（１２９ｍｇ，９６％）を無色の油状物として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２５９［Ｍ＋Ｈ］^＋．
（５） 上記化合物（１１０ｍｇ，０．４３ｍｍｏｌ）のテトラヒドロフラン（４ｍＬ）およびメタノール（１１０μＬ，２．７１ｍｍｏｌ）溶液に０℃にて水素化ホウ素リチウム（６０ｍｇ，２．７５ｍｍｏｌ）を加えた。室温にて終夜撹拌後、０℃にて反応液に水を加え、酢酸エチルで３回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮することにより、粗（４−｛［１−（トリフルオロメチル）シクロプロピル］メチル｝フェニル）メタノール（１０３ｍｇ）を無色の油状物として得た。これを更に精製せずに次の工程に使用した。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２４８［Ｍ＋ＮＨ_４］^＋． Reference Example 31:
Production of (4-{[1- (trifluoromethyl) cyclopropyl] methyl} phenyl) methanol

(1) A solution of 4-bromoiodobenzene (2150 mg, 7.60 mmol) in tetrahydrofuran (20 mL) under an argon stream at 1.78 mol / L n-butyllithium hexane solution (4.50 mL, 7.60 mmol) at −78 ° C. 52 mmol) was added dropwise. After stirring at the same temperature for 1 hour, N-methoxy-N-methyl-1- (trifluoromethyl) cyclopropanecarboxamide (synthesized by the method described in Organic Process Research and Development 2009, 13, 576, 1000 mg, 5.07 mmol) Of tetrahydrofuran (10 mL) was added dropwise and stirred at the same temperature for 1 hour. A saturated aqueous ammonium chloride solution was added to the reaction solution at −78 ° C., and then the mixture was warmed to room temperature and extracted three times with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0 → 95: 5) to give (4-bromophenyl) [1- (trifluoromethyl) cyclopropyl] methanone (783 mg, 76% ) Was obtained as a light brown oil.
¹ H-NMR (CDCl ₃ ) δ 1.36-1.50 (4H, m), 7.61 (2H, d, J = 8.7 Hz), 7.79 (2H, d, J = 8.7 Hz) ).
(2) 78% hydrazine monohydrate (1000 μL, 16.1 mmol) was added to a solution of the above compound (780 mg, 3.26 mmol) in ethanol (10 mL). The reaction mixture was heated to reflux overnight, cooled to room temperature, water was added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give crude (4-bromophenyl) [1- (trifluoromethyl) cyclopropyl] methanone hydrazone (784 mg). ) Was obtained as a light brown oil. This was used in the next step without further purification.
APCI-MS m / z: 307/309 [M + NH ₄ ] ⁺ .
(3) To a solution of the crude product (775 mg) in ethylene glycol (8 mL) was added potassium hydroxide (580 mg, 10.3 mmol), and the mixture was heated and stirred at 180 ° C. for 2 hours. After cooling to room temperature, water was added to the reaction mixture, and the mixture was extracted 3 times with diethyl ether. The organic layers were combined, washed with 2 mol / L hydrochloric acid aqueous solution, water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane), and 1-bromo-4-{[1- (trifluoromethyl) cyclopropyl] methyl} benzene (148 mg, 21%, two-step yield) was colorless. As an oil.
¹ H-NMR (CDCl ₃ ) δ 0.48-0.53 (2H, m), 0.92-0.97 (2H, m), 2.95 (2H, s), 7.04 (2H, d, J = 8.2 Hz), 7.42 (2H, d, J = 8.2 Hz).
(4) N, N-dimethylformamide of the above compound (145 mg, 0.52 mmol), palladium acetate (15 mg, 0.07 mmol), 1,1′-bis (diphenylphosphino) ferrocene (75 mg, 0.14 mmol) To a mixed solution of (5 mL) and methanol (1.1 mL), triethylamine (200 μL, 1.43 mmol) was added. The reaction solution was stirred at 90 ° C. overnight under a carbon monoxide atmosphere. After cooling to room temperature, water was added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 98: 2 → 90: 10), and methyl 4-{[1- (trifluoromethyl) cyclopropyl] methyl} benzoate (129 mg, 96 %) As a colorless oil.
APCI-MS m / z: 259 [M + H] ⁺ .
(5) Lithium borohydride (60 mg, 2.75 mmol) was added to a solution of the above compound (110 mg, 0.43 mmol) in tetrahydrofuran (4 mL) and methanol (110 μL, 2.71 mmol) at 0 ° C. After stirring at room temperature overnight, water was added to the reaction mixture at 0 ° C., and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give crude (4-{[1- (trifluoromethyl) cyclopropyl] methyl} phenyl) methanol (103 mg). ) Was obtained as a colorless oil. This was used in the next step without further purification.
APCI-MS m / z: 248 [M + NH 4] +.

（１） （４−ブロモフェニル）（シクロプロピル）メタノン（Ｐｅｓｔｉｃｉｄｅ Ｓｃｉｅｎｃｅ １９８０，１１，５１３記載の方法により合成、５．００ｇ，２２．０ｍｍｏｌ）、酢酸パラジウム（０．５２ｇ，２．３ｍｍｏｌ）、および１，１’−ビス（ジフェニルホスフィノ）フェロセン（２．５０ｇ，４．５ｍｍｏｌ）のＮ，Ｎ−ジメチルホルムアミド（１５０ｍＬ）およびメタノール（４０ｍＬ）混合溶液に、トリエチルアミン（６．７ｍＬ，４８．１ｍｍｏｌ）を加えた。反応液を一酸化炭素雰囲気下、９０℃にて終夜攪拌した。室温まで冷却後、反応液に水を加え、酢酸エチルで３回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９８：２→８０：２０）で精製し、４−（シクロプロピルカルボニル）安息香酸メチル（４．２８ｇ，９４％）を無色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２０５［Ｍ＋Ｈ］^＋．
（２） フッ素樹脂製試験管を用いて上記化合物（１０００ｍｇ，４．９０ｍｍｏｌ）をビス（２−メトキシエチル）アミノ硫酸トリフルオリド（８．０ｍＬ，４３．４ｍｍｏｌ）に溶解した。０℃においてメタノール（６０μＬ，１．４８ｍｍｏｌ）を滴下した後、８０℃で８日間加熱攪拌した。反応液を冷却後、０℃で飽和炭酸水素ナトリウム水溶液に滴下し、酢酸エチルで３回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９８：２→９０：１０）で精製し、４−［シクロプロピル（ジフルオロ）メチル］安息香酸メチル（９２４ｍｇ，８４％）を薄黄色の油状物として得た。
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ ０．６４−０．７４（４Ｈ，ｍ），１．６６-１．７９（１Ｈ，ｍ）３．８８（３Ｈ，ｓ），７．７２（２Ｈ，ｄ，Ｊ＝８．８Ｈｚ），８．０７（２Ｈ，ｄ，Ｊ＝８．８Ｈｚ）．
（３） 上記化合物（９２０ｍｇ，４．０７ｍｍｏｌ）のテトラヒドロフラン（２５ｍＬ）溶液に０℃にて水素化ホウ素リチウム（３４０ｍｇ，１５．６ｍｍｏｌ）およびメタノール（６３０μＬ，１５．５ｍｍｏｌ）を加えた。室温にて終夜撹拌後、０℃にて反応液に水を加え、酢酸エチルで３回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９５：５→６５：３５）で精製し、｛４−［シクロプロピル（ジフルオロ）メチル］フェニル｝メタノール（９０５ｍｇ，９８％）を無色の油状物として得た。
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ ０．５８−０．７１（４Ｈ，ｍ），１．６１−１．７５（１Ｈ，ｍ）４．５４（２Ｈ，ｄ，Ｊ＝５．７Ｈｚ），５．２９（１Ｈ，ｔ，Ｊ＝５．７Ｈｚ），７．４２（２Ｈ，ｄ，Ｊ＝８．８Ｈｚ），７．５０（２Ｈ，ｄ，Ｊ＝８．５Ｈｚ）． Reference Example 32:
Production of {4- [cyclopropyl (difluoro) methyl] phenyl} methanol

(1) (4-Bromophenyl) (cyclopropyl) methanone (synthesized by the method described in Pesticide Science 1980, 11, 513, 5.00 g, 22.0 mmol), palladium acetate (0.52 g, 2.3 mmol), and To a mixed solution of 1,1′-bis (diphenylphosphino) ferrocene (2.50 g, 4.5 mmol) in N, N-dimethylformamide (150 mL) and methanol (40 mL) was added triethylamine (6.7 mL, 48.1 mmol). Was added. The reaction solution was stirred at 90 ° C. overnight under a carbon monoxide atmosphere. After cooling to room temperature, water was added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 98: 2 → 80: 20) to obtain methyl 4- (cyclopropylcarbonyl) benzoate (4.28 g, 94%) as a colorless powder. It was.
APCI-MS m / z: 205 [M + H] ⁺ .
(2) The above compound (1000 mg, 4.90 mmol) was dissolved in bis (2-methoxyethyl) aminosulfuric trifluoride (8.0 mL, 43.4 mmol) using a fluororesin test tube. Methanol (60 μL, 1.48 mmol) was added dropwise at 0 ° C., and the mixture was stirred with heating at 80 ° C. for 8 days. The reaction solution was cooled, then added dropwise to a saturated aqueous sodium hydrogen carbonate solution at 0 ° C., and extracted three times with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 98: 2 → 90: 10), and methyl 4- [cyclopropyl (difluoro) methyl] benzoate (924 mg, 84%) was pale yellow. Obtained as an oil.
¹ H-NMR (DMSO-d ₆ ) δ 0.64-0.74 (4H, m), 1.66-1.79 (1H, m) 3.88 (3H, s), 7.72 (2H , D, J = 8.8 Hz), 8.07 (2H, d, J = 8.8 Hz).
(3) Lithium borohydride (340 mg, 15.6 mmol) and methanol (630 μL, 15.5 mmol) were added to a solution of the above compound (920 mg, 4.07 mmol) in tetrahydrofuran (25 mL) at 0 ° C. After stirring at room temperature overnight, water was added to the reaction mixture at 0 ° C., and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 95: 5 → 65: 35), and {4- [cyclopropyl (difluoro) methyl] phenyl} methanol (905 mg, 98%) was colorless. Obtained as an oil.
¹ H-NMR (DMSO-d ₆ ) δ 0.58-0.71 (4H, m), 1.61-1.75 (1H, m) 4.54 (2H, d, J = 5.7 Hz) , 5.29 (1H, t, J = 5.7 Hz), 7.42 (2H, d, J = 8.8 Hz), 7.50 (2H, d, J = 8.5 Hz).

３−（シクロプロピルカルボニル）安息香酸エチル（ＷＯ２００６／０６７４４５記載の方法により合成）を参考例３２−（２）および（３）に記載の方法と同様に処理することにより、｛３−［シクロプロピル（ジフルオロ）メチル］フェニル｝メタノールを得た。
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ ０．６０−０．７２（４Ｈ，ｍ），１．６１−１．７５（１Ｈ，ｍ），４．５５（２Ｈ，ｄ，Ｊ＝５．１Ｈｚ），５．３２（１Ｈ，ｔ，Ｊ＝５．４Ｈｚ）７．３９−７．４５（３Ｈ，ｍ），７．５０（１Ｈ，ｓ）． Reference Example 33:
Production of {3- [cyclopropyl (difluoro) methyl] phenyl} methanol

By treating ethyl 3- (cyclopropylcarbonyl) benzoate (synthesized by the method described in WO2006 / 067445) in the same manner as described in Reference Examples 32- (2) and (3), {3- [cyclopropyl (Difluoro) methyl] phenyl} methanol was obtained.
¹ H-NMR (DMSO-d ₆ ) δ 0.60-0.72 (4H, m), 1.61-1.75 (1H, m), 4.55 (2H, d, J = 5.1 Hz) ), 5.32 (1H, t, J = 5.4 Hz) 7.39-7.45 (3H, m), 7.50 (1H, s).

（１） アルゴン気流下、４−（シクロプロピルカルボニル）安息香酸メチル（５００ｍｇ，２．４５ｍｍｏｌ）のテトラヒドロフラン（１２ｍＬ）溶液に、−７８℃にて１ｍｏｌ／Ｌヘキサメチルジシラザンリチウムテトラヒドロフラン溶液（３．０ｍＬ，３．００ｍｍｏｌ）を滴下し、１５分間撹拌した。同温にてヨードメタン（２００μＬ，３．２１ｍｍｏｌ）を滴下し、反応液をゆっくり室温まで昇温し、終夜撹拌した。反応液に飽和塩化アンモニウム水溶液を加え、酢酸エチルで３回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１００：０→９７：３）で精製し、４−［（１−メチルシクロプロピル）カルボニル］安息香酸メチル（４５ｍｇ，８％）を無色の油状物として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２１９［Ｍ＋Ｈ］^＋．
（２） ４−［（１−メチルシクロプロピル）カルボニル］安息香酸メチルを参考例３２−（２）および（３）に記載の方法と同様に処理することにより、｛４−［ジフルオロ（１−メチルシクロプロピル）メチル］フェニル｝メタノールを得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２３０［Ｍ＋ＮＨ_４］^＋． Reference Example 34:
Production of {4- [difluoro (1-methylcyclopropyl) methyl] phenyl} methanol

(1) Under a stream of argon, a solution of methyl 4- (cyclopropylcarbonyl) benzoate (500 mg, 2.45 mmol) in tetrahydrofuran (12 mL) at −78 ° C. at 1 mol / L hexamethyldisilazane lithium tetrahydrofuran solution (3. 0 mL, 3.00 mmol) was added dropwise and stirred for 15 minutes. Iodomethane (200 μL, 3.21 mmol) was added dropwise at the same temperature, and the reaction solution was slowly warmed to room temperature and stirred overnight. A saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0 → 97: 3) to give methyl 4-[(1-methylcyclopropyl) carbonyl] benzoate (45 mg, 8%). Obtained as a colorless oil.
APCI-MS m / z: 219 [M + H] ⁺ .
(2) By treating methyl 4-[(1-methylcyclopropyl) carbonyl] benzoate in the same manner as described in Reference Examples 32- (2) and (3), {4- [difluoro (1- Methylcyclopropyl) methyl] phenyl} methanol was obtained.
APCI-MS m / z: 230 [M + NH ₄ ] ⁺ .

（４−ブロモ−２−フルオロフェニル）シクロプロピルケトンを参考例３２−（１）、（２）および（３）に記載の方法と同様に処理することにより、｛４−［シクロプロピル（ジフルオロ）メチル］−３−フルオロフェニル｝メタノールを得た。
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ ０．６０−０．７４（４Ｈ，ｍ），１．６９−１．８４（１Ｈ，ｍ），４．５５（２Ｈ，ｄ，Ｊ＝４．２Ｈｚ），５．４３（１Ｈ，ｔ，Ｊ＝５．３Ｈｚ）７．２３（１Ｈ，ｓ），７．２６（１Ｈ，ｄ，Ｊ＝６．７Ｈｚ）７．５１（１Ｈ，ｔ，Ｊ＝８．０Ｈｚ）． Reference Example 35:
Production of {4- [cyclopropyl (difluoro) methyl] -3-fluorophenyl} methanol

By treating (4-bromo-2-fluorophenyl) cyclopropyl ketone in the same manner as described in Reference Example 32- (1), (2) and (3), {4- [cyclopropyl (difluoro) Methyl] -3-fluorophenyl} methanol was obtained.
¹ H-NMR (DMSO-d ₆ ) δ 0.60-0.74 (4H, m), 1.69-1.84 (1H, m), 4.55 (2H, d, J = 4.2 Hz) ), 5.43 (1H, t, J = 5.3 Hz) 7.23 (1H, s), 7.26 (1H, d, J = 6.7 Hz) 7.51 (1H, t, J = 8) .0Hz).

の製造
（５−ブロモ−２−フルオロフェニル）（シクロプロピル）メタノン（Ｂｉｏｏｒｇａｎｉｃ ＆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ Ｌｅｔｔｅｒｓ ２０１０，２０，１６５２記載の方法により合成）を参考例３２−（１）、（２）および（３）に記載の方法と同様に処理することにより、｛３−［シクロプロピル（ジフルオロ）メチル］−４−フルオロフェニル｝メタノールを得た。
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ ０．６１−０．７４（４Ｈ，ｍ），１．６９−１．８４（１Ｈ，ｍ），４．５１（２Ｈ，ｄ，Ｊ＝４．８Ｈｚ），５．３５（１Ｈ，ｔ，Ｊ＝５．６Ｈｚ），７．２９（１Ｈ，ｄｄ，Ｊ＝１１．２，８．５Ｈｚ），７．４５−７．５２（２Ｈ，ｍ）． Reference Example 36:

(5-bromo-2-fluorophenyl) (cyclopropyl) methanone (synthesized by the method described in Bioorganic & Medicinal Chemistry Letters 2010, 20, 1652) was prepared as Reference Examples 32- (1), (2) and (3) In the same manner as described in 1., {3- [cyclopropyl (difluoro) methyl] -4-fluorophenyl} methanol was obtained.
¹ H-NMR (DMSO-d ₆ ) δ 0.61-0.74 (4H, m), 1.69-1.84 (1H, m), 4.51 (2H, d, J = 4.8 Hz) ), 5.35 (1H, t, J = 5.6 Hz), 7.29 (1H, dd, J = 11.2, 8.5 Hz), 7.45-7.52 (2H, m).

（１） ４−ブロモ−２−クロロ−Ｎ−メトキシ−Ｎ−メチルベンズアミド（Ｂｉｏｏｒｇａｎｉｃ ＆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ Ｌｅｔｔｅｒｓ ２００３，１３，３９８３記載の方法により合成、５．９０ｇ，２１．０ｍｍｏｌ）のテトラヒドロフラン（１８０ｍＬ）溶液に、０℃にて０．７ｍｏｌ／Ｌシクロプロピルマグネシウムブロミドテトラヒドロフラン溶液（６５．０ｍＬ，４５．５ｍｍｏｌ）を滴下した。同温にて４時間撹拌後、反応液に飽和塩化アンモニウム水溶液を加え、酢酸エチルで３回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１００：０→９３：７）で精製し、（４−ブロモ−２−クロロフェニル）（シクロプロピル）メタノン（３．７５ｇ，６８％）を薄黄色の油状物として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２５９／２６１／２６３［Ｍ＋Ｈ］^＋．
（２） （４−ブロモ−２−クロロフェニル）（シクロプロピル）メタノンを参考例３２−（１）、（２）および（３）に記載の方法と同様に処理することにより、｛３−クロロ−４−［シクロプロピル（ジフルオロ）メチル］フェニル｝メタノールを得た。
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ ０．６２−０．７４（４Ｈ，ｍ）１．８４−１．９８（１Ｈ，ｍ）４．５４（２Ｈ，ｄ，Ｊ＝４．５Ｈｚ）５．４２（１Ｈ，ｔ，Ｊ＝５．４Ｈｚ）７．３７（１Ｈ，ｄ，Ｊ＝８．１Ｈｚ）７．５０（１Ｈ，ｓ）７．５８（１Ｈ，ｄ，Ｊ＝７．９Ｈｚ）． Reference Example 37:
Production of {3-chloro-4- [cyclopropyl (difluoro) methyl] phenyl} methanol

(1) A solution of 4-bromo-2-chloro-N-methoxy-N-methylbenzamide (synthesized by the method described in Bioorganic & Medicinal Chemistry Letters 2003, 13, 3983, 5.90 g, 21.0 mmol) in tetrahydrofuran (180 mL) To the solution, a 0.7 mol / L cyclopropyl magnesium bromide tetrahydrofuran solution (65.0 mL, 45.5 mmol) was added dropwise at 0 ° C. After stirring at the same temperature for 4 hours, a saturated aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0 → 93: 7) to give (4-bromo-2-chlorophenyl) (cyclopropyl) methanone (3.75 g, 68%). Was obtained as a pale yellow oil.
APCI-MS m / z: 259/261/263 [M + H] ⁺ .
(2) By treating (4-bromo-2-chlorophenyl) (cyclopropyl) methanone in the same manner as described in Reference Example 32- (1), (2) and (3), {3-chloro- 4- [Cyclopropyl (difluoro) methyl] phenyl} methanol was obtained.
¹ H-NMR (DMSO-d ₆ ) δ 0.62-0.74 (4H, m) 1.84-1.98 (1H, m) 4.54 (2H, d, J = 4.5 Hz) 5 .42 (1H, t, J = 5.4 Hz) 7.37 (1H, d, J = 8.1 Hz) 7.50 (1H, s) 7.58 (1H, d, J = 7.9 Hz).

４−［シクロブチル（ジフルオロ）メチル］安息香酸エチル（ＷＯ２００５／０３２４６５記載の方法により合成、１４０ｍｇ，０．５５ｍｍｏｌ）のテトラヒドロフラン（５ｍＬ）およびメタノール（１１２μＬ，２．７６ｍｍｏｌ）溶液に０℃にて水素化ホウ素リチウム（６０ｍｇ，２．７５ｍｍｏｌ）を加えた。室温にて３時間撹拌後、０℃にて反応液に水を加え、酢酸エチルで３回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮することにより、粗｛４−［シクロブチル（ジフルオロ）メチル］フェニル｝メタノール（１１１ｍｇ）を無色の油状物として得た。これを更に精製せずに次の工程に使用した。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２３０［Ｍ＋ＮＨ_４］^＋． Reference Example 38:
Production of {4- [cyclobutyl (difluoro) methyl] phenyl} methanol

Hydrogenation of ethyl 4- [cyclobutyl (difluoro) methyl] benzoate (synthesized by the method described in WO2005 / 032465, 140 mg, 0.55 mmol) in tetrahydrofuran (5 mL) and methanol (112 μL, 2.76 mmol) at 0 ° C. Lithium boron (60 mg, 2.75 mmol) was added. After stirring at room temperature for 3 hours, water was added to the reaction mixture at 0 ° C., and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give crude {4- [cyclobutyl (difluoro) methyl] phenyl} methanol (111 mg) as a colorless oil. Obtained. This was used in the next step without further purification.
APCI-MS m / z: 230 [M + NH ₄ ] ⁺ .

（１） （４−ブロモフェニル）（シクロプロピル）メタノン（５８７ｍｇ，２．６０ｍｍｏｌ）のテトラヒドロフラン（５．２ｍＬ）溶液に、０℃にてモレキュラーシーブス４Å（５００ｍｇ）、トリメチルシリルトリフルオロメタン（７７２μＬ，５．２０ｍｍｏｌ）、テトラブチルアンモニウムフルオリド（テトラヒドロフラン溶液，１ｍｏｌ／Ｌ，３．９ｍＬ，３．９０ｍｍｏｌ）を加え、室温にて１８時間撹拌した。上記溶液を珪藻土ろ過後、１ｍｏｌ／Ｌ塩酸水溶液（１０ｍＬ）を加え、酢酸エチルで２回抽出した。有機層を合わせ、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮し、得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝２０：１→５：１）で精製することにより、１−（４−ブロモフェニル）−１−シクロプロピル−２，２，２−トリフルオロエタノール（７４７ｍｇ，９７％）を無色の油状物として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：３５３／３５５［Ｍ＋ＣＨ_３ＣＯＯ］⁻．
（２） 上記化合物（７４７ｍｇ，２．５３ｍｍｏｌ）を参考例６−（１）および（２）と同様の方法で処理することにより、１−シクロプロピル−２，２，２−トリフルオロ−１−［４−（ヒドロキシメチル）フェニル］エタノール（１１２ｍｇ，１８％）を無色の油状物として得た。
ＥＳＩ−ＭＳ ｍ／ｚ：３５３／３５５［Ｍ−Ｈ］⁻． Reference Example 39:
Preparation of 1-cyclopropyl-2,2,2-trifluoro-1- [4- (hydroxymethyl) phenyl] ethanol

(1) To a solution of (4-bromophenyl) (cyclopropyl) methanone (587 mg, 2.60 mmol) in tetrahydrofuran (5.2 mL) at 0 ° C., molecular sieves 4Å (500 mg), trimethylsilyltrifluoromethane (772 μL, 5. 20 mmol) and tetrabutylammonium fluoride (tetrahydrofuran solution, 1 mol / L, 3.9 mL, 3.90 mmol) were added, and the mixture was stirred at room temperature for 18 hours. The above solution was filtered through diatomaceous earth, 1 mol / L hydrochloric acid aqueous solution (10 mL) was added, and the mixture was extracted twice with ethyl acetate. The organic layers are combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the resulting residue is purified by silica gel column chromatography (hexane: ethyl acetate = 20: 1 → 5: 1). Gave 1- (4-bromophenyl) -1-cyclopropyl-2,2,2-trifluoroethanol (747 mg, 97%) as a colorless oil.
APCI-MS m / z: 353/355 [M + CH ₃ COO] ⁻ .
(2) By treating the above compound (747 mg, 2.53 mmol) in the same manner as in Reference Examples 6- (1) and (2), 1-cyclopropyl-2,2,2-trifluoro-1- [4- (Hydroxymethyl) phenyl] ethanol (112 mg, 18%) was obtained as a colorless oil.
ESI-MS m / z: 353/355 [M−H] ⁻ .

（１） ４−［（トリフルオロメトキシ）メチル］安息香酸（５００ｍｇ，２．２７ｍｍｏｌ）のＮ，Ｎ−ジメチルホルムアミド（２５ｍＬ）溶液に、ヨードメタン（３００μＬ，４．８２ｍｍｏｌ）および炭酸カリウム（１０００ｍｇ，７．２４ｍｍｏｌ）を加えた。室温にて終夜撹拌後、反応液に水を加え、酢酸エチルで３回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９９：１→８０：２０）で精製し、４−［（トリフルオロメトキシ）メチル］安息香酸メチル（４５３ｍｇ，８５％）を薄茶色の油状物として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２３５［Ｍ＋Ｈ］^＋．
（２） 上記化合物（４５０ｍｇ，１．９２ｍｍｏｌ）のテトラヒドロフラン（５ｍＬ）およびメタノール（１３０μＬ，３．２０ｍｍｏｌ）溶液に０℃にて水素化ホウ素リチウム（７０ｍｇ，３．２０ｍｍｏｌ）を加えた。室温にて終夜撹拌後、０℃にて反応液に水を加え、酢酸エチルで３回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝８５：１５）で精製し、｛４−［（トリフルオロメトキシ）メチル］フェニル｝メタノール（２３９ｍｇ，６０％）を無色固体として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２２４［Ｍ＋ＮＨ_４］^＋． Reference Example 40:
Production of {4-[(trifluoromethoxy) methyl] phenyl} methanol

(1) To a solution of 4-[(trifluoromethoxy) methyl] benzoic acid (500 mg, 2.27 mmol) in N, N-dimethylformamide (25 mL), iodomethane (300 μL, 4.82 mmol) and potassium carbonate (1000 mg, 7 .24 mmol) was added. After stirring overnight at room temperature, water was added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 99: 1 → 80: 20), and methyl 4-[(trifluoromethoxy) methyl] benzoate (453 mg, 85%) Obtained as an oil.
APCI-MS m / z: 235 [M + H] ⁺ .
(2) Lithium borohydride (70 mg, 3.20 mmol) was added to a solution of the above compound (450 mg, 1.92 mmol) in tetrahydrofuran (5 mL) and methanol (130 μL, 3.20 mmol) at 0 ° C. After stirring at room temperature overnight, water was added to the reaction mixture at 0 ° C., and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 85: 15) to obtain {4-[(trifluoromethoxy) methyl] phenyl} methanol (239 mg, 60%) as a colorless solid.
APCI-MS m / z: 224 [M + NH ₄ ] ⁺ .

（１） １−（４−ブロモ−２−フルオロフェニル）エタノン（１．００ｇ，４．５ｍｍｏｌ）、酢酸パラジウム（０．１２ｇ，０．５４ｍｍｏｌ）、および１，１’−ビス（ジフェニルホスフィノ）フェロセン（０．５０ｇ，０．９０ｍｍｏｌ）のＮ，Ｎ−ジメチルアセトアミド（２２ｍＬ）およびメタノール（７ｍＬ）混合溶液に、トリエチルアミン（１．３ｍＬ，９．２ｍｍｏｌ）を加えた。反応液を一酸化炭素雰囲気下、９０℃にて終夜攪拌した。室温まで冷却後、反応液を珪藻土およびシリカゲルにてろ過後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１００：０→６０：４０）で精製し、４−アセチル−３−フルオロ安息香酸メチル（０．８３ｇ，９３％）を薄黄色の粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１９４［Ｍ＋Ｈ］^＋．
（２） 上記化合物（８２５ｍｇ，４．２１ｍｍｏｌ）のテトラヒドロフラン（８．４ｍＬ）溶液に、０℃にてトリメチルシリルトリフルオロメタン（１２４０μＬ，８．４１ｍｍｏｌ）、テトラブチルアンモニウムフルオリド（テトラヒドロフラン溶液，１ｍｏｌ／Ｌ，６．３ｍＬ，６．３１ｍｍｏｌ）を加え、室温にて３時間撹拌した。上記溶液に１ｍｏｌ／Ｌ塩酸水溶液を加え、酢酸エチルで３回抽出し、有機層を合わせPhase-separater（Varian Inc.）にてろ過後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１００：０→６０：４０）で精製することにより、３−フルオロ−４−（２，２，２−トリフルオロ−１−ヒドロキシ−１−メチルエチル）安息香酸メチル（６５０ｍｇ，５８％）を薄黄色の油状物として得た。
ＥＳＩ−ＭＳ ｍ／ｚ：３２４［Ｍ−Ｈ］⁻．
（３） 上記化合物（６４８ｍｇ，２．４３ｍｍｏｌ）のテトラヒドロフラン（４ｍＬ）溶液に、０℃にて水素化アルミニウムリチウム（１１０ｍｇ，２．９２ｍｍｏｌ）を加えた。室温にて５時間撹拌後、０℃にて反応液に水および２Ｎ水酸化ナトリウム水溶液を加え、珪藻土ろ過した。ろ液を酢酸エチルで３回抽出し、有機層を合わせPhase-separater（Varian Inc.）にてろ過後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝８０：２０→４０：６０）で精製することにより、１，１，１−トリフルオロ−２−［２−フルオロ−４−（ヒドロキシメチル）フェニル］プロパン−２−オール（４９４ｍｇ，８５％）を無色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２５６［Ｍ＋ＮＨ_４］^＋． Reference example 41:
Preparation of 1,1,1-trifluoro-2- [2-fluoro-4- (hydroxymethyl) phenyl] propan-2-ol

(1) 1- (4-Bromo-2-fluorophenyl) ethanone (1.00 g, 4.5 mmol), palladium acetate (0.12 g, 0.54 mmol), and 1,1′-bis (diphenylphosphino) Triethylamine (1.3 mL, 9.2 mmol) was added to a mixed solution of ferrocene (0.50 g, 0.90 mmol) in N, N-dimethylacetamide (22 mL) and methanol (7 mL). The reaction solution was stirred at 90 ° C. overnight under a carbon monoxide atmosphere. After cooling to room temperature, the reaction solution was filtered through diatomaceous earth and silica gel, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0 → 60: 40) to obtain methyl 4-acetyl-3-fluorobenzoate (0.83 g, 93%) as a pale yellow powder. Got as.
APCI-MS m / z: 194 [M + H] ⁺ .
(2) To a solution of the above compound (825 mg, 4.21 mmol) in tetrahydrofuran (8.4 mL) at 0 ° C., trimethylsilyltrifluoromethane (1240 μL, 8.41 mmol), tetrabutylammonium fluoride (tetrahydrofuran solution, 1 mol / L, (6.3 mL, 6.31 mmol) was added, and the mixture was stirred at room temperature for 3 hours. A 1 mol / L aqueous hydrochloric acid solution was added to the above solution, and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, filtered through Phase-separater (Varian Inc.), and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0 → 60: 40) to give 3-fluoro-4- (2,2,2-trifluoro-1-hydroxy-1 -Methylethyl) methyl benzoate (650 mg, 58%) was obtained as a pale yellow oil.
ESI-MS m / z: 324 [M−H] ⁻ .
(3) To a solution of the above compound (648 mg, 2.43 mmol) in tetrahydrofuran (4 mL) was added lithium aluminum hydride (110 mg, 2.92 mmol) at 0 ° C. After stirring at room temperature for 5 hours, water and a 2N aqueous sodium hydroxide solution were added to the reaction solution at 0 ° C., followed by filtration through diatomaceous earth. The filtrate was extracted three times with ethyl acetate, the organic layers were combined, filtered through Phase-separater (Varian Inc.), and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 80: 20 → 40: 60) to obtain 1,1,1-trifluoro-2- [2-fluoro-4- (hydroxymethyl). ) Phenyl] propan-2-ol (494 mg, 85%) was obtained as a colorless powder.
APCI-MS m / z: 256 [M + NH ₄ ] ⁺ .

（１） ４−アセチル−３−クロロ安息香酸（Ｔｅｔｒａｈｅｄｒｏｎ １９８８，４４，１６３１記載の方法により合成、７００ｍｇ，３．５２ｍｍｏｌ）のＮ，Ｎ−ジメチルホルムアミド（４ｍＬ）溶液に室温にて炭酸カリウム（９７４ｍｇ，７．０５ｍｍｏｌ）およびヨードメタン（６５８μＬ，１０．５７ｍｍｏｌ）を加え、室温にて１時間撹拌した。反応液に水を加え、酢酸エチルで３回抽出し、有機層を合わせ、Phase-separator（Varian Inc.）にてろ過後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１００：０→７５：２５）で精製することにより、４−アセチル−３−クロロ安息香酸メチル（７０７ｍｇ，９４％）を薄黄色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２１３／２１５［Ｍ＋Ｈ］^＋．
（２） ４−アセチル−３−クロロ安息香酸メチルを参考例４１−（２）および（３）に記載の方法と同様に処理することにより、２−［２−クロロ−４−（ヒドロキシメチル）フェニル］−１，１，１−トリフルオロプロパン−２−オールを得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２７２／２７４［Ｍ＋ＮＨ_４］^＋． Reference Example 42:
Preparation of 2- [2-chloro-4- (hydroxymethyl) phenyl] -1,1,1-trifluoropropan-2-ol

(1) Potassium carbonate (974 mg) at room temperature in a solution of 4-acetyl-3-chlorobenzoic acid (synthesized by the method described in Tetrahedron 1988, 44, 1631, 700 mg, 3.52 mmol) in N, N-dimethylformamide (4 mL). 7.05 mmol) and iodomethane (658 μL, 10.57 mmol) were added, and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction mixture, and the mixture was extracted 3 times with ethyl acetate. The organic layers were combined, filtered through a Phase-separator (Varian Inc.), and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0 → 75: 25) to give methyl 4-acetyl-3-chlorobenzoate (707 mg, 94%) as a pale yellow powder. Obtained.
APCI-MS m / z: 213/215 [M + H] ⁺ .
(2) By treating methyl 4-acetyl-3-chlorobenzoate in the same manner as described in Reference Examples 41- (2) and (3), 2- [2-chloro-4- (hydroxymethyl) Phenyl] -1,1,1-trifluoropropan-2-ol was obtained.
APCI-MS m / z: 272/274 [M + NH ₄ ] ⁺ .

（１） ４−アセチル安息香酸メチル（７００ｍｇ，３．８５ｍｍｏｌ）のテトラヒドロフラン（７．７ｍＬ）溶液に、０℃にてペンタフルオロエチルトリメチルシラン（１３７０ｍｇ，６．９３ｍｍｏｌ）、およびテトラブチルアンモニウムフルオリド（テトラヒドロフラン溶液，１ｍｏｌ／Ｌ，５．７μＬ，５．７８ｍｍｏｌ）を加え、室温にて終夜撹拌した。上記溶液に１ｍｏｌ／Ｌ塩酸水溶液を加え、酢酸エチルで３回抽出し、有機層を合わせPhase-separator（Varian Inc.）にてろ過後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１００：０→７０：３０）で精製することにより、４−（２，２，３，３，３−ペンタフルオロ−１−ヒドロキシ−１−メチルプロピル）安息香酸メチル（７６５ｍｇ，６７％）を薄黄色の粘体として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：３１６［Ｍ＋ＮＨ_４］^＋．
（２） 上記化合物（７６０ｍｇ，２．５５ｍｍｏｌ）のテトラヒドロフラン（１３ｍＬ）溶液に０℃にて水素化ホウ素リチウム（２７８ｍｇ，１２．７ｍｍｏｌ）およびメタノール（６５１６μＬ，１２．７ｍｍｏｌ）を加えた。室温にて終夜撹拌後、０℃にて反応液に水を加え、酢酸エチルで３回抽出し、有機層を合わせPhase-separator（Varian Inc.）にてろ過後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１００：０→６０：４０）で精製することにより、３，３，４，４，４−ペンタフルオロ−２−［４−（ヒドロキシメチル）フェニル］ブタン−２−オール（５８０ｍｇ，８４％）を無色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２８８［Ｍ＋ＮＨ_４］^＋． Reference Example 43:
Production of 3,3,4,4,4-pentafluoro-2- [4- (hydroxymethyl) phenyl] butan-2-ol

(1) To a solution of methyl 4-acetylbenzoate (700 mg, 3.85 mmol) in tetrahydrofuran (7.7 mL) at 0 ° C., pentafluoroethyltrimethylsilane (1370 mg, 6.93 mmol) and tetrabutylammonium fluoride ( Tetrahydrofuran solution, 1 mol / L, 5.7 μL, 5.78 mmol) was added, and the mixture was stirred overnight at room temperature. A 1 mol / L hydrochloric acid aqueous solution was added to the above solution, followed by extraction three times with ethyl acetate. The organic layers were combined, filtered through a Phase-separator (Varian Inc.), and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0 → 70: 30) to give 4- (2,2,3,3,3-pentafluoro-1-hydroxy-1 -Methylpropyl) methyl benzoate (765 mg, 67%) was obtained as a pale yellow viscous body.
APCI-MS m / z: 316 [M + NH 4] +.
(2) To a solution of the above compound (760 mg, 2.55 mmol) in tetrahydrofuran (13 mL) was added lithium borohydride (278 mg, 12.7 mmol) and methanol (6516 μL, 12.7 mmol) at 0 ° C. After stirring overnight at room temperature, water was added to the reaction mixture at 0 ° C., and the mixture was extracted three times with ethyl acetate. The organic layers were combined, filtered through a Phase-separator (Varian Inc.), and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0 → 60: 40) to give 3,3,4,4,4-pentafluoro-2- [4- (hydroxymethyl). ) Phenyl] butan-2-ol (580 mg, 84%) was obtained as a colorless powder.
APCI-MS m / z: 288 [M + NH 4] +.

（１） ６−ブロモ−４−フルオロインダン−１−オン（５７ｍｇ，０．２６ｍｍｏｌ）のトリフルオロ酢酸（１．１ｍＬ）溶液にトリエチルシラン（１０３μＬ，０．６５ｍｍｏｌ）を加え、室温にて終夜撹拌した。反応液を氷水に加え、酢酸エチルで３回抽出した。有機層を合わせ、飽和炭酸水素ナトリウム水溶液にて洗浄し、有機層をPhase-separator（Varian Inc.）にてろ過後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１００：０）で精製し、粗６−ブロモ−４−フルオロインダン（６１ｍｇ）を黄色の油状物として得た。これを更に精製せずに次の工程に使用した。
（２） 上記粗生成物を参考例４１−（１）に記載の方法と同様に処理することにより、粗７−フルオロインダン−５−カルボン酸メチルを得た。これを更に精製せずに次の工程に使用した。
（３） 上記粗生成物を参考例４３−（２）に記載の方法と同様に処理することにより、粗（７−フルオロ−２，３−ジヒドロ−１Ｈ−インデン−５−イル）メタノールを得た。これを更に精製せずに次の工程に使用した。 Reference Example 44:
Production of (7-fluoro-2,3-dihydro-1H-inden-5-yl) methanol

(1) Triethylsilane (103 μL, 0.65 mmol) was added to a solution of 6-bromo-4-fluoroindan-1-one (57 mg, 0.26 mmol) in trifluoroacetic acid (1.1 mL) and stirred at room temperature overnight. did. The reaction solution was added to ice water and extracted three times with ethyl acetate. The organic layers were combined and washed with a saturated aqueous sodium hydrogen carbonate solution, and the organic layer was filtered through a Phase-separator (Varian Inc.) and then concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 100: 0) to give crude 6-bromo-4-fluoroindane (61 mg) as a yellow oil. This was used in the next step without further purification.
(2) Crude 7-fluoroindane-5-carboxylate was obtained by treating the crude product in the same manner as described in Reference Example 41- (1). This was used in the next step without further purification.
(3) By treating the above crude product in the same manner as described in Reference Example 43- (2), crude (7-fluoro-2,3-dihydro-1H-inden-5-yl) methanol is obtained. It was. This was used in the next step without further purification.

５−ブロモインダン−１−オンを参考例４１−（１）、（２）および（３）に記載の方法と同様に処理することにより、５−（ヒドロキシメチル）−１−（トリフルオロメチル）インダン−１−オールを得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２５０［Ｍ＋ＮＨ_４］^＋． Reference example 45:
Production of 5- (hydroxymethyl) -1- (trifluoromethyl) indan-1-ol

By treating 5-bromoindan-1-one in the same manner as in Reference Example 41- (1), (2) and (3), 5- (hydroxymethyl) -1- (trifluoromethyl) Indan-1-ol was obtained.
APCI-MS m / z: 250 [M + NH ₄ ] ⁺ .

（１） アルゴン気流下、２−（メチルチオ）ピリジン−５−カルバルデヒド（２０００ｍｇ，１２．９７ｍｍｏｌ）のテトラヒドロフラン（２０ｍＬ）溶液に、−４０℃にて０．５ｍｏｌ／Ｌシクロプロピルマグネシウムブロマイドテトラヒドロフラン溶液（２８．６ｍＬ）を加えた。反応液を同温にて１０分間撹拌後、０℃までゆっくり昇温し、１時間撹拌した。反応液に塩化アンモニウム水を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝７０：３０→３０：７０）で精製し、シクロプロピル［２−（メチルチオ）ピリミジン−５−イル］メタノール（８２２ｍｇ，３２％）を無色油状物として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１９７［Ｍ＋Ｈ］^＋
（２） 上記化合物（８１５ｍｇ，４．１５ｍｍｏｌ）のクロロホルム（１２ｍＬ）溶液に、室温にてトリエチルシラン（１．９９ｍＬ，１２．４６ｍｍｏｌ）を加えた。氷冷下、反応液にトリフルオロ酢酸（１．５４ｍＬ，２０．１５ｍｍｏｌ）を滴下後、室温までゆっくり昇温し、４日間撹拌した。反応溶液に飽和重曹水を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９５：５→７５：２５）で精製し、５−（シクロプロピルメチル）−２−（メチルチオ）ピリミジン（２２９ｍｇ，３１％）を無色油状物として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１８１［Ｍ＋Ｈ］^＋
（３） 上記化合物（２２５ｍｇ，１．２５ｍｍｏｌ）のジクロロメタン（５ｍＬ）溶液に、０℃にてメタクロロ過安息香酸（６２４ｍｇ，２．５０ｍｍｏｌ）のジクロロメタン（５ｍＬ）溶液を滴下した。反応液を室温までゆっくり昇温し、１時間３０分撹拌した後、チオ硫酸ナトリウム水溶液を加えさらに３０分撹拌した。反応溶液に飽和重曹水を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝７０：３０→３５：６５）で精製し、５−（シクロプロピルメチル）−２−（メチルスルホニル）ピリミジン（１７３ｍｇ，６５％）を無色油状物として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２１３［Ｍ＋Ｈ］^＋
（４） 上記化合物（１６９ｍｇ，０．７９６ｍｍｏｌ）のジクロロメタン（４ｍＬ）溶液に、室温にてテトラブチルアンモニウムシアニド（２３５ｍｇ，０．８７６ｍｍｏｌ）を加え、同温にて終夜撹拌した。反応液にテトラブチルアンモニウムシアニド（８５ｍｇ）を加えさらに３時間撹拌した後、飽和重曹水を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９５：５→８０：２０）で精製し、粗５−（シクロプロピルメチル）ピリミジン−２−カルボニトリル（１３０ｍｇ）を無色油状物として得た。これを更に精製せずに次の工程に使用した。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１６０［Ｍ＋Ｈ］^＋
（５） アルゴン気流下、上記粗生成物（１２５ｍｇ）のテトラヒドロフラン（３ｍＬ）溶液に−７８℃にて１．０ｍｏｌ／Ｌ水素化ジイソブチルアルミニウムトルエン溶液（０．８２ｍＬ）を加えた。同温にて２時間撹拌後、反応液にメタノールを加え、室温までゆっくり昇温した。反応液に６．０ｍｏｌ／Ｌ塩酸水溶液を加え室温にて２時間撹拌した後、飽和重曹水を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝６５：３５→３５：６５）で精製し、粗５−（シクロプロピルメチル）ピリミジン−２−カルバルデヒド（９４ｍｇ）を無色油状物として得た。これを更に精製せずに次の工程に使用した。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１６３[Ｍ＋Ｈ]^＋
（６） 上記粗生成物（８８ｍｇ）のエタノール（１ｍＬ）およびテトラヒドロフラン（１ｍＬ）混合溶液に、０℃にて水素化ホウ素ナトリウム（２４ｍｇ，０．６４３ｍｍｏｌ）を加えた。同温にて３０分撹拌後、反応液に塩化アンモニウム水溶液を加え、酢酸エチルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝５０：５０→０：１００）で精製し、［５−（シクロプロピルメチル）ピリミジン−２−イル］メタノール（２４ｍｇ）を無色油状物として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１６５［Ｍ＋Ｈ］^＋ Reference Example 46:
Production of [5- (cyclopropylmethyl) pyrimidin-2-yl] methanol

(1) Under a stream of argon, a solution of 2- (methylthio) pyridine-5-carbaldehyde (2000 mg, 12.97 mmol) in tetrahydrofuran (20 mL) at −40 ° C. with a 0.5 mol / L cyclopropyl magnesium bromide tetrahydrofuran solution ( 28.6 mL) was added. The reaction solution was stirred at the same temperature for 10 minutes, then slowly warmed to 0 ° C. and stirred for 1 hour. Aqueous ammonium chloride was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 70: 30 → 30: 70), and cyclopropyl [2- (methylthio) pyrimidin-5-yl] methanol (822 mg, 32%) was colorless. Obtained as an oil.
APCI-MS m / z: 197 [M + H] ⁺
(2) Triethylsilane (1.99 mL, 12.46 mmol) was added to a chloroform (12 mL) solution of the above compound (815 mg, 4.15 mmol) at room temperature. Under ice-cooling, trifluoroacetic acid (1.54 mL, 20.15 mmol) was added dropwise to the reaction solution, and the mixture was slowly warmed to room temperature and stirred for 4 days. Saturated aqueous sodium hydrogen carbonate was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 95: 5 → 75: 25) to give 5- (cyclopropylmethyl) -2- (methylthio) pyrimidine (229 mg, 31%) as a colorless oil. Obtained as a thing.
APCI-MS m / z: 181 [M + H] ⁺
(3) A solution of metachloroperbenzoic acid (624 mg, 2.50 mmol) in dichloromethane (5 mL) was added dropwise at 0 ° C. to a solution of the above compound (225 mg, 1.25 mmol) in dichloromethane (5 mL). The reaction solution was slowly warmed to room temperature and stirred for 1 hour and 30 minutes, and then an aqueous sodium thiosulfate solution was added and further stirred for 30 minutes. Saturated aqueous sodium hydrogen carbonate was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 70: 30 → 35: 65), and 5- (cyclopropylmethyl) -2- (methylsulfonyl) pyrimidine (173 mg, 65%) was colorless. Obtained as an oil.
APCI-MS m / z: 213 [M + H] ⁺
(4) Tetrabutylammonium cyanide (235 mg, 0.876 mmol) was added to a dichloromethane (4 mL) solution of the above compound (169 mg, 0.796 mmol) at room temperature, and the mixture was stirred at the same temperature overnight. Tetrabutylammonium cyanide (85 mg) was added to the reaction mixture, and the mixture was further stirred for 3 hr. Saturated aqueous sodium hydrogen carbonate was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 95: 5 → 80: 20) to give crude 5- (cyclopropylmethyl) pyrimidine-2-carbonitrile (130 mg) as a colorless oil. It was. This was used in the next step without further purification.
APCI-MS m / z: 160 [M + H] ⁺
(5) A 1.0 mol / L diisobutylaluminum hydride toluene solution (0.82 mL) was added to a solution of the crude product (125 mg) in tetrahydrofuran (3 mL) at −78 ° C. under an argon stream. After stirring at the same temperature for 2 hours, methanol was added to the reaction solution, and the temperature was slowly raised to room temperature. A 6.0 mol / L aqueous hydrochloric acid solution was added to the reaction mixture, and the mixture was stirred at room temperature for 2 hr. Saturated aqueous sodium hydrogen carbonate was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 65: 35 → 35: 65) to give crude 5- (cyclopropylmethyl) pyrimidine-2-carbaldehyde (94 mg) as a colorless oil. It was. This was used in the next step without further purification.
APCI-MS m / z: 163 [M + H] ⁺
(6) Sodium borohydride (24 mg, 0.643 mmol) was added to a mixed solution of the above crude product (88 mg) in ethanol (1 mL) and tetrahydrofuran (1 mL) at 0 ° C. After stirring at the same temperature for 30 minutes, an aqueous ammonium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 50: 50 → 0: 100) to give [5- (cyclopropylmethyl) pyrimidin-2-yl] methanol (24 mg) as a colorless oil. Obtained.
APCI-MS m / z: 165 [M + H] ⁺

（１） ５−クロロ−１Ｈ−インドール−２−カルボン酸エチル（５００ｍｇ，２．１７ｍｍｏｌ）、炭酸カリウム（４５０ｍｇ，３．２５ｍｍｏｌ）、ヨードエタン（２６０μＬ，３．２５ｍｍｏｌ）およびＮ，Ｎ−ジメチルホルムアミド（１０．８ｍＬ）の混合物を室温で３日間攪拌した。反応溶に水を加え、混合物を酢酸エチルで２回抽出した。有機層を合わせ、水で３回洗浄し、有機層を珪藻土、続いてシリカゲルを用いてろ過後、ろ液を減圧濃縮し、５−クロロ−１−エチル−１Ｈ−インドール−２−カルボン酸エチル（５６６ｍｇ，１００％）を油状物として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２５２／２５４［Ｍ＋Ｈ］^＋．
（２） 上記化合物（５６１ｍｇ，２．２３ｍｍｏｌ）のジエチルエーテル（１１．１ｍＬ）溶液に、０℃にて水素化アルミニウムリチウム（１２７ｍｇ，３．３４ｍｍｏｌ）を数回に分けて加え、室温で１．５時間攪拌した。反応混合物に水（１２７μＬ）、１５％水酸化ナトリウム水溶液（１２７μＬ）、水（３８１μＬ）を順次加えた後、珪藻土を用いてろ過した。ろ液を減圧濃縮して得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９：１→３：２）で精製し、標記化合物（５−クロロ−１−エチル−１Ｈ−インドール−２−イル）メタノール（４２９ｍｇ，９２％）を粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２１０／２１２［Ｍ＋Ｈ］^＋． Reference Example 47:
Production of (5-chloro-1-ethyl-1H-indol-2-yl) methanol

(1) Ethyl 5-chloro-1H-indole-2-carboxylate (500 mg, 2.17 mmol), potassium carbonate (450 mg, 3.25 mmol), iodoethane (260 μL, 3.25 mmol) and N, N-dimethylformamide ( 10.8 mL) was stirred at room temperature for 3 days. Water was added to the reaction solution, and the mixture was extracted twice with ethyl acetate. The organic layers were combined and washed three times with water. The organic layer was filtered using diatomaceous earth followed by silica gel, and then the filtrate was concentrated under reduced pressure to obtain ethyl 5-chloro-1-ethyl-1H-indole-2-carboxylate. (566 mg, 100%) was obtained as an oil.
APCI-MS m / z: 252/254 [M + H] ⁺ .
(2) To a solution of the above compound (561 mg, 2.23 mmol) in diethyl ether (11.1 mL), lithium aluminum hydride (127 mg, 3.34 mmol) was added in several portions at 0 ° C., and 1 .. Stir for 5 hours. Water (127 μL), a 15% aqueous sodium hydroxide solution (127 μL) and water (381 μL) were sequentially added to the reaction mixture, followed by filtration using diatomaceous earth. The residue obtained by concentrating the filtrate under reduced pressure was purified by silica gel column chromatography (hexane: ethyl acetate = 9: 1 → 3: 2) to give the title compound (5-chloro-1-ethyl-1H-indole- 2-yl) methanol (429 mg, 92%) was obtained as a powder.
APCI-MS m / z: 210/212 [M + H] ⁺ .

６−クロロ−１Ｈ−インドール−２−カルボン酸エチルを参考例４７−（１）および（２）に記載の方法と同様に処理することにより、標記化合物（６−クロロ−１−エチル−１Ｈ−インドール−２−イル）メタノールを得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２１０／２１２［Ｍ＋Ｈ］^＋． Reference Example 48:
Production of (6-chloro-1-ethyl-1H-indol-2-yl) methanol

By treating ethyl 6-chloro-1H-indole-2-carboxylate in the same manner as in Reference Example 47- (1) and (2), the title compound (6-chloro-1-ethyl-1H— Indol-2-yl) methanol was obtained.
APCI-MS m / z: 210/212 [M + H] ⁺ .

４−クロロ−１Ｈ−インドール−２−カルボン酸およびヨードメタンを参考例４７−（１）および（２）に記載の方法と同様に処理することにより、標記化合物（４−クロロ−１−メチル−１Ｈ−インドール−２−イル）メタノールを得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１９６／１９８［Ｍ＋Ｈ］^＋． Reference Example 49:
Production of (4-chloro-1-methyl-1H-indol-2-yl) methanol

4-Chloro-1H-indole-2-carboxylic acid and iodomethane were treated in the same manner as in Reference Example 47- (1) and (2) to give the title compound (4-chloro-1-methyl-1H -Indol-2-yl) methanol was obtained.
APCI-MS m / z: 196/198 [M + H] ⁺ .

（１） １Ｈ−インドール−２−カルボン酸メチル（１．００ｇ，５．７１ｍｍｏｌ）、シクロプロピルボロン酸（９８１ｍｇ，１１．４ｍｍｏｌ）、酢酸銅（ＩＩ）（１．０４ｇ，５．７１ｍｍｏｌ）、２，２−ビピリジル（８９２ｍｇ、５．７１ｍｍｏｌ）、炭酸ナトリウム（１．２１ｇ，１１．４ｍｍｏｌ）および１，２−ジクロロエタン（１５．０ｍＬ）の混合物を７０℃で１９時間攪拌した。シクロプロピルボロン酸（９８１ｍｇ，１１．４ｍｍｏｌ）および炭酸ナトリウム（１．２１ｇ，１１．４ｍｍｏｌ）を加えて７０℃で８時間攪拌した後、さらにシクロプロピルボロン酸（９８１ｍｇ，１１．４ｍｍｏｌ）、炭酸ナトリウム（１．２１ｇ，１１．４ｍｍｏｌ）酢酸銅（ＩＩ）（１．０４ｇ，５．７１ｍｍｏｌ）および２，２−ビピリジル（８９２ｍｇ，５．７１ｍｍｏｌ）を加えて７０℃で１６時間攪拌した。放冷後、反応混合物に飽和塩化アンモニウム水溶液を加え、珪藻土を用いてろ過し、ろ液を酢酸エチルで抽出した。有機相を水および飽和食塩水で洗浄し、硫酸ナトリウムで乾燥後、ろ液を減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝１９：１→１７：３）で精製し、１−シクロプロピル−１Ｈ−インドール−２−カルボン酸エチル（８８２ｍｇ，７２％）を粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２１６［Ｍ＋Ｈ］^＋．
（２） 上記化合物（８６５ｍｇ，４．０２ｍｍｏｌ）のトルエン（２０．１ｍＬ）溶液に、−７８℃にて１．０１ｍｏｌ／Ｌ水素化ジイソブチルアルミニウムトルエン溶液（９．９４ｍＬ，１０．０ｍｍｏｌ）を加え、−７８℃で１．５時間攪拌した。反応混合物にメタノールを加え、１ｍｏｌ／Ｌ塩酸を加えて酸性にし、混合物を酢酸エチルで抽出した。有機相を水および飽和食塩水で洗浄し、硫酸ナトリウムで乾燥後、ろ液を減圧濃縮した。得られた残渣を、シリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９：１→７：３）で精製し、（１−シクロプロピル−１Ｈ−インドール−２−イル）メタノール（７０８ｍｇ，９４％）を粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１８８［Ｍ＋Ｈ］^＋． Reference Example 50:
Production of (1-cyclopropyl-1H-indol-2-yl) methanol

(1) Methyl 1H-indole-2-carboxylate (1.00 g, 5.71 mmol), cyclopropylboronic acid (981 mg, 11.4 mmol), copper (II) acetate (1.04 g, 5.71 mmol), 2 , 2-bipyridyl (892 mg, 5.71 mmol), sodium carbonate (1.21 g, 11.4 mmol) and 1,2-dichloroethane (15.0 mL) were stirred at 70 ° C. for 19 hours. Cyclopropylboronic acid (981 mg, 11.4 mmol) and sodium carbonate (1.21 g, 11.4 mmol) were added and stirred at 70 ° C. for 8 hours, and then cyclopropylboronic acid (981 mg, 11.4 mmol), sodium carbonate (1.21 g, 11.4 mmol) Copper (II) acetate (1.04 g, 5.71 mmol) and 2,2-bipyridyl (892 mg, 5.71 mmol) were added and stirred at 70 ° C. for 16 hours. After allowing to cool, a saturated aqueous ammonium chloride solution was added to the reaction mixture, the mixture was filtered using diatomaceous earth, and the filtrate was extracted with ethyl acetate. The organic phase was washed with water and saturated brine, dried over sodium sulfate, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 19: 1 → 17: 3), and ethyl 1-cyclopropyl-1H-indole-2-carboxylate (882 mg, 72%) was powdered. Got as.
APCI-MS m / z: 216 [M + H] ⁺ .
(2) To a toluene (20.1 mL) solution of the above compound (865 mg, 4.02 mmol), 1.01 mol / L diisobutylaluminum hydride toluene solution (9.94 mL, 10.0 mmol) was added at −78 ° C., The mixture was stirred at -78 ° C for 1.5 hours. Methanol was added to the reaction mixture, the mixture was acidified with 1 mol / L hydrochloric acid, and the mixture was extracted with ethyl acetate. The organic phase was washed with water and saturated brine, dried over sodium sulfate, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 9: 1 → 7: 3), and (1-cyclopropyl-1H-indol-2-yl) methanol (708 mg, 94%) was added. Obtained as a powder.
APCI-MS m / z: 188 [M + H] ⁺ .

５−クロロ−１Ｈ−インドール−２−カルボン酸エチルを参考例５０−（１）および（２）に記載の方法と同様に処理することにより、標記化合物（５−クロロ−１−シクロプロピル−１Ｈ−インドール−２−イル）メタノールを得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２２２／２２４［Ｍ＋Ｈ］^＋． Reference Example 51:
Production of (5-chloro-1-cyclopropyl-1H-indol-2-yl) methanol

By treating ethyl 5-chloro-1H-indole-2-carboxylate in the same manner as in Reference Example 50- (1) and (2), the title compound (5-chloro-1-cyclopropyl-1H -Indol-2-yl) methanol was obtained.
APCI-MS m / z: 222/224 [M + H] ⁺ .

１−メチルインドリン−６−カルボン酸（３２１ｍｇ，１．８０ｍｍｏｌ）のテトラヒドロフラン（６ｍＬ）溶液に、室温にてＮ，Ｎ’−カルボジイミダゾール（３０９ｍｇ，１．８９ｍｍｏｌ）を加えた。５０℃にて１５分間撹拌後、０℃に冷却し、水（１ｍＬ）およびヒドロホウ素化ナトリウム（２０４ｍｇ，５．４０ｍｍｏｌ）を加え、同温にて１時間撹拌した。反応液を室温まで冷却した後、水を加え、酢酸エチルで２回抽出した。有機層を合わせ、飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮し、得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝５：１→１：１）で精製することにより、（１−メチル−２，３−ジヒドロ−１Ｈ−インドール−６−イル）メタノール（２４５ｍｇ，８３％）を淡黄色の油状物として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１６４［Ｍ＋Ｈ］^＋． Reference Example 52:
Production of (1-methyl-2,3-dihydro-1H-indol-6-yl) methanol

To a solution of 1-methylindoline-6-carboxylic acid (321 mg, 1.80 mmol) in tetrahydrofuran (6 mL) was added N, N′-carbodiimidazole (309 mg, 1.89 mmol) at room temperature. After stirring at 50 ° C. for 15 minutes, the mixture was cooled to 0 ° C., water (1 mL) and sodium hydroborate (204 mg, 5.40 mmol) were added, and the mixture was stirred at the same temperature for 1 hour. The reaction mixture was cooled to room temperature, water was added, and the mixture was extracted twice with ethyl acetate. Combine the organic layers, wash with saturated brine, dry over anhydrous sodium sulfate, concentrate under reduced pressure, and purify the resulting residue by silica gel column chromatography (hexane: ethyl acetate = 5: 1 → 1: 1). Gave (1-methyl-2,3-dihydro-1H-indol-6-yl) methanol (245 mg, 83%) as a pale yellow oil.
APCI-MS m / z: 164 [M + H] ⁺ .

（１） ３−クロロ−１Ｈ−インダゾール−６−カルボン酸メチル（８９１ｍｇ，４．２ｍｍｏｌ）のテトラヒドロフラン（１０ｍＬ）溶液を−７８℃に冷却し、同温にて水素化ジイソブチルアルミニウム（テトラヒドロフラン溶液，１ｍｏｌ／Ｌ，１２．７ｍＬ，１２．６ｍｍｏｌ）を滴下し、同温にて２時間撹拌した。反応液に水を加え、酢酸エチルで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィーヘキサン→ヘキサン：酢酸エチル＝２：１）で精製し、（３−クロロ−１Ｈ−インダゾール−６−イル）メタノール（３４４ｍｇ，４５％）を黄色固体として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：１８３／１８５［Ｍ＋Ｈ］^＋．
（２） 上記化合物（２７０ｍｇ，１．５０ｍｍｏｌ）のジクロロメタン（１５ｍＬ）溶液に、室温にて二炭酸ジ−ｔ−ブチル（３２３ｍｇ，１．５０ｍｍｏｌ）を加え、同温にて１８時間撹拌した。上記反応液にＮ，Ｎ−ジメチル−４−アミノピリジン（５ｍｇ，触媒量）を加え、１時間撹拌した。反応液を減圧濃縮し、シリカゲルカラムクロマトグラフィー（ヘキサン→ヘキサン：酢酸エチル＝２：１）で精製し、３−クロロ−６−（ヒドロキシメチル）−１Ｈ−インダゾール−１−カルボン酸 ｔｅｒｔ−ブチル（３５６ｍｇ，８５％）を淡黄色の油状物として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２８３／２８５［Ｍ＋Ｈ］^＋． Reference Example 53:
Preparation of tert-butyl 3-chloro-6- (hydroxymethyl) -1H-indazole-1-carboxylate

(1) A solution of methyl 3-chloro-1H-indazole-6-carboxylate (891 mg, 4.2 mmol) in tetrahydrofuran (10 mL) was cooled to −78 ° C., and diisobutylaluminum hydride (tetrahydrofuran solution, 1 mol) at the same temperature. / L, 12.7 mL, 12.6 mmol) was added dropwise and stirred at the same temperature for 2 hours. Water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography hexane → hexane: ethyl acetate = 2: 1) to obtain (3-chloro-1H-indazol-6-yl) methanol (344 mg, 45%) as a yellow solid. .
APCI-MS m / z: 183/185 [M + H] ⁺ .
(2) Di-t-butyl dicarbonate (323 mg, 1.50 mmol) was added at room temperature to a solution of the above compound (270 mg, 1.50 mmol) in dichloromethane (15 mL), and the mixture was stirred at the same temperature for 18 hours. N, N-dimethyl-4-aminopyridine (5 mg, catalytic amount) was added to the reaction solution and stirred for 1 hour. The reaction solution was concentrated under reduced pressure, purified by silica gel column chromatography (hexane → hexane: ethyl acetate = 2: 1), and tert-butyl 3-chloro-6- (hydroxymethyl) -1H-indazole-1-carboxylate ( 356 mg, 85%) as a pale yellow oil.
APCI-MS m / z: 283/285 [M + H] ⁺ .

（１） ２，４，６−トリフルオロベンズアルデヒド（５．００ｇ，３１．２ｍｍｏｌ）、炭酸カリウム（５．６１ｇ、４０．６ｍｍｏｌ）のＮ，Ｎ−ジメチルホルムアミド（６３ｍＬ）懸濁液に０℃にてチオグリコール酸エチル（３．４０ｇ，２８．３ｍｍｏｌ）を加えた。室温にて終夜撹拌後、６０℃にて６時間加熱攪拌した。室温まで冷却後、反応液に水を加え、酢酸エチルで抽出した。有機層を水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９７：３→９３：７）で精製し、４，６−ジフルオロ−１−ベンゾチオフェン−２−カルボン酸エチル（１．９５ｇ，２９％）を薄黄色固体として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２４３［Ｍ＋Ｈ］^＋．
（２） アルゴン気流下、上記化合物（１０００ｍｇ，４．１３ｍｍｏｌ）のジエチルエーテル（２１ｍＬ）溶液に０℃で水素化アルミニウムリチウム（２３５ｍｇ，６．１９ｍｍｏｌ）を少量ずつ加え、室温にて４０分撹拌した。反応液に氷冷下、水（０．２４ｍＬ）および１５％水酸化ナトリウム水溶液（０．２４ｍＬ）を加え、さらに水（０．７２ｍＬ）を加えた後、室温で攪拌した。不溶物をろ別し、ジエチルエーテルで洗浄後、ろ液と洗液をあわせて減圧濃縮した。得られた残渣をヘキサン−ジイソプロピルエーテルで洗浄し、（４，６−ジフルオロ−１−ベンゾチエン−２−イル）メタノール（７３１ｍｇ，８８％）を無色粉末として得た。
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ ４．７４（２Ｈ，ｄ，Ｊ＝５．７Ｈｚ），５．７５（１Ｈ，ｔ，Ｊ＝５．９Ｈｚ），７．２６（１Ｈ，ｄｔ，Ｊ＝１０．１，２．１Ｈｚ），７．３０（１Ｈ，ｓ），７．７７（１Ｈ，ｄｄ，Ｊ＝８．８，２．１Ｈｚ）． Reference Example 54:
Production of (4,6-difluoro-1-benzothien-2-yl) methanol

(1) A suspension of 2,4,6-trifluorobenzaldehyde (5.00 g, 31.2 mmol) and potassium carbonate (5.61 g, 40.6 mmol) in N, N-dimethylformamide (63 mL) at 0 ° C. Then ethyl thioglycolate (3.40 g, 28.3 mmol) was added. After stirring overnight at room temperature, the mixture was stirred with heating at 60 ° C. for 6 hours. After cooling to room temperature, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 97: 3 → 93: 7), and ethyl 4,6-difluoro-1-benzothiophene-2-carboxylate (1.95 g, 29%). ) Was obtained as a pale yellow solid.
APCI-MS m / z: 243 [M + H] ⁺ .
(2) Under a stream of argon, lithium aluminum hydride (235 mg, 6.19 mmol) was added in portions to a solution of the above compound (1000 mg, 4.13 mmol) in diethyl ether (21 mL) at 0 ° C., and the mixture was stirred at room temperature for 40 minutes. . Under ice-cooling, water (0.24 mL) and 15% aqueous sodium hydroxide solution (0.24 mL) were added to the reaction mixture, water (0.72 mL) was further added, and the mixture was stirred at room temperature. The insoluble material was filtered off and washed with diethyl ether, and the filtrate and the washing solution were combined and concentrated under reduced pressure. The obtained residue was washed with hexane-diisopropyl ether to obtain (4,6-difluoro-1-benzothien-2-yl) methanol (731 mg, 88%) as a colorless powder.
¹ H-NMR (DMSO-d ₆ ) δ 4.74 (2H, d, J = 5.7 Hz), 5.75 (1H, t, J = 5.9 Hz), 7.26 (1H, dt, J = 10.1, 2.1 Hz), 7.30 (1H, s), 7.77 (1H, dd, J = 8.8, 2.1 Hz).

（１） ５，７−ジフルオロ−１−ベンゾチオフェン−２−カルボン酸（ＷＯ２００３／０５５８７８記載の方法により合成、１．９５ｇ，９．１０ｍｍｏｌ）、Ｎ，Ｏ−ジメチルヒドロキシアミン塩酸塩（９７７ｍｇ，１０．０ｍｍｏｌ）、１−エチル−３−（３’−ジメチルアミノプロピル）カルボジイミド塩酸塩（１．９２ｇ，１０．０ｍｍｏｌ）、およびＮ−ヒドロキシベンゾトリアゾール（１．３５ｇ，１０．０ｍｍｏｌ）のジクロロメタン（２０ｍＬ）溶液に室温にてトリエチルアミン（１．９０ｍＬ，１３．７ｍｍｏｌ）を加えた。室温にて終夜撹拌後、反応液に１０％塩酸水溶液を加え、クロロホルムで抽出した。有機層を飽和炭酸水素ナトリウム水溶液で洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮することにより、粗５，７−ジフルオロ−Ｎ−メトキシ−Ｎ−メチル−１−ベンゾチオフェン−２−カルボキサミド（２．４８ｇ）を無色固体として得た。これを更に精製せずに次の工程に使用した。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２５８［Ｍ＋Ｈ］^＋．
（２） アルゴン気流下、上記粗生成物（２．４５ｇ）のテトラヒドロフラン（４０ｍＬ）溶液に、−７０℃にて１ｍｏｌ／Ｌ水素化ジイソブチルアルミニウムトルエン溶液（１４．３ｍＬ，１４．３ｍｍｏｌ）を滴下した。反応液をゆっくり−４０℃まで昇温した後、反応液に１０％塩酸水溶液（５０ｍＬ）を加え、ジエチルエーテルで抽出した。有機層を飽和食塩水で洗浄し、無水硫酸マグネシウムで乾燥後、減圧濃縮することにより、５，７−ジフルオロ−１−ベンゾチオフェン−２−カルバルデヒド（１．６７ｇ，９２％、二段階収率）を無色固体として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２１３［Ｍ＋Ｈ＋ＭｅＯＨ−Ｈ_２Ｏ］^＋．
（３） 上記化合物（１０００ｍｇ，５．０５ｍｍｏｌ）のメタノール（２５ｍＬ）溶液に、０℃にて水素化ホウ素ナトリウム（３８３ｍｇ，１０．１ｍｍｏｌ）を加えた。室温にて４０分間撹拌後、反応液に水を加え、酢酸エチルで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をシリカゲルカラムクロマトグラフィー（ヘキサン：酢酸エチル＝９０：１０→７０：３０）で精製し、（５，７−ジフルオロ−１−ベンゾチエン−２−イル）メタノール（９３３ｍｇ，９２％）を無色固体として得た。
^１Ｈ−ＮＭＲ（ＤＭＳＯ−ｄ_６） δ ４．７７（２Ｈ，ｄｄ，Ｊ＝５．７，０．９Ｈｚ），５．８４（１Ｈ，ｔ，Ｊ＝５．７Ｈｚ），７．２８（１Ｈ，ｄｔ，Ｊ＝９．９，２．３Ｈｚ），７．３５（１Ｈ，ｄ，Ｊ＝３．６Ｈｚ），７．５４（１Ｈ，ｄｄ，Ｊ＝９．４，２．１Ｈｚ）． Reference Example 55:
Production of (5,7-difluoro-1-benzothien-2-yl) methanol

(1) 5,7-difluoro-1-benzothiophene-2-carboxylic acid (synthesized by the method described in WO2003 / 055878, 1.95 g, 9.10 mmol), N, O-dimethylhydroxyamine hydrochloride (977 mg, 10 0.0 mmol), 1-ethyl-3- (3′-dimethylaminopropyl) carbodiimide hydrochloride (1.92 g, 10.0 mmol), and N-hydroxybenzotriazole (1.35 g, 10.0 mmol) in dichloromethane (20 mL). ) To the solution was added triethylamine (1.90 mL, 13.7 mmol) at room temperature. After stirring at room temperature overnight, a 10% aqueous hydrochloric acid solution was added to the reaction mixture, and the mixture was extracted with chloroform. The organic layer was washed with a saturated aqueous sodium hydrogen carbonate solution, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give crude 5,7-difluoro-N-methoxy-N-methyl-1-benzothiophene-2-carboxamide (2 .48 g) was obtained as a colorless solid. This was used in the next step without further purification.
APCI-MS m / z: 258 [M + H] ⁺ .
(2) A 1 mol / L diisobutylaluminum hydride toluene solution (14.3 mL, 14.3 mmol) was added dropwise to a solution of the crude product (2.45 g) in tetrahydrofuran (40 mL) at −70 ° C. under an argon stream. . The temperature of the reaction solution was slowly raised to −40 ° C., 10% aqueous hydrochloric acid (50 mL) was added to the reaction solution, and the mixture was extracted with diethyl ether. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 5,7-difluoro-1-benzothiophene-2-carbaldehyde (1.67 g, 92%, two-step yield) ) Was obtained as a colorless solid.
APCI-MS m / z: 213 [M + H + MeOH-H 2 O] +.
(3) To a solution of the above compound (1000 mg, 5.05 mmol) in methanol (25 mL) was added sodium borohydride (383 mg, 10.1 mmol) at 0 ° C. After stirring at room temperature for 40 minutes, water was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane: ethyl acetate = 90: 10 → 70: 30), and (5,7-difluoro-1-benzothien-2-yl) methanol (933 mg, 92%) was added. Obtained as a colorless solid.
¹ H-NMR (DMSO-d ₆ ) δ 4.77 (2H, dd, J = 5.7, 0.9 Hz), 5.84 (1H, t, J = 5.7 Hz), 7.28 (1H , Dt, J = 9.9, 2.3 Hz), 7.35 (1H, d, J = 3.6 Hz), 7.54 (1H, dd, J = 9.4, 2.1 Hz).

７−クロロ−１−ベンゾチオフェン−２−カルボン酸（Ｊｏｕｒｎａｌ ｏｆ Ｃｈｅｍｉｃａｌ Ｓｏｃｉｅｔｙ Ｐｅｒｋｉｎ Ｔｒａｎｓ．１，１９８４，３８５記載の方法により合成、１．００ｇ，４．７０ｍｍｏｌ）のテトラヒドロフラン（１７ｍＬ）溶液に、０℃にて０．９５ｍｏｌ／Ｌボラン−テトラヒドロフラン錯体テトラヒドロフラン溶液（９．９０ｍＬ，９．４１ｍｍｏｌ）を加えた。室温にて終夜撹拌後、反応液に水を加え、減圧濃縮で溶媒を留去した。得られた残渣に飽和炭酸水素ナトリウム水溶液を加え、酢酸エチルで２回抽出した。有機層を合わせ、水および飽和食塩水で洗浄し、無水硫酸ナトリウムで乾燥後、減圧濃縮した。得られた残渣をヘキサン−ジイソプロピルエーテルで洗浄し、（７−クロロ−１−ベンゾチエン−２−イル）メタノール（８４２ｍｇ，９０％）を無色粉末として得た。
ＡＰＣＩ−ＭＳ ｍ／ｚ：２１６／２１８［Ｍ＋ＮＨ_４］^＋． Reference Example 56:
Production of (7-chloro-1-benzothien-2-yl) methanol

To a solution of 7-chloro-1-benzothiophene-2-carboxylic acid (synthesized by the method described in Journal of Chemical Society Perkin Trans. 1, 1984, 385, 1.00 g, 4.70 mmol) in tetrahydrofuran (17 mL) at 0 ° C. 0.95 mol / L borane-tetrahydrofuran complex tetrahydrofuran solution (9.90 mL, 9.41 mmol) was added. After stirring overnight at room temperature, water was added to the reaction mixture, and the solvent was evaporated by concentration under reduced pressure. Saturated aqueous sodium hydrogen carbonate solution was added to the resulting residue, and the mixture was extracted twice with ethyl acetate. The organic layers were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was washed with hexane-diisopropyl ether to obtain (7-chloro-1-benzothien-2-yl) methanol (842 mg, 90%) as a colorless powder.
APCI-MS m / z: 216/218 [M + NH ₄ ] ⁺ .

ヨーロピアン ジャーナル オブ オーガニック ケミストリー１９９９年、１７７５ページ（Ｅｕｒ．Ｊ．Ｏｒｇ．Ｃｈｅｍ．１９９９，１７７５）記載と同様の方法で得た（２Ｓ）−１−（１，３，２−ジオキサボロラン−２−イルオキシ）−３−メチル−１，１−ジフェニルブタン−２−アミン（３３ｍｇ，０．１ｍｍｏｌ）をテトラヒドロフラン５ｍＬに懸濁し、ボラン・ジメチルスルフィド錯体（１０ｍｏｌ／Ｌ，０．１ｍＬ，１ｍｍｏｌ）を室温で加えた。その温度で２０分攪拌後、米国特許第６１５９９９６号記載と同様の方法で得た５−トリフルオロメトキシインダン−１−オン（０．２１７ｇ，１ｍｍｏｌ）を１時間かけて少しずつ加え、室温で一晩攪拌した。５℃に冷却後メタノール２ｍＬを加え、その温度で１時間攪拌後反応液を濃縮後、クロロホルムを加えた。このクロロホルム溶液を飽和塩化アンモニウム水溶液に注ぎクロロホルムで３回抽出し、有機層は飽和食塩水で洗浄した。硫酸マグネシウムで乾燥後、濃縮し得られた残渣にジエチルエーテルとヘキサンを加え、生じた白色固体をろ過で除き、ろ液部を濃縮し、粗５−（トリフルオロメトキシ）インダン−１−オール（６２．５ｍｇ）を得た。これを更に精製せずに次の工程に使用した。 Reference Example 57:
Production of 5- (trifluoromethoxy) indan-1-ol

(2S) -1- (1,3,2-dioxaborolan-2-yloxy) obtained in the same manner as described in European Journal of Organic Chemistry 1999, page 1775 (Eur. J. Org. Chem. 1999, 1775). -3-Methyl-1,1-diphenylbutan-2-amine (33 mg, 0.1 mmol) was suspended in 5 mL of tetrahydrofuran, and borane-dimethyl sulfide complex (10 mol / L, 0.1 mL, 1 mmol) was added at room temperature. . After stirring at that temperature for 20 minutes, 5-trifluoromethoxyindan-1-one (0.217 g, 1 mmol) obtained in the same manner as described in US Pat. No. 6,159,996 was added little by little over 1 hour, and the mixture was stirred at room temperature. Stir overnight. After cooling to 5 ° C., 2 mL of methanol was added. After stirring at that temperature for 1 hour, the reaction mixture was concentrated and chloroform was added. The chloroform solution was poured into a saturated aqueous ammonium chloride solution and extracted three times with chloroform, and the organic layer was washed with saturated brine. After drying over magnesium sulfate, diethyl ether and hexane were added to the residue obtained by concentration, the resulting white solid was removed by filtration, the filtrate was concentrated, and crude 5- (trifluoromethoxy) indan-1-ol ( 62.5 mg) was obtained. This was used in the next step without further purification.

Pharmacological experiment TRPM8 inhibition test
Test compound:
The compounds described in the above examples were used for the TRPM8 inhibition test.
Method:
The functional activity of the compounds was evaluated by measuring changes in intracellular calcium concentration using a calcium sensitive fluorescent dye. Changes in the fluorescence signal could be easily detected by activating menthol with an increase in intracellular calcium concentration measured using cell imaging technology by Hamamatsu Photonics Functional Drug Screening System (FDSS).
HEK293 cells stably expressing human TRPM8 were cultured in a flask. On the day of the assay, the medium was removed, and the cells were washed with phosphate-buffered saline (PBS) and then collected with PBS containing 2 mM ethylenediaminetetraacetic acid disodium salt (EDTA · 2Na). The cells were then incubated for 60 minutes with a measuring solution containing 3 μM Fura-2AM and 0.01% Pluronic F-127. Subsequently, 20,000 to 50,000 suspended cells per well were incubated with various concentrations of test compound in each well for 20 minutes at 37 ° C. Changes in intracellular calcium concentration induced by 100 μM menthol were measured for 2 minutes using FDSS. The IC ₅₀ value was calculated from a concentration response test at 4 points. Curves were generated using an average of 4 wells for each data point.
result:
The IC ₅₀ values for each test compound are shown in Table 19 below.

2. In vivo TRPM8 antagonism test in rats
Test compound:
The compounds of the examples were used for the TRPM8 antagonism test in rats.
Method:
The antagonistic activity of the compounds was evaluated in a rat wet-dog sharks (WDS) model. Rats show trembling behavior in response to menthol, a TRPM8 agonist. Pretreatment of rats with a TRPM8 blocker prior to menthol administration suppresses the tremor behavior observed.
To evaluate the inhibitory activity of TRPM8 blocker on menthol-induced tremor behavior in male Sprague Dawley (SD) rats, menthol load (50 mg / kg, intraperitoneal administration, 10% macrogol 15 hydroxystearate / saline solution) ) Was administered a test compound (3 mg / kg, oral administration, 0.5% methylcellulose solution; N = 3-4 / group) 1 hour before. Spontaneous WDS was counted for 5 minutes after menthol administration. Inhibition of spontaneous WDS behavior compared to vehicle pretreatment is expressed as inhibition rate and calculated as follows:
Suppression rate (%) = [1− (number of treatment WDS times / number of vehicle WDS)] × 100
result:
Table 20 below shows the inhibition rate of each test compound at 3 mg / kg.

  The pharmaceutical composition containing the compound represented by the formula (I) of the present invention contains various diseases involving TRPM8 (for example, neuropathic pain (preferably neuropathic pain caused by cold allodynia or diabetic neuropathy)). It is useful for the prevention and treatment of chronic pain.

Claims (15)

The following general formula:

[Where:

Is a bicyclic aromatic heterocycle in which pyridine and benzene are condensed, and Y and Z are either CR ^2d and the other is a chemical bond,
Ring B represents (a) a monocyclic or bicyclic aromatic hydrocarbon; (b) a monocyclic or bicyclic alicyclic hydrocarbon; (c) a monocyclic or bicyclic aromatic hydrocarbon; A heterocycle; or (d) a monocyclic or bicyclic non-aromatic heterocycle,
Ring C is (a) benzene; or (b) a monocyclic aromatic heterocycle,
R ¹ is (a) hydrogen; (b) optionally substituted alkyl; (c) optionally substituted cycloalkyl; (d) optionally substituted alkoxy; (e) substituted. Or (f) halogen; or (g) nitrile,
R ^2a , R ^2b , R ^2c and R ^2d are each independently (a) hydrogen; (b) optionally substituted alkyl; (c) optionally substituted cycloalkyl; (d) substituted (E) an optionally substituted phenyl; (f) an optionally substituted monocyclic aromatic heterocyclic group; (g) an optionally substituted monocyclic. A non-aromatic heterocyclic group; (h) a halogen; or (i) a nitrile,
R ^3a , R ^3b , R ^3c and R ^3d are each independently (a) hydrogen; (b) optionally substituted alkyl; (c) optionally substituted cycloalkyl; (d) substituted (E) an optionally substituted cycloalkoxy; (f) an optionally substituted phenyl; (g) an optionally substituted monocyclic aromatic heterocyclic group; h) an optionally substituted monocyclic non-aromatic heterocyclic group; (i) an optionally substituted phenoxy; (j) a halogen; or (k) a hydroxy, or
Two substituents selected from R ^3a , R ^3b , R ^3c and R ^3d together form an oxo;
R ⁵ and R ⁶ are each independently (a) hydrogen; (b) alkyl; (c) halogenoalkyl; (d) cycloalkyl; or (e) halogenocycloalkyl, or R ⁵ and R 6 ⁶ bind to each other at their ends to form a monocyclic alicyclic hydrocarbon with adjacent carbon atoms;
n is 0, 1 or 2;
X is carboxy, alkoxycarbonyl, hydroxyalkyl, optionally substituted aminocarbonyl, or optionally substituted alkanoyl. ]
Or a pharmacologically acceptable salt thereof as an active ingredient. R ¹ is, (a) hydrogen; _(b) C 3 -C _{7 cycloalkyl,} C 1 -C ₆ alkoxy, halogen, optionally substituted with 1-7 groups selected from oxo and hydroxy _{C 1} -C ₆ alkyl; _{(c) C} 1 -C _{6 alkyl,} C 1 -C ₆ alkoxy and 1-7 pieces of good _C 3 -C ₇ cycloalkyl optionally substituted by a group selected from halogen; (d) C ₃ -C _{7 cycloalkyl,} C 1 -C ₆ alkoxy, halogen and optionally substituted with 1-7 groups selected from hydroxy _C 1 -C ₆ alkoxy; _(e) C 1 -C ₆ alkyl C ₁ -C ₆ halogenoalkyl, C ₃ -C ₇ cycloalkyl, C ₃ -C ₇ halogenocycloalkyl, C ₁ -C ₆ alkoxy, C ₁ -C ₆ halogenoalkoxy and halogen Phenyl optionally substituted with 1-3 groups selected from: (f) halogen; or (g) nitrile,
R ^2a , R ^2b , R ^2c and R ^2d are each independently selected from (a) hydrogen; (b) C ₁ -C ₆ alkoxy, C ₃ -C ₇ cycloalkyl, halogen, oxo and hydroxy -7 amino optionally _C 1 -C ₆ alkyl optionally substituted with group; _(c) C 1 -C _{6 alkyl,} substituted with 1-7 groups selected from C 1 -C ₆ alkoxy and halogen C ₃ -C ₇ cycloalkyl which may be substituted; (d) C ₁ -C which may be substituted with ₁ to 7 groups selected from C ₁ -C ₆ alkoxy, C ₃ -C ₇ cycloalkyl and halogen ₆ alkoxy; _(e) C 1 -C _{6 alkyl,} C 1 -C _{6 halogenoalkyl,} C 3 -C _{7 cycloalkyl,} C 3 -C ₇ halogenocyclopropyl _alkyl, C 1 -C _{6 alkoxy,} C 1 -C ₆ 1-3 phenyl which may be substituted with a group selected from the Rogenoarukokishi and halogen; _(f) C 1 -C _{6 alkyl,} C 1 -C _{6 halogenoalkyl,} C 3 -C ₇ cycloalkyl, C ₃ -C ₇ halogenocyclopropyl _alkyl, C 1 -C _{6 alkoxy,} C 1 -C ₆ halogenoalkoxy and monocyclic aromatic of 1-3 5-6 membered optionally substituted with a group selected from a halogen group a heterocyclic group; _(g) C 1 -C _{6 alkyl,} C 1 -C _{6 halogenoalkyl,} C 3 -C _{7 cycloalkyl,} C 3 -C ₇ halogenocyclopropyl _alkyl, C 1 -C ₆ alkoxy, _{C 1} - C ₆ halogenoalkoxy and non-aromatic heterocyclic group monocyclic 1-3 4-7 membered optionally substituted by a group selected from halogen, (h) halogen; or (i) nitrile Yes,
R ^3a , R ^3b , R ^3c and R ^3d are each independently (a) hydrogen; (b) C ₃ -C ₇ cycloalkyl, C ₃ -C ₇ halogenocycloalkyl (the cycloalkyl and halogenocycloalkyl). Each independently may be substituted with 1-3 groups selected from C ₁ -C ₆ alkyl and C ₁ -C ₆ halogenoalkyl), C ₁ -C ₆ alkoxy, C ₁ -C ₆ Halogenoalkoxy, phenyl, 5-6 membered monocyclic aromatic heterocyclic group, 4-7 membered monocyclic nonaromatic heterocyclic group (the phenyl, aromatic heterocyclic group and nonaromatic heterocyclic ring) groups are each independently _C 1 -C _{6 alkyl,} C 1 -C _{6 halogenoalkyl,} C 3 -C _{7 cycloalkyl,} C 3 -C ₇ halogenocyclopropyl _alkyl, C 1 -C ₆ alkoxy, _{C 1} - ₆ halogenoalkoxy with alkoxy and 1-3 groups selected from halogen may be substituted), halogen, oxo and 1-7 pieces of good C ₁ -C ₆ alkyl optionally substituted by a group selected from hydroxy (C) substituted with 1-7 groups selected from C ₁ -C ₆ alkyl, C ₁ -C ₆ halogenoalkyl, C ₁ -C ₆ alkoxy, C ₁ -C ₆ halogenoalkoxy, halogen and hydroxy; C ₃ -C ₇ cycloalkyl; (d) C ₃ -C ₇ cycloalkyl, C ₃ -C ₇ halogenocycloalkyl (the cycloalkyl and halogenocycloalkyl are each independently C ₁ -C ₆ alkyl) And optionally substituted with 1-3 groups selected from C ₁ -C ₆ halogenoalkyl), C ₁ -C ₆ alkoxy, C ₁ -C ₆ halogenoalkoxy, phenyl, 5-6 membered monocyclic aromatic heterocyclic group, 4-7 membered monocyclic non-aromatic heterocyclic group (the phenyl, aromatic heterocyclic group and non-aromatic group) Group heterocyclic groups are each independently C ₁ -C ₆ alkyl, C ₁ -C ₆ halogenoalkyl, C ₃ -C ₇ cycloalkyl, C ₃ -C ₇ halogenocycloalkyl, C ₁ -C ₆ alkoxy, C _{1 1} -C ₆ halogenoalkoxy and may be substituted with 1-3 groups selected from halogen), 1-7 pieces are substituted with a group C ₁ optionally -C selected from halogen and hydroxy ₆ Alkoxy; (e) 1-7 groups selected from C ₁ -C ₆ alkyl, C ₁ -C ₆ halogenoalkyl, C ₁ -C ₆ alkoxy, C ₁ -C ₆ halogenoalkoxy, halogen and hydroxy In optionally substituted _C 3 -C ₇ cycloalkoxy; _(f) C 1 -C _{6 alkyl,} C 1 -C _{6 halogenoalkyl,} C 3 -C _{7 cycloalkyl,} C 3 -C ₇ halogenoalkyl cycloalkyl, Phenyl optionally substituted with 1-3 groups selected from C ₁ -C ₆ alkoxy, C ₁ -C ₆ halogenoalkoxy and halogen; (g) C ₁ -C ₆ alkyl, C ₁ -C ₆ halogeno _alkyl, C 3 -C _{7 cycloalkyl,} C 3 -C ₇ halogenocyclopropyl _alkyl, C 1 -C _{6 alkoxy,} optionally substituted with 1-3 groups selected from C 1 -C ₆ halogenoalkoxy and halogen monocyclic aromatic heterocyclic group having good 5-6 membered; _(h) C 1 -C _{6 alkyl,} C 1 -C _{6 halogenoalkyl,} C 3 -C _{7 cycloalkyl,} C 3 -C ₇ Rogge Bruno cycloalkyl alkyl, C ₁ -C ₆ alkoxy, C ₁ -C ₆ halogenoalkoxy and non-aromatic heterocyclic monocyclic 1-3 4-7 membered optionally substituted by a group selected from halogen ring group; _(i) C 1 -C _{6 alkyl,} C 1 -C _{6 halogenoalkyl,} C 3 -C _{7 cycloalkyl,} C 3 -C ₇ halogenocyclopropyl _alkyl, C 1 -C _{6 alkoxy,} C 1 -C ₆ Phenoxy optionally substituted with 1-3 groups selected from halogenoalkoxy and halogen; (j) halogen; or (k) hydroxy, or
Two substituents selected from R ^3a , R ^3b , R ^3c and R ^3d together form an oxo;
R ⁵ and R ⁶ are each independently (a) hydrogen; (b) C ₁ -C ₆ alkyl; (c) C ₁ -C ₆ halogenoalkyl; (d) C ₃ -C ₇ cycloalkyl; or (E) C ₃ -C ₇ halogenocycloalkyl or R ⁵ and R ⁶ are bonded to each other at their ends to form a 3-7 membered monocyclic alicyclic hydrocarbon with adjacent carbon atoms And
X is, (a) carboxy; from _(d) C 1 -C _{6 alkyl,} C 1 -C ₆ alkoxy and nitriles; _(b) C 1 -C ₆ alkoxycarbonyl; (c) hydroxy _-C 1 -C ₆ alkyl one nitrogen atoms may aminocarbonyl optionally substituted by a group selected; or (e) 1-3 pieces of a medicament according to claim 1, wherein the halogen is a good C ₂ -C ₇ alkanoyl optionally substituted with Composition. The pharmaceutical composition according to claim 1 or 2 , wherein ring C is benzene, X is carboxy, and the carboxy is 4-position of the aminosulfonyl group in ring C. Ring B is (a) a monocyclic or bicyclic aromatic hydrocarbon; or (b) a monocyclic or bicyclic aromatic heterocycle,
The pharmaceutical composition according to claim 3 , wherein n is 0 or 1. Ring B is (a) a monocyclic aromatic hydrocarbon; or (b) a monocyclic aromatic heterocycle,
The pharmaceutical composition according to claim 3, wherein n is 1. Partial structure

Is the following formula (A)

The pharmaceutical composition according to claim 4 or 5 . Partial structure

Is the following formula (B)

The pharmaceutical composition according to claim 4 or 5 . R ¹ is (a) C ₁ -C ₆ alkyl optionally substituted with 1-7 halogens; (b) C ₃ -C ₇ cycloalkyl; (c) C ₁ -C ₆ alkoxy; or (d ) Halogen,
R ^2a , R ^2b and R ^2c are hydrogen,
R ^2d is (a) hydrogen; (b) C ₁ -C ₆ alkyl optionally substituted with 1-7 halogens; (c) C ₃ -C ₇ cycloalkyl; or (d) C ₁ -C ₆ alkoxy,
R ^3a and R ^3b are each independently (a) hydrogen; (b) C ₃ -C ₇ cycloalkyl, wherein the cycloalkyl is selected from C ₁ -C ₆ alkyl and C ₁ -C ₆ halogenoalkyl 1-3 may be substituted with a _group), C 1 -C _{6 alkoxy,} C 1 -C ₆ halogenoalkoxy, and optionally _{C 1} optionally substituted with 1-7 groups selected from halogen -C ₆ alkyl; (c) C ₁ -C ₆ alkyl, C ₁ -C ₆ halogenoalkyl, and C ₃ -C ₇ cycloalkyl optionally substituted with 1-7 groups selected from halogen; _d) C 3 -C _{7 cycloalkyl,} C 1 -C _{6 alkoxy,} C 1 -C ₆ halogenoalkoxy, and 1-7 amino substituted with a group _C 1 -C ₆ optionally alcohol selected from halogen A or (e) halogen; Shi
R ^3c and R ^3d are hydrogen,
R ⁵ and R ⁶ are hydrogen,
The pharmaceutical composition according to claim 4, 5, 6 or 7 , wherein n is 1. Ring B is benzene or pyridine,
R ¹ Is methyl, trifluoromethyl, isopropyl, cyclopropyl, or methoxy;
R ^2a , R ^2b And R ^2c Is hydrogen,
R ^2d (A) hydrogen; (b) C optionally substituted with 1-7 halogens ₁ -C ₆ Alkyl; (c) C ₃ -C ₇ Cycloalkyl; or (d) C ₁ -C ₆ Is alkoxy,
R ^3a And R ^3b Each independently (a) hydrogen; (b) C ₃ -C ₇ Cycloalkyl (the cycloalkyl is C ₁ -C ₆ Alkyl and C ₁ -C ₆ Optionally substituted with 1-3 groups selected from halogenoalkyl), C ₁ -C ₆ Alkoxy, C ₁ -C ₆ C optionally substituted with 1-7 groups selected from halogenoalkoxy and halogen ₁ -C ₆ Alkyl; (c) C ₃ -C ₇ Cycloalkyl; (d) C optionally substituted with 1-7 halogens ₁ -C ₆ Alkoxy; or (e) halogen,
R ^3c And R ^3d Is hydrogen,
R ⁵ And R ⁶ Is hydrogen,
The pharmaceutical composition according to claim 6, wherein n is 1. 4-({(4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-{[[3-Fluoro-4- (trifluoromethoxy) benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-({(1-cyclopropyl-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-{[[4- (1-Ethoxy-2,2,2-trifluoro-1-methylethyl) benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-({(3-methylquinolin-2-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-{[[4-Fluoro-3- (trifluoromethyl) benzyl] (3-methylquinolin-2-yl) amino] sulfonyl} benzoic acid;
4-{[(4-t-butylbenzyl) (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[[[4- (Cyclopropylmethyl) benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[[4-Fluoro-3- (trifluoromethyl) benzyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[(4-methylisoquinolin-3-yl) (2-naphthylmethyl) amino] sulfonyl} benzoic acid;
4-({(1-methoxy-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-({(4-chloroisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-{[(4-Methylisoquinolin-3-yl) (5,6,7,8-tetrahydronaphthalen-2-ylmethyl) amino] sulfonyl} benzoic acid;
4-{[(2,3-dihydro-1H-inden-5-ylmethyl) (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[[(1,1-dimethyl-2,3-dihydro-1H-inden-5-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[[(2,2-dimethyl-2,3-dihydro-1H-inden-5-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[[(3,3-dimethyl-2,3-dihydro-1-benzofuran-6-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[[[(1-benzothiophen-2-yl) methyl] (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-({(1,4-dimethylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid; and 4-({(4-methylisoquinolin-3-yl) [4 -(2,2,2-trifluoro-1-methoxy-1-methylethyl) benzyl] amino} sulfonyl) benzoic acid;
A pharmaceutical composition comprising as an active ingredient a compound selected from the group consisting of : or a pharmacologically acceptable salt thereof. 4-({(1-cyclopropyl-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-({(1-methoxy-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-({(1-Isopropyl-4-methylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-{[{3-chloro-4- [cyclopropyl (difluoro) methyl] benzyl} (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-({(4-cyclopropylisoquinolin-3-yl) [4- (trifluoromethoxy) benzyl] amino} sulfonyl) benzoic acid;
4-{[{3-chloro-4- [cyclopropyl (difluoro) methyl] benzyl} (1-cyclopropyl-4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[{4- [cyclopropyl (difluoro) methyl] -3-fluorobenzyl} (4-methylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-({[4- (trifluoromethoxy) benzyl] [4- (trifluoromethyl) isoquinolin-3-yl] amino} sulfonyl) benzoic acid;
4-[((4-cyclopropylisoquinolin-3-yl) {[5- (trifluoromethyl) pyridin-2-yl] methyl} amino) sulfonyl] benzoic acid;
4-{[{3-chloro-4- [cyclopropyl (difluoro) methyl] benzyl} (4-cyclopropylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-{[{4- [cyclopropyl (difluoro) methyl] -3-fluorobenzyl} (4-cyclopropylisoquinolin-3-yl) amino] sulfonyl} benzoic acid;
4-({(4-cyclopropylisoquinolin-3-yl) [5- (trifluoromethoxy) -2,3-dihydro-1H-inden-1-yl] amino} sulfonyl) benzoic acid;
4-({{3-chloro-4- [cyclopropyl (difluoro) methyl] benzyl} [4- (trifluoromethyl) isoquinolin-3-yl] amino} sulfonyl) benzoic acid; and 4-({{4- [Cyclopropyl (difluoro) methyl] -3-fluorobenzyl} [4- (trifluoromethyl) isoquinolin-3-yl] amino} sulfonyl) benzoic acid;
A pharmaceutical composition comprising as an active ingredient a compound selected from the group consisting of : or a pharmacologically acceptable salt thereof. The pharmaceutical composition according to any one of claims 1 to 11, which is a prophylactic or therapeutic agent for chronic pain, headache, urological disease, cancer disease, respiratory disease, digestive tract disease, mental illness, neurological disease, or skin disease. . The pharmaceutical composition according to any one of claims 1 to 11, which is a preventive or therapeutic agent for chronic pain. The pharmaceutical composition according to claim 13, wherein the chronic pain is neuropathic pain. The pharmaceutical composition according to any one of claims 1 to 11, which is a TRPM8 blocker.